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Summary 
Background 
The adverse consequences of poor injection practices have been reported for a few decades. 
However, key elements of evidence and information were lacking to allow decision-makers to 
formulate policies for the safe and appropriate use of injections. We conducted studies to (1) 
estimate the frequency of injection use and of poor injection practices, (2) estimate the 
consequences of poor injection practices in terms of death and disability, (3) formulate best 
infection control practices for intradermal, subcutaneous and intramuscular injections, (4) 
quantify the effectiveness of interventions to reduce unnecessary and unsafe use of injections and 
(5) estimate the cost-effectiveness of national policies for the safe and appropriate use of 
injections. 
Methods 
WHO's Global Burden of Disease project defined 14 regions based on geography and mortality 
patterns. The analysis excluded four regions (predominantly affluent, developed nations) where 
reuse of injection equipment in the absence of sterilization was assumed to be negligible.  
To estimate the frequency of poor injection practices in the year 2000, data sources included 
published studies and unpublished WHO reports. Studies were reviewed using a standardized 
decision-making algorithm based upon the quality of the data to generate region-specific 
estimates of the annual number of injections per person and of the proportion of injections 
reused in the absence of sterilization.  
To estimate the consequences of unsafe injections in the year 2000 in terms of death and 
disability for 2000-2030 as part of the 2000 update of WHO’s Global Burden of Disease study, 
we modelled the fraction of new injection-associated HBV, HCV and HIV infections on the 
basis of the annual number of injections, the proportion of injections administered with reused 
equipment, the probability of transmission following percutaneous exposure, the prevalence of 
active infection, the prevalence of immunity and the total incidence. Infections in 2000 were 
converted into disability-adjusted life years (DALYs) in 2000-2030 using natural history 
parameters, background mortality, duration of disease, disability weights, age weights and a 3% 
discount rate. 
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A guideline development group summarized evidence-based best practices to prevent injection-
associated infections in resource-limited settings. The development process included (1) a 
breakdown of the WHO reference injection safety definition into a list of potentially critical 
steps, (2) a review of the literature for each of these potentially critical steps, (3) the formulation 
of best practices and (4) the submission of the draft document to peer review. 
To estimate the effectiveness of interventions to reduce the unnecessary and unsafe use of 
injections, we searched electronic databases. In addition, we reviewed WHO reports and 
unpublished assessments made available to WHO. We selected studies that contained 
quantitative and qualitative information on the effect of interventions and that provided 
information on study design, type of interventions, targeted participants and targeted behaviours. 
To estimate the cost-effectiveness of national policies for the safe and appropriate use of 
injections, the consequences in 2000-2030 of a "do nothing" scenario for the year 2000 (as 
modelled for the Global Burden of Disease study) were compared to a set of counterfactual 
scenarios incorporating the health gains of effective interventions. Resources needed to 
implement effective interventions were costed for each sub-region and expressed in international 
dollars (I$). 
Results 
Four regions in the Global Burden of Disease study where reuse of injection equipment in the 
absence of sterilization was negligible were excluded from the analysis. In the 10 other regions, 
the annual ratio of injections per person was 3.4 (Range: 1.7 - 11.3) for a total of 16.7 thousand 
million injections received. Of these, 39.3% (Range: 1.2% - 75.0%) were administered with 
equipment reused in the absence of sterilization. Reuse was highest in the South East Asia region 
“D” (seven countries, mostly located in South Asia), the Eastern Mediterranean region “D” (nine 
countries, mostly located in the Middle East crescent) and the Western Pacific region “B” (22 
countries) which together accounted for 88.4% of the 6.5 thousand million injections given in the 
year 2000 with equipment reused in the absence of sterilization. In 2000, contaminated injections 
caused an estimated 21 million HBV infections, two million HCV infections and 260 000 HIV 
infections, accounting for 32%, 40% and 5% respectively of new infections for a burden of 
9 177 679 DALYs between 2000 and 2030. 
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Eliminating unnecessary injections is the highest priority to prevent injection-associated 
infections. However, when intradermal, subcutaneous or intramuscular injections are medically 
indicated, best infection control practices include (1) the use of sterile injection equipment, (2) 
the prevention of contamination of injection equipment and medication, (3) the prevention of 
needle-stick injuries to the provider and (4) the prevention of access to used needles. 
We identified twenty-one articles, abstracts, unpublished reports and assessments containing 
information on the effectiveness of interventions aiming at reducing injection use (n=19) and at 
decreasing the unsafe use of injections (n=5). Studies showed a reduction in injection use ranging 
from 1% to 53% (gain over control groups: 3%-27%). Interventions aiming at reducing the reuse 
of injection equipment in the absence of sterilization reported an absolute decrease of 30%-82% 
in the intervention groups (relative decrease: 40-100%). Interventions implemented in the year 
2000 for the safe (provision of single use syringes, assumed effectiveness: 95%) and appropriate 
use (patients-providers interactional group discussions, assumed effectiveness: 30%) of injections 
could reduce the burden of injection-associated infections by as much as 96.5% (8.86 million 
DALYs) for an average yearly cost of I$ million 905 (average cost-effectiveness per DALY 
averted: I$102, range by region: 14-2 293).  
Conclusions 
In 2000, in developing and transitional countries, 16 thousand million injections were 
administered for a ratio of 3.4 injections per person. More than a third of all these injections were 
administered with injection equipment reused in the absence of sterilization, accounting for a 
substantial burden of infection with bloodborne pathogens. Best infection control practices could 
make injections safer for the recipient, the health care workers and the community, all the more 
as effective interventions are available to reduce injection use and to achieve a safe use of 
injections. These interventions can also be considered very cost-effective on the basis of a cost 
per DALY averted that is below one year of average per capita income. Remaining areas of 
uncertainty include (1) the formulation of routine methods to describe injection use and to 
quantify needs of injection equipment, (2) the description of unsafe practices in greater detail to 
prevent all opportunities of transmission, (3) the need to generate better estimates of the 
proportion of HIV infections that may be attributed to unsafe health care injections, (4) the 
identification of the role of engineered technologies in policies to achieve injection safety, (5) the 
recovery of experience in the scaling-up of successful interventions and (6) the assessment of the 
cost-effectiveness of scaled-up national interventions. 
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Résumé 
Contexte 
Les conséquences délétères des mauvaises pratiques d’injection sont connues depuis plusieurs 
années. Cependant, des données scientifiques manquaient pour permettre de documenter des 
politiques pour l’utilisation sûre et appropriée des injections. Nous avons conduit des études dans 
le but de (1) estimer la fréquence des injections et des pratiques dangereuses, (2) estimer les 
conséquences des injections dangereuses en terme de décès et d’invalidité, (3) formuler des 
« bonnes pratiques » de lutte contre l’infection pour les injections intradermiques, sous-cutanées 
et intramusculaires, (4) quantifier l’efficacité des interventions pour réduire l’utilisation des 
injections et les pratiques dangereuses et (5) estimer le rapport coût/efficacité des politiques 
nationales pour l’utilisation sûre et appropriée des injections. 
Méthodes 
Le projet OMS de la charge globale de maladies définit 14 régions sur la base de la géographie et 
des profils de mortalité. L’analyse a exclu quatre régions, essentiellement riches et développées, 
où la réutilisation du matériel en l’absence de stérilisation a été considérée comme négligeable.  
Pour estimer la fréquence des mauvaises pratiques d’injection pour l’année 2000, les sources 
d’information ont inclus des études publiées et des rapports OMS non publiés. Ces études ont été 
revues avec un algorithme de décision standardisé tenant compte de la qualité des données pour 
générer des estimations régionales du nombre annuel d’injections par personne et de la 
proportion d’injections administrées avec du matériel réutilisé en l’absence de stérilisation.  
Pour estimer les conséquences des injections dangereuses au cours de l’année 2000 en termes de 
décès et d’invalidité en 2000-2030 dans le contexte de la mise à jour en 2000 de l’étude OMS sur 
la charge globale de maladies, nous avons modélisé la proportion des infections par le virus de 
l'hépatite B (VHB), le virus de l'hépatite (VHC) et le virus de l'immunodéficience humaine (VIH) 
sur la base du nombre annuel d’injections, de la proportion des injections administrées avec du 
matériel réutilisé, de la probabilité de transmission à la suite d’une exposition percutanée, de la 
prévalence des infections actives, de la prévalence de l’immunité et de l’incidence totale. Les 
infections en l’an 2000 ont été converties en années de vie ajustées pour l’invalidité pour 2000-
2030 en utilisant les paramètres d’histoire naturelle des maladies, la mortalité par d’autres causes, 
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la durée de la maladie, les coefficients de pondération pour l’invalidité et pour l’âge et un taux 
d’escompte de 3%. 
Un groupe de développement de règles directrices a utilisé les données disponibles pour résumer 
les meilleures pratiques pour prévenir les infections associées aux injections dans des contextes de 
ressources limitées. Le procédé de développement a inclus (1) une analyse de la définition OMS 
de référence pour la sécurité des injections pour obtenir une liste de points critiques, (2) une 
revue de la littérature pour chacun de ces points critiques, (3) la redaction de bonnes pratiques et 
(4) la soumission d’un premier document pour commentaires et suggestions. 
Pour estimer l’efficacité des interventions pour réduire l’utilisation et l’utilisation dangereuse des 
injections, nous avons recherché des études dans des bases de données électroniques. De plus, 
nous avons revu des rapports OMS et des évaluations non publiées mises à disposition de l’OMS. 
Nous avons sélectionné des études contenant des informations quantitatives et qualitatives sur 
l’effet des interventions qui détaillaient le type d’étude, le type d’intervention, les participants 
ciblés et les objectifs en termes de comportement chez les patients et les soignants. 
Pour estimer le rapport coût/efficacité des politiques nationales pour l’utilisation sûre et 
appropriée des injections, les conséquences pour 2000-2030 d’un scénario de « statu quo »  pour 
l’année 2000 (tel qu’estimé pour l’étude de la charge globale de maladies) furent comparées à des 
scénarios alternatifs incorporant les gains pour la santé des interventions jugées efficaces. Les 
ressources nécessaires pour la mise en place d’interventions efficaces ont été estimées pour 
chaque région et exprimées en dollars internationaux (I$). 
Résultats 
Quatre régions de l’étude de la charge globale de maladies où la réutilisation de matériel injectable 
était négligeable ont été exclues de l’analyse. Dans les 10 autres régions, le ratio annuel 
d’injections par personne était de 3.4 (Extrêmes: 1.7 - 11.3) pour un total de 16.7 milliards 
d’injections reçues. Parmi celles-ci, 39.3% (Extrêmes: 1.2% - 75.0%) étaient administrées avec du 
matériel réutilisé sans stérilisation. La réutilisation était la plus fréquente dans la région d’Asie du 
Sud Est “D” (sept pays, surtout localisés en Asie du Sud), la région méditerranéenne orientale 
“D” (neuf pays, surtout localisés dans le croissant du Moyen Orient) et la région du Pacifique 
occidental “B” (22 pays) qui, ensemble, comptabilisaient 88.4% des 6.5 milliards d’injections 
données en l’an 2000 avec du matériel réutilisé sans stérilisation. En l’an 2000, les injections 
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contaminées ont causé 21 millions d’infections par le VHB, deux millions d’infections par le 
VHC et 260 000 infections par le VIH, représentant respectivement 32%, 40% et 5% des 
nouvelles infections pour une charge de 9 177 679 années de vie ajustées pour l’invalidité entre 
2000 et 2030. 
Eliminer les injections non nécessaires est la plus haute priorité pour prévenir les infections 
associées aux injections. Cependant, quand les injections intradermiques, sous-cutanées ou 
intramusculaires sont indiquées médicalement, les bonnes pratiques de contrôle des infections 
incluent (1) l’utilisation de matériel d’injection stérile, (2) la prévention de la contamination du 
matériel d’injection et des médicaments, (3) la prévention des piqûres chez les soignants et (4) la 
prévention de l’accès au matériel usagé et contaminé. 
Nous avons identifié 21 articles, résumés et rapports non publiés contenant des informations sur 
l’efficacité des interventions pour réduire l’utilisation des injections (n=19) et pour réduire 
l’utilisation dangereuse des injections (n=5). Les études ont montré une réduction de l’utilisation 
de 1% à 53% (gain sur le groupe témoin: 3%-27%). Les interventions ciblant la réduction de la 
réutilisation du matériel injectable en l’absence de stérilisation ont rapporté une efficacité en 
valeur absolue de 30% à 82% dans les groupes d’intervention (efficacité en valeur relative: 40%-
100%). Les interventions en 2000 pour l’utilisation sûre (distribution de matériel d’injection à 
usage unique, efficacité assumée: 95%) et appropriée (groupes de discussion patients-soignants, 
efficacité assumée: 30%) des injections pourraient réduire la charge de maladie due aux injections 
d’au moins 96.5% (8.86 millions d’années de vie ajustées pour l’invalidité) pour un coût moyen de 
905 millions de dollars internationaux (Ratio moyen de coût/efficacité par année de vie ajustée 
pour l’invalidité: 102I$, extrêmes par régions: 14-2 293).  
Conclusions 
En l’an 2000, dans les pays en voie de développement et les pays en transition, 16 milliards 
d’injections ont été administrées pour un ratio de 3.4 injections par personne.  Plus d'un tiers de 
ces injections a été administré avec du matériel réutilisé en l’absence de stérilisation, donnant lieu 
à une charge substantielle d’infections par les pathogènes liés au sang. La mise en place de bonnes 
pratiques de lutte contre les infections pourrait rendre les injections sûres pour les patients, les 
soignants et la population, d’autant plus que des interventions efficaces sont disponibles pour 
réduire l’utilisation des injections et pour assurer une utilisation sûre. Ces interventions peuvent 
aussi être considérées comme ayant un bon rapport coût/efficacité car le coût par année de vie 
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gagnée ajustée pour l’invalidité est inférieur à une année de revenu moyen par habitant. Les zones 
d’incertitude persistantes incluent (1) la formulation de méthodes de routine pour décrire 
l’utilisation des injections et pour quantifier les besoins en matériel d’injection, (2) la description 
plus détaillée des pratiques dangereuses afin de prévenir toutes les opportunités de transmission, 
(3) le besoin d'estimer plus précisement la proportion des infections par le VIH attribuables aux 
injections dangereuses, (4) l’identification du rôle des nouvelles technologies dans les politiques 
de sécurité des injections, (5) l’acquisition d’expérience dans la généralisation des interventions 
efficaces et (6) l’évaluation du rapport coût/efficacité des interventions étendues au niveau 
national. 
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“Si tu sais que tu ne sais pas, tu sauras. Si tu ne sais pas que tu ne sais pas, tu ne sauras pas.” 
Hamadou Hampaté Bah 
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General introduction 
Background 
Unsafe injection practices have been increasingly recognized as a substantial source of infection 
with bloodborne pathogens, including hepatitis B virus (HBV) and hepatitis C virus (HCV). 
Similarly, standards of care have been raised in public health initiatives and the “first do no 
harm” principle is now at the heart of the delivery of key public health interventions, including 
immunization. As a consequence, WHO scaled up its activities for the safe and the appropriate 
use of injections in 1999 and created the Safe Injection Global Network (SIGN) alliance to 
ensure that this goal could be reached through the active participation of all public and private 
stakeholders. 
The safe and appropriate use of injections was not conceptualized as an independent public 
health issue before 1999. In addition, WHO needed a basis of evidence to assist countries in the 
benchmarking, planning, assessment, implementation and evaluation of national injection safety 
policies. Thus, as part of the strategic planning for 2000-2003, resources were allocated to 
building an evidence base that could constitute the foundation of national policies for the safe 
and appropriate use of injections. 
Goals and objectives 
The goal of this work was to develop an evidence base upon which countries could make 
informed decisions regarding national policies for the safe and appropriate use of injections. The 
specific objectives included: 
1. Describe injection practices worldwide in terms of (a) injection frequency and (b) injection 
safety (Chapter 1); 
2. Estimate the global burden of disease associated with contaminated health care injections in 
terms of (a) attributable fractions for HBV, HCV and HIV infections and (b) secondary 
burden in terms of death and disability, as expressed in disability-adjusted life years (DALYs, 
Chapter 2); 
3. Formulate best infection control practices for intradermal, subcutaneous and intramuscular 
injections (Chapter 3); 
4. Review the effectiveness of interventions to reduce the use of injections and the unsafe use 
of injections (Chapter 4); 
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5. Estimate the cost-effectiveness of national policies for the safe and appropriate use of 
injections in terms of cost per DALY averted (Chapter 5). 
Methods used to achieve the objectives 
The methods used to reach the specific objectives included: 
 
1. A review of studies using a standardized decision-making algorithm based upon the quality of 
the data to generate region-specific estimates of the annual number of injections per person 
and of the proportion of injections reused in the absence of sterilization (Chapter 1); 
2. A model of the fraction of new injection-associated HBV, HCV and HIV infections on the 
basis of the annual number of injections, the proportion of injections administered with 
reused equipment, the probability of transmission following percutaneous exposure, the 
prevalence of active infection, the prevalence of immunity and the total incidence (Chapter 
2); 
3. The development of evidence-based best practices through (a) a breakdown of the WHO 
reference injection safety definition into a list of potentially critical steps, (b) a review of the 
literature for each of these potentially critical steps, (c) the formulation of best practices and 
(d) the submission of the draft document to peer review (Chapter 3); 
4. A review of published studies, WHO reports and unpublished assessments made available to 
WHO containing quantitative and qualitative information on the effect of interventions and 
providing information on study design, type of interventions, targeted participants and 
targeted behaviours (Chapter 4); 
5. A comparison of the consequences in 2000-2030 of a "do nothing" scenario for unsafe 
injections in the year 2000 with a set of counterfactual scenarios incorporating the health 
gains of effective interventions and estimating the resources needed to implement them in 
each sub-region using international dollars (Chapter 5). 
The literature review was integrated to the respective chapters, as appropriate. 
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Chapter 1: Overuse and unsafe use of injections in health care 
settings worldwide, 2000 
"La vida no es la que uno vivió, sino la que uno recuerda y como la recuerda para contarla." 
Gabriel Garcia Marquez, “Vivir para contarla” 
 
Yvan J. F. Hutin, (1) Anja M. Hauri, (1) Gregory L. Armstrong (2) 
 
1. Department of Blood Safety and Clinical Technology, World Health Organization, Geneva, 
Switzerland. 
2. Division of Viral Hepatitis, National Center for Infectious Diseases, Centers for Disease 
Control and Prevention, Atlanta, GA, USA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This manuscript was published in the British Medical Journal (Overuse and unsafe use of 
injections worldwide: Literature review and regional estimates. BMJ 2003; 327: 1075-8). 
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Introduction 
Poor injection practices have been reported in health care settings worldwide. 1 During the 
twentieth century, injection use increased tremendously and today injection is probably the most 
common health care procedure. 2 Many injections given for curative purposes in developing and 
transitional countries are unnecessary as they are prescribed for the treatment of conditions that 
could be treated with oral drugs or for which medications are not indicated. 1,3 In addition to 
being unnecessary, many injections are unsafe. Of particular concern is the reuse of injection 
equipment in the absence of sterilization. A common practice consists of rinsing injection 
equipment between injections in a pot of tepid water (Figure 1). 
Figure 1: Injection equipment soaked in tepid water before reuse in the absence of 
sterilization, Africa, 2000* 
1
2
 
The combination of injection overuse and unsafe practices results in a major route of 
transmission for bloodborne pathogens. Epidemiological studies have indicated that unsafe 
injections commonly transmit hepatitis B virus (HBV, Abstract 7) 4 and hepatitis C virus (HCV). 5 
The transmission of the human immunodeficiency virus (HIV) through unsafe health care 
injections has also been reported. 6 Other complications of unsafe injections include abscesses, 7,8 
septicemia, 9 malaria 10 and infection with viral hemorrhagic fever viruses. 11,12  
As part of the Comparative Risk Assessment component 13 of the 2000 update of WHO's Global 
Burden of Disease study, 14 we have estimated the global burden of disease attributable to 
contaminated injections in health care settings. These estimates were based on mathematical 
models similar to those previously used to estimate the worldwide number of infections 
attributable to unsafe injections. 15,16 This paper summarizes the input parameters of this model in 
                                                 
* Note the disposable syringes rinsed in the tepid water (arrow 1) and the multi-dose medication vials (arrow 2). 
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terms of (1) the annual number of injections per person and (2) the proportion of injections 
administered with syringes and/or needles reused in the absence of sterilization. The results of 
the analysis suggest that four decades after the widespread availability of disposable injection 
equipment and two decades into the HIV pandemic, poor injection practices in health care 
settings remain an uncontrolled and dangerous vector of bloodborne and emergent pathogens. 
Methods 
Definitions 
Health care injection 
We defined a health care injection as a procedure that introduces a substance into the body 
through a piercing of the skin or of a mucosal membrane. This includes intradermal, 
subcutaneous, intramuscular and intravenous injections for curative or preventive health care 
purposes, whether administered in formal health care settings (e.g., clinics, hospitals) or other 
settings (e.g., homes, pharmacies). Injections of illicit drugs were not considered in this study. 
Reuse of injection equipment in the absence of sterilization 
We defined reuse of injection equipment in the absence of sterilization as the administration of 
an injection to a recipient with a syringe and or a needle that had been previously used on 
another person and that was reused in the absence of sterilization. In this paper, reuse of 
injection equipment in the absence of sterilization will simply be referred to as “reuse of injection 
equipment”. 
Sources of information used for the estimation of injection practice indicators  
Regions used 
The Global Burden of Disease 2000 regions used for this analysis were based upon the WHO 
regions, i.e., the American region (AMR), the African region (AFR), the Eastern Mediterranean 
region (EMR), the European region (EUR), the South East Asia region (SEAR) and the Western 
Pacific region (WPR). 17 These WHO regions were then subdivided into subgroups (Table 1) 
similar for selected vital statistics, including child and adult mortality. Subgroups were designated 
with a letter (“A” reflecting the lowest mortality and “E” reflecting the highest mortality). 17 
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Table 1: Countries included in the Global Burden of Disease regions 
Afr D includes: Algeria, Angola, Benin, Burkina Faso, Cameroon, Cape Verde, Chad, Comoros, 
Equatorial Guinea, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Madagascar, Mali, 
Mauritania, Mauritius, Niger, Nigeria, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, 
Togo.  Afr E includes: Botswana, Burundi, Central African Republic, Congo, Côte d'Ivoire, 
Democratic Republic of the Congo, Eritrea, Ethiopia, Kenya, Lesotho, Malawi, Mozambique, 
Namibia, Rwanda, South Africa, Swaziland, Uganda, United Republic of Tanzania, Zambia, 
Zimbabwe.  Amr B includes: Antigua and Barbuda, Argentina, Bahamas, Barbados, Belize, 
Brazil, Chile, Colombia, Costa Rica, Dominica, Dominican Republic, El Salvador, Grenada, 
Guyana, Honduras, Jamaica, Mexico, Panama, Paraguay, Saint Kitts and Nevis, Saint Lucia, Saint 
Vincent and the Grenadines, Suriname, Trinidad and Tobago, Uruguay, Venezuela. Amr D 
includes: Bolivia, Ecuador, Guatemala, Haiti, Nicaragua, Peru.  Emr D includes: Afghanistan, 
Djibouti, Egypt, Iraq, Morocco, Pakistan, Somalia, Sudan, Yemen.  Eur B includes: Albania, 
Armenia, Azerbaijan, Bosnia and Herzegovina, Bulgaria, Georgia, Kyrgyzstan, Poland, Romania, 
Slovakia, Tajikistan, The Former Yugoslav Republic of Macedonia, Turkey, Turkmenistan, 
Uzbekistan, Yugoslavia. Eur C includes: Belarus, Estonia, Hungary, Kazakhstan, Latvia, 
Lithuania, Republic of Moldova, Russian Federation, Ukraine. Sear B includes: Indonesia, Sri 
Lanka, Thailand. Sear D  includes: Bangladesh, Bhutan, Democratic People's Republic of 
Korea, India, Maldives, Myanmar, Nepal.  Wpr B includes: Cambodia, China, Cook Islands, Fiji, 
Kiribati, Lao People's Democratic Republic, Malaysia, Marshall Islands, Micronesia (Federated 
States of), Mongolia, Nauru, Niue, Palau, Papua New Guinea, Philippines, Republic of Korea, 
Samoa, Solomon Islands, Tonga, Tuvalu, Vanuatu, Viet Nam 
Injection practice indicators 
Four regions (European A, Eastern Mediterranean B, American A and Western Pacific A) 
representing mostly countries with high per capita gross national product were excluded as the 
proportion of reuse was considered negligible. To overcome the paucity of information available 
regarding injection practices in the published literature, we used exhaustive search strategies and 
unpublished reports. We searched published studies in MEDLINE and in the Index Medicus 
using “injection”  as keyword. In addition, we searched WHO unpublished reports, including 
evaluations of the Expanded Programme of Immunization (EPI) and other reports circulated 
since 1999 through the electronic mail list server of the Safe Injection Global Network 
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(SIGN). 18,19 We also reviewed relevant references quoted in identified articles. We reviewed all 
studies using a standardized study abstraction instrument, appraised them, ranked them according 
to their quality and entered them in an electronic database. 
To estimate the annual number of injections per person for each region, age, and gender stratum, 
we restricted our selection to (1) population-based surveys conducted for the purpose of 
estimating the frequency of injections and (2) other population-based data providing injection 
frequency estimates. Within each region, we averaged the estimates of all studies, corrected for 
the distribution of injections among male to female and/or among age groups if one of the 
studies in the region provided that information. Finally, we corrected for additional immunization 
injections among children under five years of age if the data source did not take this factor into 
account.  
To estimate the proportion of reuse for each region stratum, we restricted our selection to (1) 
observational studies of injection practices using the WHO standardized injection safety 
assessment survey tool 20  and (2) studies of injection practices conducted using other, non-
standardized methods. In the absence of data in some regions, we (3) back-calculated the 
proportion of reuse using a mass action equation  16  and the relative risks of infection with 
bloodborne pathogens associated with receiving injections in published analytical epidemiological 
studies. Within each region, we averaged the estimates of all studies. Estimates based upon non-
standardized methods were excluded if assessments using the WHO standardized tool was 
available (Non-standardized assessments presented a number of limitations, including non-
representative sampling, small sample size and the absence of observational data). Estimates 
based upon back-calculation were only considered if higher quality information was not available 
(except in the Eastern Mediterranean region where the injection safety assessment focused mostly 
on the informal private sector). 
Uncertainty analysis 
Lower and upper estimates were calculated for the annual number of injections per person and 
the proportion of reuse using standard error formulae for means and proportions. When the 
proportion of reuse was estimated on the basis of measures of association, the standard error was 
derived from the proportion and the sample size of the study as if the proportion had been 
obtained on the basis of a single random sampling of the individuals included in the study. For 
regions for which good quality data was available on injection frequency (injection frequency 
surveys) or injection safety (standardized or non-standardized injection safety surveys), the lower 
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and upper estimates were calculated on the basis of standard error (+/- 2 SE). For regions for 
which only lower quality data were available for injection frequency (other population-based 
injection frequency data) or injection safety (back-calculated estimates), an arbitrarily larger 
interval was used to account for added uncertainty (+/- 4 SE). For regions for which no data was 
available and for which inferences were made using other regions, an even larger interval was 
arbitrarily used to account for added uncertainty (+/- 6 SE). 
Results 
Regional estimates of the annual number of injections per person 
A variety of sources of information were available to estimate the annual number of injections 
per person (Table 2). In eight regions, surveys had been conducted with the objective of 
estimating injection frequency, either as part of a large project supported in the early 1990s by the 
WHO global programme on AIDS to monitor exposures to potential risk factors for HIV 
infection 21 or with a more specific objective of assessing injection practices (Abstract 
4). 22,23,24,25,26,27,28 In seven regions, other population-based information was obtained from control 
groups of case control studies that examined injection use as a potential risk factor for 
hepatocellular carcinoma, 29 paralytic polio, 30,31 HIV infection, 32,33,34 HCV infection, 35,5 HBV 
infection 36,37 and gluteal fibrotic contracture. 38 Final regional estimates were based upon (1) 
population-based injection frequency surveys (three regions), other population-based data (two 
regions) and a combination of these two methods (five regions). EUR C was the region with the 
highest injection frequency (11.3 injections per person and per year), followed by EUR B (5.2 
injections per person and per year, Figure 2). The regions with the lowest annual number of 
injections per person were AMR B (1.7 injections per person and per year) and AMR D (1.9 
injections per person and per year). Overall, we estimated that the 4.9 thousand million persons 
living in the 10 regions included in the study received 16.7 thousand million injections annually 
(lower and upper estimates: 15.2 and 18.1 thousand million, respectively) for a ratio of injections 
per person and per year of 3.4 (lower and upper estimates: 3.1 and 3.7, respectively). 
Regional estimates of the proportion of reuse 
Different types of studies and reports were available to estimate the proportion of reuse of 
injection equipment (Table 3). First, 11 observational injection safety surveys had been conducted 
using the standard WHO tool in three regions (WHO unpublished data). Second, four non-
standardized observational injection safety surveys had been conducted in four regions. 39,40,41,42 
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Third, two epidemiological studies were available to provide relative risks associated with 
receiving injections (Abstract 7). 4,43 Final estimates were based upon (1) standardized WHO 
injection safety assessments (three regions), (2) non-standardized injection practice surveys (three 
regions), (3) back-calculations using the mass action equation and the relative risks of infection 
with bloodborne pathogens associated with receiving injections (one region) and (4) a 
combination of the second and the third methods (one region). No quantitative data were 
available for six regions. For two of them, AMR B and AMR D, there were qualitative reports of 
reuse. For the AMR B region, these reports suggested that reuse was uncommon. 44,45,46 Thus, 
estimates from the other region with the lowest frequency of reuse (EUR B) were extrapolated. 
For AMR D, as qualitative reports suggested that reuse was more common than in AMR B, 47 
estimates from the region with the second lowest frequency of reuse (EUR C) were extrapolated. 
For four regions (EUR A, EMR B, AMR A and WPR A), representing mostly countries with a 
high per capita gross national product, the proportion of reuse was considered negligible. Among 
regions for which quantified estimates were available, SEAR D was the region with the highest 
proportion of reuse (75%), followed by EMR D (70%) and WPR B (30%, Figure 2). The region 
with the lowest proportion of reuse was EUR B (1.2%). Overall, we estimated that among the 
16.7 thousand million injections administered each year in the 10 regions included in the study, 
6.7 thousand million (39.3%. Lower and upper estimates: 4.0 and 9.7 thousand million, 
respectively) were given with reused equipment. 
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Table 2: Regional injection frequency estimates and data sources used, by region, 2000 
 AFR D AFR E AMR B AMR D EMR D EUR B EUR C SEAR B SEAR D WPR B 
Annual number of injections per 
person* 
2.2 2.0 1.7 1.9 4.3 5.2 11.3 2.1 4.0 2.4 
Lower and upper estimates 2.1-2.3 2.0-2.0 1.6--1.8 1.2-2.7 4.2-4.3 4.3-6.1 10.1-12.5 2.1-2.2 3.8-4.2 2.1-2.7 
Countries from which injection 
frequency surveys were used 
Guinea Bissau 
[21] 
CAR  
Cote d'Ivoire 
Tanzania 
Zambia 
Burundi [21] 
Uganda [22] 
Brazil [21] - Egypt [24] Romania [27] Moldova [28] Thailand [21,23] 
 
Indonesia [25] 
India [26] - 
Countries from which other 
population-based data were used 
Cameroon [30] 
Nigeria [29] 
Tanzania [33] 
 
Uganda [32] 
Latino 
communities in 
the USA [46] 
Haiti [34] Pakistan [5] - - - India [31] 
 
China, Province 
of Taiwan 
[38,35,36,37] 
Use of different estimates for 
males and females  
No Yes No No No Yes Yes No No No 
Addition of 0.5 injections per year 
among 1-4 years of age to account 
for immunization  
Yes Yes Yes Yes Yes No† No † No † Yes No † 
                                                 
* Estimates age-adjusted using age group-specific population sizes to simplify data presentation. The total estimate is based upon age- and gender-specific estimates. 
† Not applicable: age-specific injection frequency estimate takes into account immunization injections. 
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Table 3: Regional estimates of the proportion of injections administered with reused equipment and data sources used, by region, 2000 
 AFR D AFR E AMR B  AMR D  EMR D EUR B EUR C SEAR B SEAR D WPR B 
Proportion of reuse 19% 17% 1.2% 11% 70% 1.2% 11% 30% 75% 30% 
Lower and upper estimates 15-23% 13-21% 0-8% 0-23% 58%-82% 0-4% 3-19% 23-37% 60-88% 0-63% 
Methods used (See text) Standard WHO 
survey  
Standard WHO 
survey 
Extrapolation Extrapolation Combination of 
methods 
Standard WHO 
survey 
Back-calculation Non standard 
surveys 
Non standard 
surveys 
Non standard 
surveys 
Countries from which WHO 
standardized injection safety 
surveys were used 
Five countries in 
the region * † 
Five countries in 
the region * † 
- - - 
 
 
Kyrgyztan † - - - - 
Countries from which non 
standardized surveys were used 
- - - - Pakistan 39 - - Indonesia 39 India 41 China 42 
Countries from which back-
calculated estimates were used 
- - - - Egypt 43 - Moldova 4 - - - 
Use of other regions’ data  - - EUR B‡ EUR C§ - - - - - - 
                                                 
* Unpublished WHO reports. List of actual countries not available to the general public. 
† Julia Fitzner, Department of Vaccine and Biologicals, WHO, personal communication. 
‡ Qualitative information available on injection safety for AMR B [44,45,46] suggested occurrence of reuse in the absence of sterilization. To generate a conservative estimate, estimates for the region with the lowest proportion 
were extrapolated. 
§ Qualitative information available on injection safety for AMR D [47] suggested occurrence of reuse in the absence of sterilization with a higher frequency than AMR B. Thus, estimated for the region with the second lowest 
proportion were extrapolated. 
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Figure 2: Number of injections per person and per year and proportion of these 
administered with injection equipment reused in the absence of sterilization, by region, 
2000. 
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Discussion 
The safe and appropriate use of injections remains elusive despite decades of knowledge about 
the consequences of poor injection practices. 48,49 Since the early 1990s, epidemiological studies 
have indicated that unsafe injections are a risk factor for new HBV, HCV and HIV infections. 1 
Currently, almost five thousand million people live in regions where reuse of injection equipment 
occurs. According to the results of this analysis, persons in these regions receive an average of 3.4 
injections each year, of which 39.3% are given with reused injection equipment. These figures 
constitute a call for action since effective and affordable interventions are available to reduce 
injection overuse and to achieve safe injection practices. 
The high frequency of injections reported in developing and transitional countries contrasts with 
the paucity of data that is available to describe injection practices. In that respect, our study 
should be seen more as a first attempt to organize information in this field to raise awareness and 
underline the need for better quality data. Until recently, few standardized tools for assessment or 
evaluation were available to routinely collect information on injection frequency or injection 
safety. With respect to injection use, the WHO programme on essential drugs proposed the 
proportion of prescriptions including at least one injection as a critical indicator of rational drug 
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use. 50 This indicator has been widely used for initial assessments 51 or for the evaluation of 
interventions to improve the rational use of injections. 52 However, it does not provide a direct 
estimate of the annual number of injections per person as it does not take into account (1) the 
number of prescriptions per year, (2) the number of injections per prescription and (3) the 
injections prescribed or directly administered in the informal private sector. The Demographic 
and Health Surveys (DHS) 53 have included questionnaire items regarding injections received in 
some countries. Although the data are publicly available, the results of these analyses have not 
been published. With respect to injection safety, the Expanded Programme on Immunization 
(EPI) has conducted non-standardized injection safety surveys for a number of years. Since 2000, 
these assessments are conducted systematically and with a standardized tool. 20  
Our analysis indicates that there are over 16 thousand million injections each year in the 10 
regions included in our study. Four of these regions stood out with particularly high estimates. 
The crude annual number of injections per person was the highest in the former Socialist 
economies of Europe and central Asia, reaching 5.2 and 11.3 in EUR B and EUR C, respectively. 
Most injections in these countries are administered in public health care facilities by physicians or 
nurses, with a high number of injections per prescription (Abstract 4). 27,28 While health care 
providers commonly emphasize patient demand as a major driver of injection overuse, the 
importance of this factor may be exaggerated. Surveys suggest that patients do not necessarily 
prefer injections for the administration of medications and that they are open to alternatives to 
injections (Abstract 4). 27,54 In fact, prescribers have a tendency to overestimate patients' 
preference for injections (Abstract 3). 55 They also often have false preconceptions about the 
effectiveness of injectable medications (Abstract 3) 55 and these preconceptions are sometimes 
supported by non evidence-based official treatment protocols. 56 Thus, prescribers’ attitudes also 
contribute to injection overuse. Injection use was also high in the Middle East and in South Asia 
where the annual number of injections per person reached 4.3 in EMR D and 4.0 in SEAR D, 
respectively. In these regions, a high proportion of injections are administered by private 
providers who may have no formal medical qualification. 24,39,41  In such informal settings, health 
care providers’ attitudes also drive injection overuse. 5,37,57 However, the reference to standard 
treatment guidelines is uncommon. Injections are frequently used on an "ad hoc" basis to 
administer mixtures of antibiotics, analgesics, vitamins or anti-histamines in the desire to meet 
what is believed to be the demand of the user. 39,57 
Reducing injection overuse would only be a matter of promoting rational drug use if injections 
were administered safely. However, our analysis indicates that injections are given in a way that 
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may harm the injection recipient. Determinants of these unsafe injection practices include the 
lack of supplies of new, single use injection equipment, 58 the lack of awareness among patients 
and providers regarding the risks associated with unsafe practices 39,26 and the absence of an 
efficient sharps waste management system to prevent recycling of contaminated equipment. 59 It is 
of interest that the results of our analysis suggest that injection practices are safer in sub-Saharan 
African (19% and 17% of reuse in AFR D and AFR E, respectively) than in the Middle East and 
South Asia (70% and 75% reuse in EMR D and SEAR D, respectively). The proportion of the 
population aware of the potential risk of HIV infection through unsafe injections was 24% in 
Pakistan in 1998, 60 19% in India in 1999, 26 and 52% in Burkina Faso in 2001 (Abstract 12). 61 The 
social and economic consequences of the HIV pandemic have been perceived more acutely on 
the African continent than in Asia. Thus, a higher awareness regarding the risks of HIV infection 
associated with unsafe injections in sub-Saharan Africa 62 may partly explain this difference 
observed in the proportion of reuse. 
This study has three main limitations. First, our injection frequency estimates may underestimate 
the total number of injections received in the population. The frequency distribution of the 
number of injections received in the population tends to be skewed to the right because of the 
small proportion of the population that receives a very high number of injections (e.g., diabetics). 
Some of the studies that we included may have had a sample size too small to include these rare 
individuals. This effect limits the usefulness of our estimates to forecast needs in injection devices 
although it does not affect their usefulness to compare regions. Second, publication bias could 
have led to an overestimate of the proportion of reuse if studies were initiated in response to a 
perception that injection practices were poor in a particular location (e.g., in Pakistan). This 
limitation may be of greater concern than potential observer-induced behaviour modifications 
among health care providers leading to better practices during health care facility surveys. Thus, 
overall, we may have overestimated the proportion of reuse. Third, the reuse of injection 
equipment that we used as a critical indicator is only a partial reflection of unsafe injection 
practices. It does not reflect other breaks in infection control practices that can also lead to 
infection, including unhygienic use of multi-dose medication vials 63 and cross contamination 
while preparing injections (Abstract 5) 64. It also does not reflect the risk of needle-stick injuries 
among health care workers and the adverse health consequences of the poor management of 
sharps waste.  
Policies for the safe and appropriate use of injections aim simultaneously to eliminate 
unnecessary injections and to achieve safe injection practices. Such initiatives should not 
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constitute separate programmes but should be integrated into other routine activities. 65 First, 
HIV prevention programmes should communicate the risks associated with unsafe injections to 
patients and health care workers. Second, essential drugs programmes should ensure access to 
sufficient quantities of single use, disposable injection equipment in each health care facility and 
build rational use of injections within the national drug policy. Third, donors and lenders who 
supply injectable substances (e.g., vaccines, contraceptives) should also fund adequate quantities 
of safe injection equipment to administer these. Fourth, health systems should manage sharps 
waste to prevent needle-stick injuries and the reuse of dirty equipment. Fifth, critical indicators of 
injection frequency and injection safety should be monitored as technical quality indicators of 
health system performance. Finally, the specific issue of injection overuse and poor practices 
among informal, providers may require specific targeted interventions. The "Injection practices: 
Rapid assessment and response guide (Appendix 1) " 66 recently developed by WHO proposes a 
list of such indicators together with instruments to collect the relevant information so that 
injection practices can be systematically assessed. 
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Chapter 2: The global burden of disease attributable to 
contaminated health care injections  
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Introduction 
Injection overuse and unsafe practices have been reported in many countries.1  Of particular 
concern is the reuse of injection equipment in the absence of sterilization. 2,3,67 In developing and 
transitional countries, persons receive an average of 3.4 injections per year of which 39.3% are 
administered with reused equipment (Chapter 1).  
Unsafe injections lead to infections with bloodborne pathogens, including hepatitis B virus 
(HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). The causal nature of 
this association is supported by many causality criteria, 68,69,70,71,72,73,74,75,76 including the results of 
prospective studies that consistently indicated a strong association, 5,77,78 some of which reported a 
dose-response relationship 36,39,78 and a timing of infections that followed exposures (Abstract 
7). 4,78,43  
Studies estimating the proportion of new infections with HBV (Abstract 2, Abstract 7), 4, 
36,77,37,79,80,81,82,83,84,85 HCV, 5,35,37,43,81,86,87,88,89,90 and HIV 78,91,92,93 that are attributable to unsafe 
injections cannot be used directly to estimate the global burden of disease as they do not cover all 
world regions. Thus, as part of the Comparative Risk Assessment component 13  of the 2000 
update of the Global Burden of Disease study,14  we updated previous models 15,16 estimating the 
number of infections associated with unsafe injection practices and projected these infections 
into future death and disability. We considered only HBV, HCV and HIV infections because of 
the substantial literature documenting their association with injections and because these 
pathogens probably account for the majority of injection-associated infections. Other 
complications of unsafe injections were not addressed. 7,8,9,10,11,12  
Methods 
Approach 
Comparative Risk Assessment 13,94 collaborating groups were requested to define the exposure of 
interest and to estimate (1) its prevalence in the population and (2) the relative risk of disease 
among those exposed. These statistics were used to estimate attributable fractions in 14 regions 
(Table 1). For contaminated health care injections, we defined the exposure of interest as 
receiving one or more contaminated injections in a year. We used mathematical models to 
transform diverse sources of data available on unsafe injections and the risks associated with 
these practices into the necessary statistics. 
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Definitions 
We defined health care injections as those given for curative or preventive purposes in health 
care facilities or other settings (e.g., homes, pharmacies). Injections of illicit drugs were not 
considered. We defined reuse of injection equipment as the administration of an injection with a 
syringe and or a needle that had been previously used on another person and that was reused in 
the absence of sterilization. A contaminated injection, the exposure of interest, was defined as an 
injection given with a needle or a syringe previously used on an infected patient and then reused. 
Mass action model 
The incidence of infection attributable to unsafe injection (Iu) was estimated in a “mass action” 
model that assumed 
Iu = ps [1 – (1 –pt pr pv)n] 
in which ps is the proportion of the population susceptible, pt is the probability of transmission 
after percutaneous exposure, pr is the probability that injection equipment will have been reused, 
pv is the prevalence of active infection and n is the annual number of injections per person. The 
incidence of the three pathogens under consideration is small enough that the equation can be 
simplified to 
Iu = ps * pt * nc 
in which nc is the average annual number of contaminated injections. 
nc = pr * pv * n 
The probability of transmission (pt) was based upon studies estimating the risk of infection with 
HBV, HCV and HIV following a needle-stick exposure from an infected source-patient. For 
HBV, pt was assumed to be 0.06 and 0.3 for hepatitis B e-antigen (HBeAg)-negative and HBeAg-
positive source-patients, respectively. 71 For HCV, pt was assumed to be 0.018. 72 For HIV, pt was 
assumed to be 0.012, the mean of the average risk from needle-stick injuries (0.003) 73 and risk 
associated with deep needle-stick injuries (0.023). 73;95  
Mass action model-based estimates of the proportion of the population exposed 
If each person in the population could receive only one injection then pc, the probability of 
receiving at least one contaminated injection, would equal nc. Assuming individuals can receive 
more than one contaminated injection per year and the number of contaminated injections per 
individual follows a Poisson distribution with an average of nc per individual, then the probability 
of receiving no injection would be exp (-nc), and the probability of receiving at least one injection 
would be 
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pc = 1 – exp(-nc) 
Thus when nc is very small, pc is approximately equal to nc and each exposed person will receive on 
average only one contaminated injection per year. In most other situations, pc will be slightly 
smaller than nc and each exposed person will receive on average nc / (1 – exp(-nc)) contaminated 
injections per year. 
Estimates of the relative risk from the mass action model 
Attributable fraction can be estimated from pc and RRc, the relative risk associated with exposure 
to at least one contaminated injection, with the following equation: 96 
AF = pc * (RRc – 1) / [1 + pc * (RRc – 1)]. 
Attributable fraction can also be estimated from the mass action model. The total incidence of 
infection in the population, It, is composed of the incidence due to contaminated injections, Iu, 
and the incidence in the population if contaminated injections could be eliminated, Ib. Thus, the 
attributable fraction is: 
AF = Iu / It 
Combining the two equations and solving for RRc: 
RRc = 1 + Iu  / (pc * (It - Iu)) 
This equation was used to estimate relative risk from the mass action model except in regions in 
which Iu approached It, where the equation produced unstable estimates. 
Estimates of the relative risk from epidemiological studies 
In situations where Iu approaches It, relative risks were estimated using epidemiological studies 
estimating the association between injections and infection. Reported relative risks were adjusted 
for the frequency of contaminated injections among all injections. To avoid underestimating the 
relative risk because of non-susceptible controls, we assumed that the number of injections 
received in the prior year was proportional to the probability of having been previously infected. 
Sources of information for input parameters 
Injection practice parameters 
The proportion of reuse (pr) and the annual number of injections per person (n) were based upon 
a literature review (Chapter 1).  To avoid overestimating the attributable fraction, we assumed 
that those receiving a number of injections above the 90th percentile were immune. This decision 
led to an adjustment of the input parameters for EUR B 27 (Abstract 4) and EUR C. 28 For the 
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other regions, estimates were calculated on the basis of data reported in tabulated form which 
already eliminated the upper 10% of the frequency distribution. 
Prevalence and incidence of infections 
Estimates for the proportion of the population chronically infected with HBV, HCV and HIV 
(pv) were obtained from the WHO programmes on HBV and HCV 97 and from the United 
Nations Programme on HIV/AIDS (UNAIDS). 98 To estimate the incidence of HBV and HCV 
infection, catalytic models were generated using various hypothetical scenarios of annual 
incidence of infection that were applied uniformly to all age groups in the absence of any cohort 
effect (i.e., assuming equilibrium). The age-specific simulated estimates of the prevalence of 
susceptibility were then compared to the actual region-specific estimates of prevalence to identify 
which level of incidence led to the best fit. HIV incidence estimates were obtained from 
UNAIDS. 98 
Uncertainty analysis 
Lower and upper estimates were generated for the injection practice parameters as described 
elsewhere (Chapter 1) and included in the equations to obtain lower and upper estimates of the 
proportion of the population exposed and the relative risks. Lower and upper estimates for the 
relative risks that were study-based were calculated on the basis of the confidence interval of the 
relative risk in the original studies. 
Estimation of the Disability-Adjusted Life Years (DALYs) 
HBV, HCV and HIV infections attributable to contaminated injections were converted into 
DALYs using theoretical cohorts of infected individuals followed for (1) background mortality 
and (2) disability and infection-associated deaths from acute hepatitis, hepatocellular carcinoma, 
end-stage liver disease and AIDS. We used standard average duration of disease and disability 
weights. 99 For HBV and HCV infection, natural history parameters included the rate of 
progression to chronic infection,100,101 annual sero-reversion rates 102 and mortality rates associated 
with chronic liver disease among infected persons (Figure 3 and Figure 4). 101,103,104 In addition, for 
HBV, we took into account the risk of acute hepatitis and fulminant hepatitis. 100,105,106,107 We used 
parameters of progression of HIV infection to AIDS and death developed by WHO and 
UNAIDS (Neff Walker, UNAIDS, personal communication). DALYs were age-adjusted and 3% 
discounted. 108 
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Results 
Injection practices 
In the regions considered, the annual ratio of injections per person was 3.4 (Range: 1.7 to 11.3) 
for a total of 16.7 thousand million injections received. Of these, 39.3% (Range: 1.2% - 75.0%) 
were administered with equipment reused in the absence of sterilization (Table 4). The exclusion 
of persons with injection frequencies above the 90th percentile lowered the estimated injection 
frequency in EUR B and EUR C from 5.2 and 11.3 to 2.5 and 3.5, respectively. 
Fraction of new infections attributable to contaminated injections 
In the regions where reuse of injection equipment was reported, the fractions of incident HBV, 
HCV and HIV infections attributable to contaminated injection were 31.9%, 39.9% and 5.4%, 
respectively (Table 4). For HBV, this proportion was highest in the EMR D region (58.3%) and 
lowest in the EUR B (0.9%) region. For HCV, this proportion was highest in the EMR D region 
(81.7%) and lowest in the EUR B region (0.9%). For HIV, this proportion was highest in the 
SEAR D region (24.3%) and lowest in the AMR B region (0%). In absolute numbers of 
infections, our analysis indicated that globally, in 2000, contaminated injections may have caused 
20.6 million new HBV infections, 2.0 million HCV infections and 260 000 HIV infections. 
Estimation of the burden in DALYs 
The 21 million HBV infections in the year 2000 would lead to an estimated 26 492 deaths from 
fulminant hepatitis in the year 2000 and to 49 000 future additional early deaths from the 
consequences of chronic infection between 2000 and 2030 for a total burden of 3 114 539 
DALYs (34% of the burden associated with contaminated injections, Table 5). The two million 
HCV infections in 2000 would lead to 24 000 future early deaths between 2000 and 2030 for a 
burden of 324 198 DALYs (4% of the burden associated with contaminated injections). Finally, 
210 000 of the 260 000 persons infected with HIV through contaminated injections in 2000 are 
expected to die prematurely from AIDS between 2000 and 2030 for a burden of 5 738 942 
DALYs (63% of the burden associated with contaminated injections). The total burden in 2000-
2030 because of contaminated injections in 2000 amounted to 309 492 future early deaths and 
9 177 679 DALYs. 
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Discussion 
In the year 2000, four decades after the widespread availability of single use injection equipment 
and two decades into the HIV pandemic, contaminated injections account for close to one-third 
of new HBV infections, 40% of new HCV infections and 5% of new HIV infections. These 
infections translate to a substantial preventable burden of acute hepatitis, AIDS, hepatocellular 
carcinoma and end-stage liver disease. 
HBV infection is the most common consequence of contaminated health care injections, with 20 
million infections annually. Among the three pathogens examined, HBV is the most prevalent 109 
and the one most easily transmitted through injections. 71 The fractions of new HBV infections 
attributable to injections were compatible with those reported in epidemiological studies, 
including 2% 81 to 73.9% 36 in WPR B (compared with 33.6% in our model), 49.7% 84 to 53.3% 77 in 
SEAR D (compared with 53.6% in our model) and 27.7% 82 to 52% 85 in EMR D (compared with 
58.3% in our model). A number of other sources of infections, including perinatal exposure, 
horizontal transmission among children and unsafe sex explain the HBV infections that are not 
attributable to injections. Overall, the burden of injection-associated HBV infections in terms of 
DALYs is low in comparison to the number of infections. The 20 million HBV infections lead to 
three million DALYs. This was caused by the low rate of progression to chronic infections and 
the delay between infection and death during which infected persons may die from other causes 
of mortality. 
In absolute numbers, HCV infection is the second most common consequence of contaminated 
injections with more than two million infections each year, about ten times less than for HBV. 
However, the fraction of new HCV infections attributable to contaminated injections was higher 
than that for HBV infection. The high attributable fractions that we modelled were compatible 
with those reported in epidemiological studies, including 20.1% 86 to 90.6% 81 in WPR B 
(compared with 37.6% in our model) and 9.9% 87 to 87.9% in EMR D 43 (compared with 81.7% in 
our model). Unlike HBV, HCV is primarily transmitted through percutaneous exposure to 
blood. 110 Perinatal transmission is relatively uncommon. 110 Transmission among sexual partners 
is not efficient, 110,111 although it may account for a higher proportion of infections in 
industrialized countries where percutaneous procedures are generally conducted using sterile 
equipment. 112,113 In some developing countries, including Egypt and Pakistan, unsafe health care 
injections have been major vehicles that transmitted HCV so that it reached high endemic levels 
in the community. 567 In terms of burden of disease, the conservative parameters that we used to 
describe the progression of HCV infection towards chronic liver disease and its consequences are 
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uncertain. The studies we used were conducted in industrialized countries and little is known 
regarding the risk of cirrhosis among infected patients beyond 20 years of follow-up. If the 
parameters used in our model are accurate, injection-associated HCV infections do not constitute 
a major avoidable burden of severe disease between 2000 and 2030. However, if we 
underestimated the severity of the natural history of HCV infection, then countries highly 
endemic for HCV will be confronted with the public health challenge of an ageing population 
with substantial mortality and morbidity related to HCV-associated liver disease during the 21st 
Century. 
Historically, health care injections have not been viewed as a major vehicle of HIV infection. 114 
However, the risk of HIV infection associated with health care exposures may have been 
underestimated in the past. 115 Most nosocomial outbreaks of HIV infection have been reported 
from countries with low prevalence of HIV infection.  1,6,116,117 In other countries where HIV 
infection and poor injection practices are more common, injection-associated HIV infections are 
likely to occur but they have rarely been detected or reported. Our analysis suggests that 
contaminated injections may cause 5.4% of new cases of HIV infections worldwide, representing 
63% of the burden of disease. Few epidemiological studies were available to validate our 
estimates. 115 This lack of information represents a substantial source of uncertainty. In AFR E 
where prospective studies were available, 78,91,92,93 the lowest attributable fraction calculated on the 
basis of the data provided by the authors (8%) 92 exceeds our 2.5% modelled attributable fraction, 
suggesting that our estimate is conservative. In EMR D and in SEAR D, our model suggests that 
the attributable proportion could reach 7.1% and 24.3%, respectively. These high estimates are 
not validated by epidemiological studies and may be overestimated. Beyond concerns relating to 
attributable fractions, unsafe health care injections could transform dendritic HIV transmission 
networks into more effective cyclic ones  (e.g., in the case of the unsafe use of injected antibiotics 
among commercial sex workers). 118,119 Studies assessing the risk factors for HIV infection should 
ensure that data are collected in a way that allows examination of the association between HIV 
infection and various types of injections. In the meantime, HIV prevention programmes should 
communicate the risk of HIV infection associated with health care injections, particularly in Asia 
where the high frequency of unsafe injection practices coincides with emerging HIV epidemics. 
This study is subject to a number of limitations. First, the transmission potentials of HBV, HCV 
and HIV through contaminated injections were obtained on the basis of studies that estimated 
the risk of infection associated with a needle-stick injury. Contaminated injections could have a 
different, either higher or lower, transmission potential. Second, our model only estimated the 
Evidence and information for injection safety policies 49
incidence of infections with HBV, HCV and HIV caused by reuse of injection equipment on one 
patient. It did not take into account the fact that injection equipment can be reused on multiple 
patients, 1 the transmission associated with unhygienic use of multi-dose medication vials 120 and 
the transmission that may occur through cross-contamination while preparing injections 
(Abstract 5). 64 Third, in the absence of data, our analysis did not take into account any theoretical 
“close network effect” by which high injection frequencies and high probability of exposure to 
unsafe practices would not be distributed independently. However, we excluded persons 
presenting with high injection frequencies and adjusted the model for the possibility that persons 
receiving high numbers of injections could already be immune. All these limitations could have 
led to an underestimation or an overestimation of our attributable fractions. Thus, validation of 
these estimates with epidemiological studies is important.  For HBV and HCV, the similar order 
of magnitude between the attributable fractions reported in epidemiological studies and those 
generated by the model suggests that our estimates can be used for decision-making. In the case 
of HIV, uncertainty remains are more information is needed.  
The burden of disease associated with unsafe injections makes it necessary to eliminate 
unnecessary injections and to achieve safe injection practices. WHO proposes that national 
strategies for the safe and appropriate use of injections address behaviour change among health 
care workers and patients, provision of equipment and supplies and sharps waste management. 65 
Such initiatives should not constitute separate programmes but should be integrated into other 
activities, including HIV prevention and care, essential medicines, immunization and health 
systems management. Finally, research is needed to address two key areas of uncertainty. First, 
cohort studies must be conducted to describe the long term natural history of HCV infection, 
particularly in developing countries. Second, epidemiological data are needed to better estimate 
the proportion of HIV infections attributable to contaminated injections in various regions of the 
world. These include (1) careful investigation of cases of HIV infection that could be associated 
to health care exposures and (2) prospective cohort and case-control studies examining all 
potential risk factors for recent HIV infection.  
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Table 4: Injection use, unsafe injection practices and proportion of new infections with HBV, HCV and HIV attributable to unsafe 
injections by region, 2000. 
  Global Burden of Disease regions  
  African  American  Eastern 
Mediter-
ranean  
European  South East Asia  Western 
Pacific  
 
  AFR D AFR E AMR B AMR D EMR D EUR B EUR C SEAR B SEAR D WPR D World 
Injections per person 
and per year 
2.2 2.0 1.7 1.9 4.3 2.5 * 3.5 * 2.1 4.0 2.4 3.4 
Proportion of reuse 19% 17% 1.2% 11% 70% 1.2% 11% 30% 75% 30% 39.8% 
Hepatitis B 
virus 
10.9% 
(8.2%-
13.9%) 
9.2% 
(6.9%-
11.5%) 
2.3% 
(0.0%-
16.3%) 
9.3% 
(0.0%-
26.9%) 
58.3% 
(26.2%-
82.4%) 
0.9% 
(0.0%- 
3.3%) 
7.7% 
(1.8%-
15.0%) 
22.4% 
(16.5%-
28.7%) 
53.6% 
(21.6%-
79.9%) 
33.6% 
(0.0%-
79.0%) 
31.9% 
(9.4%-
56.9%) 
Hepatitis C 
virus  
16.4% 
(12.3%-
20.8%). 
13.0% 
(9.8%-
16.2%) 
0.9% 
(0.0%- 
6.4%) 
9.2% 
(0.0%-
26.7%) 
81.7% ‡ 
(52.1%-
95.0%) 
0.9% 
(0.0%-
3.4%) 
21.2% § 
(6.1%-
34.7%) 
30.8% 
(22.8%-
39.2%) 
59.5% ** 
(40.4%-
93.6%) 
37.6% 
(0.0%-
89.8%) 
39.9% 
(18.2%-
66.7%) 
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HIV 2.5% 
(1.9%- 
3.1%) 
2.5% 
(1.9%- 
3.1%) 
0.2% 
(0.0%- 
1.5%) 
1.5% 
(0.0%- 
4.5%) 
7.1% ‡ 
(5.7%- 
8.5%) 
0.0% 
(0.0%- 
0.0%) 
0.6% 
(0.2%- 
1.2%) 
7.0% 
(5.2%- 
8.9%) 
24.3% †† 
(18.3%-
30.1%) 
2.5% 
(0.0%- 
5.9%) 
5.4% 
(3.9%- 
7.0%) 
                                                 
* Excludes injections received above the 90th percentile. Crude values are 5.2 and 11.3 for EUR B and EUR C, respectively. 
† Lower and upper estimate into brackets 
‡ Study-based relative risk from  EMR D used. 
§ Model-based relative risk from  EUR B that has similar prevalence pattern used. 
** Model-based relative risk from  WPR B that has similar prevalence pattern used. 
†† Study-based relative risk from  EMR D that has similar injection practices and prevalence patterns used. 
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Table 5: HBV, HCV and HIV infections attributable to contaminated injections in 2000 (absolute numbers, lower and upper estimates) 
and secondary disability-adjusted life years (DALYs) projected for 2000 - 2030, by region. 
   
AFR D 
 
AFR E 
 
AMR B 
 
AMR D 
 
EMR D 
 
EUR B 
 
EUR C 
 
SEAR B 
 
SEAR D 
 
WPR B 
 
World 
Number of  
infections 
639 498 
(478 834- 
814 351) 
630 976 
(474 379-
792 536)
14 118
(112-98 872)
28 570 
(16-
82 490)
2 533 443 
(1 140 352-
3 580 611)
21 122
(156
78 639)
193 636
(46 035-
378 229)
942 038
(694 606-
1 205 102)
8 019 210
(3 237 944-
11 954 579)
7 610 161 
(2 126-
17 868 925) 
20 632 772 
(6 074 558-
36 854 335) 
 
 
HBV 
DALYs 80 414 76 163 2 167 4 565 397 486 3 196 32 241 139 408 1 279 719 1 099 179 3 114 539 
Number of  
infections 
54 681 
(41 078- 
69 402) 
54 131
(40 819-
67 794)
2 282
(18-
15 985)
6 304
(4-
18 215)
645 486
(412 078-
750 452)
2 110
(16-
7 729)
35 668 
(10 287-
58 378)
94 873
(70 235-
120 979)
498 166
(338 548-
784 474)
608 200 
(172- 
1 454 478) 
2 001 901 
(913 254- 
3 347 885) 
 
 
HCV 
DALYs 9 283 8 140 352 1 092 113 918 283 3 629 15 261 79 703 92 537 324 198 
Number of  
infections 
18 317 
(13 765- 
23 243) 
64 412
(48 520-
80 759)
305
(2-
2 132)
911
(1-
2 626)
2 210
(1 775-
2 668)
0
(0-
0)
1 526
(374-
2 903
6 260
(4 638-
7 980)
156 663
(118 235-
194 187)
5 549 
(2- 
13 378) 
256 152 
(187 312- 
329 877) 
 
 
HIV 
DALYs 465 948 1 584 279 6 564 21 674 48 297 0 28 863 126 120 3 361 444 95 753 5 738 942 
Total DALYs 555 644 1 668 583 9 083 27 332 559 702 3 479 64 733 280 789 4 720 866 1 287 470 9 177 679 
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Figure 3: Decision tree for the theoretical cohort used for the calculation of the years of life lost (YLLs) from hepatitis B virus infection 
 
Year 0
Year 1
Year 2
Year 3 and subsequent years
Clearance of viral infection
(70% among under 5
94% among 5 and older)
Mortality from other causes at age N
(GBD Life Tables)
Sero-reversion
(1%)
Mortality from other causes  at age N +1
(GBD Life Tables)
Mortality from chronic HBV infection
(Age and sex specific modelled rate)
Follow-up over time using an
annual scenario similar to year 2
(...)
Survival with chronic HBV infection
Survival with chronic
HBV infection
Acute hepatitis
5% under 5 years of age
40% for 5 years of age and older
(0.6% of which fulminant with 70% fatality)
Initial HBV infections at age N
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Figure 4: Decision tree for the theoretical cohort used for the calculation of the years of life lost (YLLs) from hepatitis C virus infection 
 
Year 0
Year 1
Year 1
Year 2-19
Year 20
Year 21
Year 22 and subsequent years
Clearance of viral infection
(37% among under 40
20% among 40 and older)
Mortality from other causes at age N
(GBD Life Tables)
Mortality from other causes  at age N +21
(GBD Life Tables)
Mortality from hepatocellular carcinoma and
chronic liver failure (3.7%)
Follow-up over time using an annual
scenario similar to year 21
Survival with cirrhosis
Survival with cirrhosis
(5% for persons infected before the age of 40 years
20% for persons infected after the age of 40 years)
Survival with chronic HCV infection
(No subsequent death from HCV infection)
(no subsequent cirrhosis)
Mortality from other causes at age N + 20
(GBD life tables)
20 years latency
(Chronic infection with no cirrhosis,
 annual death rate from background
mortality using GBD life tables)
Survival with chronic HCV infection
Initial HCV infections at age N
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Chapter 3: Best practices for injections 
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Introduction 
In transitional and developing countries where unnecessary injections are common, the average 
annual number of health care injections per person was estimated to be 3.7 (this estimate includes 
all health care injections, including those given to diabetics for the administration of insulin, 
Chapter 1).  In addition to being unnecessary, many injections are unsafe. Each year, in the world, 
reuse of injection equipment may cause 20 million infections with hepatitis B virus (HBV), two 
million infections with hepatitis C virus (HCV) and 250 000 human immunodeficiency virus 
(HIV) infections (Chapter 2). These chronic infections lead to a high burden of morbidity and 
mortality (Chapter 2).  
No evidence-based guidelines are available to guide injection providers through the steps they 
should follow to prevent injection-associated infections. Thus, WHO developed best practices 
(Box 1) using the WHO recommended processes to formulate evidence-based guidelines. 
Development process 
Intended users 
The primary audience includes public health professionals, clinicians and infection control 
practitioners. The secondary audience includes injection providers reached through training or 
communication material developed on the basis of these best practices. 
Methods 
Definitions 
The development group defined an injection as a procedure that introduces a substance into the 
body through a piercing of the skin or of a mucosal membrane. Injections may be administered 
with a needle or with needleless devices, including jet injectors. However, for the purpose of 
these best practices, only needle injections were considered. WHO defines a safe injection as one 
that does not harm the recipient, does not expose the provider to any avoidable risk and does not 
result in waste that is dangerous to other people. 
Analysis of the reference definition  
The steering group broke down this reference definition into 24 potentially critical issues (Table 
6). 
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Review of evidence  
The steering group searched the English-language literature using MEDLINE with a list of key 
words. The search terms included injection(s), infection, sterilization, disinfection, vial, ampoule, 
medication, skin (preparation, cleaning, disinfection), hand hygiene, antisepsis, needle-stick(s), 
recapping, sharps (container, collection, disposal). Identified articles were used to select additional 
key and MeSH terms for further searches. Relevant references in identified articles and additional 
studies made available by members of the development group were also reviewed. 
Table 6: Potentially critical issues to prevent infection among injection recipients, 
injection providers and the community 
A. Prevention of infection among injection recipients 
Potential source of contamination  Stage at which contamination may occur Potentially critical issues 
• Sterilization  • Sterilization of injection equipment 
• Storage • Duration and conditions of storage  
• Injection equipment 
• Handling  • Handling of injection equipment 
• Type of medication • Before opening  
• Medication and vial check 
• Swabbing of stopper / neck • During opening 
• Filing and breaking of ampoules and vials 
• Injected substance 
• After opening • Handling of multi-dose vials 
• Site of injection administration • Skin of the recipient • Introduction of the needle 
• Skin preparation 
• Injection preparation area • Environment • Injection preparation 
• Aseptic techniques 
• Hands of the provider • Injection preparation and administration • Hand hygiene 
B. Prevention of infection among injection providers 
Potential exposure source  Stage at which exposure may occur Potentially critical issues 
• During injection administration  • Patient preparation and / or restraint 
• Recapping 
• Needle removal  
• Needle cutting  
• Handling of injection equipment after use 
• Rinsing and dissembling of sterilizable equipment 
• Use of sharps containers  
• Quality of sharps containers 
• Collection of contaminated equipment  
• Improperly disposed of sharps  
• Exposure to the injection 
recipient’s blood through needle-
stick injury 
• Sharps waste management  • Removal of containers used to collect used sharps 
C. Prevention of infection in the community 
Potential exposure source  Stage at which exposure may occur Potentially critical issues 
• Storage of containers used to collect used sharps • Exposure to the injection 
recipient’s blood through needle-
stick injury 
• Sharps waste management  
• Terminal disposition of sharps waste  
Formulation of best practices 
The steering group formulated best practices for each of the potentially critical issues identified. 
Best practices strongly supported by well designed analytical, observational or intervention 
studies were characterized as category I (Box 1). Those supported by theoretical rationale and 
suggestive, descriptive evidence were characterized as category II. Those recommended on the 
basis of expert consensus and theoretical rationale were characterized as category III. For a 
number of other practice issues, best practices were not formulated. However, recommendations 
were formulated on the basis of expert consensus and theoretical rationale. The development 
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group then reviewed a draft and disseminated it for public comment through SIGNpost, the 
electronic forum of the Safe Injection Global Network (SIGN). All comments obtained from this 
peer review process were archived to keep a track of decisions made to modify, or not, the 
document. Finally, a summary was edited and reorganized so that it would be reader-friendly and 
separate the best practices from the other practice issues. 
Analysis of available evidence 
Prevention of infections among injection recipients 
Best infection control practices to prevent infections among injection recipients include the use 
of sterile injection equipment and the prevention of contamination of injection equipment and 
medication. 
Use of sterile injection equipment 
Use of a sterile syringe and needle for each injection and to reconstitute each unit of medication 
is the most essential infection control measure to prevent infection among injection recipients. 
Reuse of injection equipment in the absence of sterilization has been reported from many 
countries (Chapter 1).  These practices have been associated with infections (Chapter 2). 
Use of a new, single use syringe and needle provides the highest level of safety to the recipient. 
However, unreliable and insufficient supplies may lead to reuse.58  Even though boiling for 20 
minutes does not achieve sterilization, 121 use of pans to boil single use injection equipment is 
common in developing and transitional countries. In many instances these pans are used as 
containers of tepid water where injection equipment is simply rinsed and soaked between 
injections.39 While use of injection equipment taken from compromised packages has not been 
associated with infection, it is necessary to use injection equipment that is inspected before use 
for breaches in barrier integrity and discarded if punctured, torn or damaged. 
When new single use injection equipment is not available, equipment designed for sterilization 
may be used. Sterilizable injection equipment is now made of plastic that can undergo steam 
sterilization. A steam sterilization procedure includes initial cleaning, is conducted according to 
WHO recommendations 122 and is controlled using Time, Steam and Temperature [TST] spot 
indicators. 121 Breakdowns in health systems lead to breaks in sterilization procedures.58 Health 
systems using sterilizable injection equipment have poorer injection safety records than those 
using single use equipment 59 and use of sterilizable injection equipment has been specifically 
associated with infections. 86,77 
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Prevention of contamination of injection equipment and medication 
Work environment 
It is important to prepare injections in a clean designated area, where blood or body fluid 
contamination is unlikely. HBV persists for up to seven days on surfaces, 123 potentially leading to 
environmental contamination. Environmental contamination is a potential source of HBV 
infection in chronic hemodialysis settings. 123 Factors that may facilitate HBV transmission 
among patients receiving chronic hemodialysis include (1) a high prevalence of HBV infection, 
(2) an environmental contamination with blood, (3) a high frequency of percutaneous procedures 
and (4) the presence of patients with high levels of viremia. These factors may be found in other 
health care settings because of (1) high HBV endemicity, (2) limited implementation of standard 
precautions, (3) overuse of injections and (4) presence of individuals (e.g., children) replicating 
HBV actively. In Romania, where some of these conditions were present, HBV infection was 
associated with receiving injections in 1998 (Abstract 2).83  However, review of injection practices 
in the country suggested that single use syringes and needles were not reused and that HBV 
transmission was most likely related to preparation of injections in environments potentially 
contaminated with blood or body fluids (Abstract 5). 64,,124 Preparation of injections in 
contaminated environments may also lead to bacterial infection 125 and cause infections among 
injection drug users (Abstract 6, Abstract 9). 126 
Multi-dose vials 
It is important to use single-dose vials rather than multi-dose vials whenever possible. While 
preservatives decrease the survival of bacteria, 127 multi-dose vials remain prone to bacterial 
contamination. 125,128,129 Use of multi-dose vials were reported as a potential source of infection in 
19 studies (Table 8, Abstract 8). 9,120,125,128,130,131,132,133,134,135,136,137,138,139,140,141,142,143 In two episodes, a 
needle had been left in the septum of the vial. 131,136 Needles left in the septum of multi-dose vials 
may facilitate use of the same syringe to repeatedly draw medications for one patient, a practice 
that may lead to vial contamination 129 and infections among subsequent patients. 136 Thus, if 
multi-dose vials must be used, it is essential to pierce the septum with a sterile needle and 
important not to leave any needle in place in the stopper. 
Breaking of vials and ampoules 
Injection providers may lacerate their hands while opening glass ampoules. 144 These lacerations 
may bleed and cause infections. 145 Thus, it is important to use pop-open ampoules rather than 
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ampoules that require the use of a metal file to open them, and to protect fingers with a clean 
barrier (e.g., small gauze pad) when opening ampoules that require a metal file to open. 
Compromised packaging 
Cracks and leaks represent a potential source of contamination for medications. 146 While the 
effectiveness of a visual examination of the vial is unknown, it is necessary to inspect for and 
discard medications with visible contamination or breaches of integrity (e.g., cracks, leaks) and to 
follow product-specific recommendations for use, storage and handling. 
Aseptic techniques 
Medical devices may be contaminated with bacteria if touched. Thus, it is necessary that a needle 
that has touched any non-sterile surface be discarded. 
Other practice issues 
Provider's hand hygiene and skin integrity 
Hand hygiene (i.e., washing or disinfecting hands) is a standard procedure before preparing 
injection material. Injections have been administered in the absence of hand washing and without 
causing infection among diabetic patients. 147 The need for hand hygiene between each injection 
will vary based on the setting and whether there was contact with soil, blood or body fluids. Skin 
lesions and skin irritation are associated with bacterial contamination. 148 Thus, it is necessary to 
avoid giving injections if skin integrity is compromised by local infection or other skin conditions 
(e.g., weeping dermatitis) and to cover any small cut. 
Swabbing vial tops or ampoules 
Swabbing of vial tops or ampoules with an antiseptic or disinfectant is unnecessary. 125,149 Cotton 
balls and gauze stored wet in antiseptics may become contaminated and have contributed to 
infections among patients, particularly when benzalkonium chloride was used. 130,150,151 Thus, if 
swabbing with an antiseptic is selected for use, it is necessary to use a clean, single use swab and 
to maintain product-specific recommended contact time. Cotton balls stored wet in a multi-use 
container must not be used. 
Skin preparation before injection 
While skin that is visibly soiled or dirty must be washed, swabbing of the clean skin before giving 
an injection is unnecessary. Studies did not report an increased risk of infection when injections 
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are given in the absence of skin preparation (Table 7). 147,149,152,153,154,155 Bacteria from the skin flora 
may be introduced through skin piercing. 155 However, the majority of these bacteria are non-
pathogenic and the number introduced is lower than the minimal infectious dose for pus 
formation. 156 Skin preparation protocols traditionally used, including wiping with 70% alcohol, 
may be insufficient to eliminate the skin flora because of a limited contact time 154,157 While the 
benefit of skin preparation is unclear, unsafe skin preparation protocols may be harmful. 150,151 
Thus, if swabbing with an antiseptic is selected for use, it is necessary to use a clean, single use 
swab and to maintain product-specific recommended contact time. Cotton balls stored wet in a 
multi-use container must not be used. 
Table 7: Studies reporting insulin injections given to diabetic patients with or without 
skin preparation* 
Author Follow-up Study type Physical 
examination 
of injection 
sites 
Number 
of patients
Skin 
preparation 
protocol 
Number of 
injections 
without skin 
preparation 
Number of 
injections with 
skin 
preparation 
Number of 
infections at 
injection site 
Fleming 152 0.5-59 
years 
Retrospective No 21 N/A† 66 807‡ N/A† 0 
 
Fleming 152 20 weeks Prospective Yes 42 Alcohol  7,275‡ 6445 0 
 
McCarthy 153 N/A Prospective Yes 50 1) Alcohol 
 
2) Tap water 
600§ 1) 600§ 
 
2) 600§ 
0 
Borders 147 1 week Retrospective Yes 47 N/A† N/A† N/A† 0 
Stepanas 155 ≥ 1 week Prospective No 3 N/A† N/A † N/A† 0 
Koivisto 154 3-5 
months 
Prospective Yes 13 70% alcohol Over 1700 Over 1700 0 
Prevention of infections among injection providers 
Injuries from sharp devices have been associated with transmission of more than 40 pathogens, 
including HBV, HCV and HIV. 158,159 
Prevention of needle-stick injuries to the provider  
Best infection control practices to prevent infections among injection providers address the 
prevention of patient movements, the prevention of unsafe recapping and the collection of 
contaminated sharps in puncture and liquid-proof containers. 
                                                 
* Assuming that 0.01% of injections with skin preparation would lead to infection, a power calculation suggests that the pooled data would allow 
the detection of a relative risk of 12.5 or higher with a power of 80% and an alpha risk of 5%. 
† Not available. 
‡ Injections given through clothing. 
§ Individual patients reused their own injection equipment. 
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Patient movements 
Needle-stick injuries during injections are usually attributable to abrupt patient movement during 
the procedure (Abstract 1). 159,160 Thus, it is important that providers anticipate and take measures 
to prevent sudden patient movement during and after injection. In some instances, physical 
assistance from other health care workers or family members may help in ensuring that the 
procedure is carried out under appropriate circumstances. 
Recapping and other hand manipulation of used needles 
Avoiding recapping and other hand manipulations of used needles (e.g., rinsing and dissembling 
of sterilizable equipment) is essential to prevent needle-stick injuries. In one study describing the 
epidemiology of needle-stick injuries, 2.8% of all injuries were attributed to cleaning of surgical 
equipment. 161 In countries where injection providers have to dissemble injection devices after use 
(e.g., Mongolia, Uzbekistan), needle-stick injuries are common. (Abstract 16, Jean Pierre Stamm, 
Swiss cooperation, personal communication) Also, high proportions of needle-stick injuries are 
attributable to two-handed recapping. 159 Teaching of the one-handed, scooping-resheathing-
recapping technique was effective in reducing the risk of recapping-related needle-stick injuries in 
one study. 162 Thus, it is essential to use the single-handed scoop technique if recapping is 
necessary (e.g., in circumstances where a sharps container is not available). 
Sharps collection 
It is important to collect and properly contain syringes and needles at the point of use in a sharps 
container that is puncture- and leak-proof and that is sealed before completely full. Unsafe sharps 
waste collection causes between 5% and 28% of needle-stick injuries. 160,161 Puncture- and liquid-
proof containers designed for the collection of contaminated sharps are associated with a lower 
risk of needle-stick injuries than regular cardboard boxes. 163 Presence of sharps containers close 
to the point of use reduces the incidence of recapping 164,165 and of recapping-related needle-stick 
injuries. 166,167 Interventions that combine provision of sharps containers and risk 
communications decrease the total number of needle-stick injuries. 160,168 
Other practice issues 
Engineered technologies 
Current hypodermic needles and syringes with safety features to prevent needle-stick injuries 
require a provider-dependent activation step. Their effectiveness is unclear. 169,170,171 None are able 
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to protect the provider when giving an injection as the safety feature is only activated after use. 
Reports on the effectiveness of other safer needle-bearing devices (e.g., intravenous catheters, 
phlebotomy needles) to protect health care personnel from needle-sticks are 
encouraging. 172,173,174,175 Thus, whenever possible, devices designed to prevent needle-stick injury 
that have been shown to be effective for patients and providers are preferable. 
Prevention of infections in the community 
Contaminated sharps are a potential source of biohazard to the community at large. To prevent 
these exposures, it is important to seal sharps containers for transport to a secure area in 
preparation for disposal. 176 After closing and sealing, sharps containers must not be opened, 
emptied, reused or sold. In South Asia, used injection equipment is sought for recycling, mostly 
for the plasticware industry (Abstract 15). 177 Such practices may lead to needle-stick injuries 
among waste pickers and can lead to illegal repackaging of syringes for reuse in health care 
settings. Finally, it is important to manage sharps waste in an efficient, safe and environment-
friendly way. Contaminated sharps could be observed in the immediate surroundings of a high 
proportion of health care facilities in developing countries.59 Such unsafe sharps waste 
management expose the community to needle-stick injuries. 178 
Discussion 
We used WHO recommended processes to formulate best infection control practices for 
intradermal, subcutaneous and intramuscular injections and address the use of sterile injection 
equipment, the prevention of contamination of injection equipment and medication, the 
prevention of needle-stick injuries to the provider and the prevention of access to used needles. 
In addition, we addressed other practice issues of relevance to injection providers. Although we 
addressed the safety of injections from the perspectives of injection recipients, injection providers 
and communities, the burden of disease associated with unsafe injections is of a different 
magnitude among these three groups. In 2000, WHO estimated that contaminated injections may 
have caused 260 000 HIV infections among injection recipients (Chapter 2) while needle-stick 
injuries may have caused 1 000 HIV infections among injection providers. 179 No estimates are 
available regarding the burden of disease among the general population associated with unsafe 
sharps waste disposal; the low frequency of needle-stick injuries in this group suggests that it 
would be of an even lower magnitude.  Thus, making injections safe to the injection recipients 
should be the first priority from a public health point of view. Sharps waste management 
Evidence and information for injection safety policies 64
addresses a smaller burden of disease and may require the setting up of an infrastructure. Careful 
planning and integration throughout the health sector will limit costs and ensure sustainability. 
The best practices do not constitute a standard for regulatory purposes or prescriptive guidelines. 
Rather, they distill critical steps believed to prevent injection-associated infections for resource-
limited settings. While this approach removes some elements that could make them directly 
applicable to a particular setting, it allows adaptation by specific programmes or countries on the 
basis of practicality, feasibility or cost-effectiveness issues. For example, the recommendation to 
avoid multi-dose vials is not applicable in immunization services that make extensive use of them 
in developing countries. However, when multi-dose vials are used in immunization services, 
specific messages to providers will ensure their safe use. 
These best practices did not address the use of specific engineered technologies, allowing the 
development group to avoid issues that could lead to actual or perceived conflicts of interest. 
Newer technologies supporting a safer use of injections have been developed. These include 
auto-disable (AD) syringes that inactivate themselves after one use (mostly for immunization and 
family planning services) and single use injection devices with other re-use prevention features 
(for therapeutic applications). A policy statement from WHO and UNICEF already recommends 
the exclusive use of AD syringes in immunization services. 180 For therapeutic applications, two 
research questions need to be addressed before best practices could recommend the generalized 
use of devices with reuse prevention features. First, there is a need to assess the user acceptability 
of these syringes in various settings. Second, their field effectiveness in eliminating re-use of 
injection equipment needs to be documented. Other safety mechanisms have been proposed to 
prevent needle-stick injuries. Policy decisions to recommend the use of these devices need to 
analyze in a cost-effectiveness evaluation (1) the probability of achieving safe practices in the 
absence of the device, (2) the effectiveness of the device in the setting where use is being 
considered and (3) the incremental cost involved. 
These best practices do not include a recommendation to prepare the skin with an antiseptic. 
Skin preparation protocols have an influence on the risk of infection for intravenous catheters. 181 
However, in this case, baseline rates of infections are higher and most infections are presumed to 
result from inward migration of bacteria from the insertion site. 181 Among injection drug users, 
skin cleaning may be associated with a lower risk of bacterial infections. 152 
These best practices have a number of limitations. First, the scope of the document was limited 
to intradermal, subcutaneous and intramuscular injections that constitute the majority of 
injections and that are homogeneous in terms of infection control requirements. Second, because 
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infections constitute the most common adverse effect associated with injections, the scope of 
these best practices was restricted to infection control and did not address other recommended 
practices (e.g., ensuring that the right dose of injection is given to the right patient, at the right 
time, etc.). Third, quality of medications and equipment was not addressed, as it depends upon 
national regulatory authorities rather than upon injection providers. Fourth, in the absence of 
data, the practice of removing needles after injections to collect sharps waste separately was not 
addressed. Disassembling injection equipment may cause needle-stick injuries. 159 In addition, it is 
unclear whether removing needles might produce splatters and aerosols as needle cutters do. 182 
Thus, safety evaluations are needed before this practice can be recommended. In January 2004, 
WHO conducted an informal consultation to define the research agenda that is needed for WHO 
to address needle removers in a future revision of these best practices. Fifth, while calling for a 
reduction of injection overuse, our best practices do not provide details regarding the strategies 
proven effective in reducing the use of injections. Additional details regarding the rational use of 
injections may be obtained from the WHO Department of Essential Drugs and Medicine policy.  
WHO will promote the use of these best practices to prevent injection-associated infections. 
Pictograms (Figure 5) were developed to illustrate each of the steps. The best practices are also 
used as a reference for a WHO set of education tools and for a tool to assess injection safety in 
health care facilities. To ensure that these best practices continue to be useful, users of the 
document should continue reviewing scientific literature for new information and WHO will plan 
for revisions using the same methodology five years after the initial development, i.e. in 2005. 
Figure 5: Three pictograms illustrating selected best practices, including (1) the use of 
new single use equipment, (2) the collection of dirty sharps in safety boxes and (3) the 
safe sharps waste management. 
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Table 8: Epidemiological studies reporting an association between infections and use of multi-dose vials 
Author  Pathogen Infection Number 
infected 
Type of 
study 
Positive 
vial 
culture 
Reported practices 
Inman 133 Mycobacterium abscessus Abscess 12 Descriptive  N/A*  Reuse of syringes among different patients and 
decanting 
Kothari 140 Pseudomonas  Septic 
Arthritis 
1 Descriptive  Yes N/A* 
Black 138 Streptococcus  Abscess 1 Descriptive  Yes N/A* 
Borghans 131 Mycobacterium chelonei Abscess 47 Descriptive  N/A * Permanent insertion of a needle, reuse of aspiration 
needle, reuse of injection needles after boiling, 
storage of residual vaccine for successive sessions 
and use of petroleum ether for skin preparation 
Cabrera 134 Pseudomonas  Bloodstream 
infection 
5 Descriptive  Yes Use of multi-dose vials of saline for preparation of 
injectable medications 
Katzenstein 120 HIV HIV 
infection 
1 Descriptive  N/A * Use of multi-dose vials changed daily, repeated 
aspiration of medication for one patient followed 
by discarding of vial, aspiration needles discarded 
after use for individual patients 
Kidd-Lungren 136 HBV HBV 
infection 
2 Descriptive  N/A * Permanent insertion of a needle and reuse of 
syringe to draw medication 
Philipps 128 Streptococcus Peritonitis 1 Descriptive  Yes Stopper wiped with antiseptic  
Widell 137 HCV HCV 
infection 
10 Descriptive  N/A * N/A* 
Widell 137 HCV HCV 
infection 
9 Descriptive  N/A * N/A* 
Massari 138 HCV HCV 
infection 
4 Descriptive  N/A * Administration of medications in an IV line without 
an anti-reflux valve 
Greaves 135 Streptococcus Abscess 7 Analytical  Yes Skin preparation with cotton balls soaked in alcohol
Alter 63 HBV HBV 
infection 
10 Analytical  N/A Vials shared among patients †, medications prepared 
by patients and multi-dose vials not discarded at 
end of day 
                                                 
*  Not available. 
† In a hemodialysis unit. 
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Author  Pathogen Infection Number 
infected 
Type of 
study 
Positive 
vial 
culture 
Reported practices 
Archibald 9 Enterococcus  Bloodstream 
infection 
6 Analytical  N/A * Stoppers wiped with povidone-iodine, introduction 
of needles before drying of povidone-iodine, no 
hand hygiene and cluttered work surfaces 
Grohskopf 143 Serratia  Bloodstream 
infection 
20 Analytical  Yes Pooling of residual medications for reuse  
Krause 142 HCV HCV 
infection 
4 Analytical  N/A * N/A* 
Nakashima 130 Serratia  Arthritis 8 Analytical  Yes Storage of filled syringes for use during next day, 
stoppers and skin wiped with cotton balls soaked in 
benzalkonium chloride, rinsing of storage canisters 
with tap water, no hand hygiene and no use of 
gloves 
Oren 131 HBV HBV 
infection 
5 Analytical  N/A * Preparation of multi-dose heparin and saline 
solution, changed daily 
Simon 125 Streptococcus Abscess 8 Analytical  N/A * Handling in contaminated areas, stopper wiped 
with sterile cotton soaked in alcohol and use of 
sterile single use needles and syringes 
Stelter 141 Streptococcus Abscess 12 Analytical  N/A * Stopper and skin wiped with cotton balls soaked in 
alcohol 
Stelter 141 Streptococcus Abscess 7 Analytical  Yes Stopper and skin wiped with disposable alcohol 
swabs 
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Box 1: Summarized best infection control practices for intradermal, 
subcutaneous and intramuscular needle injections 
Eliminating unnecessary injections is the highest priority to prevent injection-associated 
infections. When injections are medically indicated, they should be administered safely. These best 
practices are measures that have been determined through scientific evidence or expert consensus most 
effectively to protect patients, providers and communities. 
1. Use sterile injection equipment * 
• Use a sterile syringe and needle for each injection and to reconstitute each unit of medication. *† 
• Ideally, use a new, single use syringe and needle. * Inspect packaging for breaches in barrier 
integrity. Discard a needle or syringe if the package has been punctured, torn or damaged. ‡ 
• If single use syringes and needles are unavailable, use equipment designed for steam sterilization. 
Sterilize equipment according to WHO recommendations and document the quality of the 
sterilization process using Time, Steam, Temperature (TST) spot indicators. ‡ 
2. Prevent contamination of injection equipment and medication 
• Prepare each injection in a clean designated area, where blood or body fluid contamination is 
unlikely. † 
• Use single-dose vials rather than multi-dose vials. † If multi-dose vials must be used, always pierce 
the septum with a sterile needle. * Avoid leaving a needle in place in the stopper of the vial.  † 
• Select pop-open ampoules rather than ampoules that require use of a metal file to open. If using an 
ampoule that requires a metal file to open, protect fingers with a clean barrier (e.g., small gauze pad) 
when opening the ampoule. † 
• Inspect for and discard medications with visible contamination or breaches of integrity (e.g., cracks, 
leaks). ‡ Follow product-specific recommendations for use, storage and handling. ‡ Discard a needle 
that has touched any non-sterile surface. ‡ 
3. Prevent needle-stick injuries to the provider 
• Anticipate and take measures to prevent sudden patient movement during and after injection. † 
                                                 
* Category I: Strongly recommended and strongly supported by well-designed experimental or epidemiological studies. 
† Category II: Recommended on the basis of theoretical rationale and suggestive, descriptive evidence. 
‡ Category III: Recommended on the basis of expert consensus and theoretical rationale. 
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• Avoid recapping and other hand manipulations of needles. If recapping is necessary, use a single-
handed scoop technique. * 
• Collect used syringes and needles at the point of use in an enclosed sharps container that is 
puncture- and leak-proof and that is sealed before completely full. † 
4. Prevent access to used needles 
• Seal sharps containers for transport to a secure area in preparation for disposal. After closing and 
sealing sharps containers, do not open, empty, reuse or sell them. † 
• Manage sharps waste in an efficient, safe and environment-friendly way to protect people from 
voluntary and accidental exposure to used injection equipment. † 
5. Other practice issues ‡ 
• Engineered technology. Whenever possible, use devices designed to prevent needle-stick injury 
that have been shown to be effective for patients and providers. Auto-disable (AD) syringes are 
increasingly available to prevent reuse of injection equipment in selected settings, including 
immunization services. 
• Provider's hand hygiene and skin integrity. Perform hand hygiene (i.e., wash or disinfect hands) 
before preparing injection material and giving injections. The need for hand hygiene between each 
injection will vary based on the setting and whether there was contact with soil, blood or body 
fluids. Avoid giving injections if skin integrity is compromised by local infection or other skin 
conditions (e.g., weeping dermatitis). Cover any small cuts. 
• Gloves. Gloves are not needed for injections. Single use gloves may be indicated if excessive 
bleeding is anticipated. 
• Swabbing of vial tops or ampoules. Swabbing of clean vial tops or ampoules with an antiseptic 
or a disinfectant is unnecessary. If swabbing with an antiseptic is selected for use, use a clean, single 
use swab and maintain product-specific recommended contact time. Do not use cotton balls stored 
wet in a multi-use container. 
• Skin preparation before injection. Wash skin that is visibly soiled or dirty. Swabbing of the clean 
skin before giving an injection is unnecessary. If swabbing with an antiseptic is selected for use, use 
a clean, single use swab and maintain product-specific recommended contact time. Do not use 
cotton balls stored wet in a multi-use container. 
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Members of the injection safety best practices steering group and development 
group 
The steering group and the development group approved these best practices. 
Steering group 
Yvan Hutin (Injection Safety, WHO), Anja Hauri (Injection Safety, WHO), Linda Chiarello 
(Epidemiologist, CDC), Mary Catlin (Research Specialist, University of Arizona Cancer Center), 
Barbara Stilwell (Behavioural Science and Methodology, WHO), Tesfa Ghebrehewit (Nursing and 
Health Policy Adviser, ICN) and Julia Garner (Infection Control Consultant, WHO). 
Development group 
Baheeja Abdulla  (Infection Control Officer, Salaminya Medical Complex, Bahrain), Naima Al-Gasseer 
(Nursing and Midwife Services, WHO), Aranya Chaowalit (Dean, Faculty of Nursing, Prince of 
Songkla University, Thailand), Cynthia Chasokela (Director of Nursing Services, Ministry of Health and 
Child Welfare, Zimbabwe), John Nicolas Crofts (Deputy Director, Macfarlane Burnet Centre for 
Medical Research, Australia), Philippe Duclos (Immunization Safety, WHO), Pilar Gavinio (Hepatitis C 
Prevention, WHO), Catherine MacCaulay (Senior Quality Assurance Advisor, The Quality Assurance 
Project, USA), Henry Francis, Director, (Center on AIDS and Other Medical Consequences of Drug 
Abuse, National Institute on Drug Abuse, USA), Annette Pruess (Health Care Waste Management, 
WHO) and Arnaud Tarantola (Medical Officer, Groupe d’Etude sur le Risque d’Exposition des 
Soignants aux agents infectieux [GERES], France). 
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Chapter 4: The effectiveness of interventions to improve injection 
use  
 
"I am old and cannot sleep forever like the young, nor hope that death will be novelty but endless wakefulness. 
When I put down my work and go to bed: how much of what we did was good? Everything seems to move beyond 
our remedy. Come shield this wound. At this hour, nothing can be done, just before dawn the birds begin, the 
warblers who prefer the dark, the caged birds answering: to work. Outside this room, the chill of grace lies heavy on 
the morning grass. " 
Chou En Lai final aria 
“Nixon in China” 
John Adams, composer 
Alice Goodman, libretto  
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Introduction 
Poor injection practices, including injection overuse and unsafe techniques have been reported 
worldwide.1 However, in developing and transitional countries, the cost associated with poor 
injection practices is particularly high. WHO's Global Burden of Disease study for the year 2000 
suggests that each year reuse of injection equipment in the absence of sterilization may cause 22 
million cases of hepatitis B virus (HBV) infections (30% of the total), two million cases of 
hepatitis C virus (HCV) infections (40% of the total) and 260 000 cases of HIV infection (five 
percent of the total, Chapter 2). In addition, epidemiological studies suggest that unsafe injections 
were a dominant vector for the introduction of HCV at high endemic levels in some countries, 
including Egypt and Pakistan. 67,5,39 According to the "first do no harm" principle, these infections 
associated with unsafe injections are unacceptable and should be prevented. 
While the public health consequences of unsafe injection practices have become indisputable, the 
solutions that could be brought to the problem may appear unclear or difficult to achieve.183 
Injection overuse appears to many public health professionals as an overwhelming plague of 
health systems.49 Studies have indicated that in most cultures, injecting a substance into the body 
has been re-interpreted according to the local social and anthropological context so that 
injections have become procedures that patients appreciate and ask for.3 However, other studies 
clearly indicate that reduction of injection use is an attainable goal if communication between 
patients and health care providers is improved.52 Similarly, safe injection practices, including the 
"one syringe, one patient" rule seemed so out of reach with standard single use syringes that 
innovative technological solutions were sought to design injection equipment that disables itself 
after a single use.184 However, simple solutions, including ensuring universal access to sufficient 
quantities of single use injection equipment are underused (Abstract 5).58  
To recommend successful strategies for national policies for the safe and appropriate use of 
injections, we identified, reviewed and produced a synthesis of studies that provided evidence 
regarding the effectiveness of interventions aimed at the reduction of injection use and the 
decrease in unsafe use of injections in various health systems. 
Methods 
Literature search 
We searched electronic databases including “Medline” (1966 to 2001), “Healthstar” (1975 to 
2001), "Embase Psychiatry" (1990 to 2001) and the “Cochrane” library. Cochrane Evidence 
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Based Medicine Reviews included the "Cochrane" Database of Systematic Reviews until 2001, 
ACP Journal Club (1991 to October 2001), the Database of Abstracts of Reviews of 
Effectiveness until 2001 and the "Cochrane" Controlled Trials Register until 2001. In addition, 
we included WHO reports and unpublished assessments made available to WHO through the 
International Network for the Rational Use of Drugs (INRUD).185 Studies were included 
regardless of languages. 
Selection of studies 
We selected studies that contained quantitative and qualitative information on the effect of 
interventions on injection use and injection safety. In addition, we restricted the review to studies 
that provided information on study design, type of interventions, targeted participants and 
targeted behaviours.  
Ranking of the quality of the evidence 
We ranked all studies in four categories according to the level of evidence provided (Table 9). 
Category one (highest quality) included randomized controlled trials. Category two included non-
randomized controlled trials, before-after comparisons with control groups and controlled 
interrupted time series. Category three included before-after comparisons and time series without 
control groups. Category four (lowest quality) included historical comparisons. 
Table 9: Ranking of studies according to quality of evidence 
Level of evidence * Selected study designs n (%) 
Category 1  Randomized controlled trials  4 (19%) 
Category 2  Non-randomized controlled trials  
Before-after comparison with control groups 
Controlled interrupted time series 
5 (24%) 
Category 3  Before-after comparison without control groups 
Uncontrolled time series studies 
9 (48%) 
Category 4  Historical comparisons 2 (10%) 
Information collected  
We collected information on the characteristics of the interventions in an electronic database. 
Information abstracted included study identification, country, setting (e.g., facility or population 
based), study type, study objectives, sampling units, sampling methods, sample size, age group, 
gender, type and characteristics of interventions, frequency and duration of delivery of 
                                                 
* 1 denotes highest quality and 4 denotes lowest quality. 
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interventions, target population, coverage, time interval between two assessments, indicators used 
and change in these indicators. Interventions aiming at modifying the practices of health care 
workers were characterized as training or interactive communication. Interventions that aimed at 
educating the population or at increasing access to safe injection equipment were characterized as 
such. 
To measure the effectiveness of interventions to reduce injection use, we used prescription-based 
indicators (e.g., the proportion of prescriptions including at least one injection) 186 and 
population-based indicators (e.g., the self-reported annual number of injections per person). To 
measure the effectiveness of interventions to reduce unsafe use of injections, we used the 
proportion of injections given with injection equipment reused in the absence of sterilization. We 
did not consider other practices that may also lead to a risk to the injection recipient (e.g., 
inappropriate use of multi-dose vials), the injection provider (e.g., unsafe sharps waste collection) 
and the community (e.g., unsafe sharps waste management). 
The effect size in the intervention group was calculated as the difference between the value of the 
indicator before and after the intervention. In studies where a trial design or a before-after 
comparison with the control group was used, the effect size was calculated as the gain in the 
intervention group, i.e. the difference between the percent improvement in the intervention 
group and the percent improvement in the comparison group: 
Effect size = (%after - %before) intervention – (%after - %before)control 
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Table 10: Summarized characteristics of studies assessing the effectiveness of interventions aimed at reducing injection use * 
   Characteristics of the intervention    Decrease in injection use  
in intervention group 
Author,  
Reference 
Country Year † Training of 
providers 
Interactive 
communication 
with providers 
Education of the 
population 
Type of study 
(design) 
Quality of 
evidence  
(Category) ‡ 
Indicator Absolute impact Gain over control 
group 
Agyepong 188 Ghana 1996 Continuous Once No RCT § 1 Prescription-based ‡‡ -4% -7% 
Bexell 187 Zambia 1992 Multiple 
sessions 
Multiple sessions No RCT § 1 Prescription-based ‡‡ -3% -7% 
Kafle 189 Nepal 1995 Continuous Multiple sessions No RCT § 1 Prescription-based ‡‡ -5% -10% 
Prawitasari 52 Indonesia 1996 Once Once Once RCT § 1 Prescription-based ‡‡ -27% -19% 
Casado 193 Spain 1993 Once Continuous No Non-R CT § 2 Prescription-based ** -23% -19% 
Kafuko 192 Uganda 1997 Continuous Continuous No Before-after 
/control 
2 Prescription-based ‡‡ -6% -7% 
Ofori-Adjei 190 †† Ghana 1995 Once Once No Before-after 
/control 
2 Prescription-based ‡‡ -1% 0% 
Thuo 191 §§ Kenya 1997 Multiple 
sessions 
Multiple sessions No Before-after 
/control 
2 Prescription-based ‡‡ -3% +3% 
Widyastuti 194 Indonesia 1997 No Continuous No Before-after 
/control 
2 Prescription-based ‡‡ -39% -27% 
Ahmed 201 ‡ Pakistan 1999 Multiple 
sessions 
Multiple sessions Yes Before-after 3 Population-based *** -19% N/A 
Audi 196 Kenya 1997 Once Once No Before-after 3 Prescription-based ‡‡ -4% N/A 
                                                 
* By decreasing order of study quality. 
† Year of publication. 
‡ Ranking according to type of studies, quality of data and evidence (1=highest / 4=lowest quality); 1: randomized controlled trials; 2: non-randomized controlled trials, before-after  comparisons with control group; 3: before-
after comparisons and time series study without control group; 4: historical comparisons. 
§ Randomized control trial. 
** Proportion of prescriptions including at least one injected antibiotic. 
†† Addressed injection use for the treatment of malaria. 
‡‡ OT8 indicator: Proportion of prescriptions including at least one injection. 
§§ Addressed injection use in inpatient settings. 
*** Proportion of the population reporting at least one injection in the last year. 
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   Characteristics of the intervention    Decrease in injection use  
in intervention group 
Author,  
Reference 
Country Year Training of 
providers 
Interactive 
communication 
with providers 
Education of the 
population 
Type of study 
(design) 
Quality of 
evidence  
(Category) * 
Indicator Absolute impact Gain over control 
group 
Birrel 195 Tanzania 2000 Once Continuous No Before-after 3 Prescription-based ‡‡ -3% N/A 
Brook 202 USA 1976 Continuous Once No Before-after 3 Prescription-based † -25% N/A 
Christensen 197  Uganda 1990 Once Once No Before-after 3 Prescription-based ‡‡ -9% N/A 
Luby 60 ‡ Pakistan 2002 No No Continuous Before-after 3 Population-based § -7% N/A 
Luby 200 Pakistan 2002 Multiple 
sessions 
Multiple sessions No Before-after 3 Population-based ** -14% N/A 
Ogwal-Okeng 198 Uganda 1997 Continuous Multiple sessions No Before-after 3 Prescription-based ‡‡ -13% N/A 
Santoso 203 Indonesia 1994 Multiple 
sessions 
Multiple sessions No Time series 3 Prescription-based ‡‡ -53% N/A 
Vos 199 Tanzania 1998 Once No Continuous Before-after 3 Prescription-based ‡‡ -1% N/A 
                                                 
* Ranking according to type of study, quality of data and evidence (1=highest / 4=lowest quality); 1: randomized controlled trials; 2: non-randomized controlled trials, before-after  comparisons with control group; 3: before-
after comparisons and time series study without control group; 4: historical comparisons. 
† Number of injections prescribed per visit. 
‡ Also addressed the reduction of unsafe use. 
§ Proportion of the population reporting more than five injections in the last year. 
** Proportion of the population reporting one injection in the last two weeks. 
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Results 
We selected 21 studies for the review. This included 10 articles, three abstracts and eight 
unpublished reports. Nineteen studies reported information on the effectiveness of interventions 
aimed to reduce injection use (Table 10), five reported the effectiveness of interventions aimed to 
decrease the unsafe use of injections (Table 11) and three reported interventions that combined 
both objectives. Four studies (19%) presented category one evidence.52,187,188,189 Five studies 
presented category two evidence (24%). 190,191,192,193,194 Nine studies (48%) presented category three 
evidence. 60,52,194,195,196,197,198,199,200,201,202,203 Two studies (10%) presented category four evidence.64,204 
Finally, we separately examined the effectiveness of an additional intervention that compared 
intervention and control areas after an intervention because measurement of effectiveness could 
not be directly compared with the others.205 
Effectiveness of interventions aimed at reducing injection use  
Interventions that aimed at reducing injection use were based upon communication strategies 
that included training of providers (n=17), interactive communication with providers (n=17) and 
education of the population (n=4, Table 10). Activities to train providers included the 
development and distribution of guidelines, workshops and seminars. Interactive communication 
with providers included interactive problem-based discussions, role play, focus group discussions 
to develop treatment norms, continuous assessment and feedback, monitoring of progress 
(including peer review systems to verify prescription against medical guidelines), on site visits for 
verbal case review and discussions during staff meetings. A unique intervention consisted in what 
was referred to as "interactive group discussions" that brought together patients and health care 
workers so that prescribers could be confronted with the absence of expressed preference for 
injections in the population.52 Education of the population mostly consisted in health education 
programmes with production and distribution of Information, Education and Communication 
(IEC) material, announcements during religious gatherings and small group discussions. One 
single study used financial incentives to influence prescribers' behaviours through a link between 
use of injections and reimbursement policies.202 Indicators used were prescription-based in 17 
cases and population-based in two cases. The average length of follow-up was 12.2 months 
(Range: 3-48). 
The reduction of injection use reported ranged from 1% to 53% with a gain in controlled studies 
ranging from 3% to 27%. This reduction in injection use was smaller for studies of better quality 
although the difference was not statistically tested (4%, 6% and 13% median reduction in 
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category 1, 2 and 3, respectively). The 15 interventions that solely targeted providers 
187,188,189,190,191,192,193,194,195,196,197,198,200,202,203 reduced injection use by a median of 6% (range 1-53%). 
The four studies that targeted the general population in addition to providers 52,60,199,201 reduced 
injection use by a larger magnitude (median: 16%, range 7-27%). The two studies from 
industrialized countries (Spain and USA) reported a higher effectiveness for interventions to 
reduce injection use (median reduction: 24%) than the 17 studies from developing countries 
(median reduction: 7%, range: 1-53%). The additional study that could not be included in the 
table compared areas with and without an intervention that consisted in (1) seminars and (2) 
supply of drug ration kits restricting access to unnecessary injectable medications. The 
intervention area had a statistically significant lower proportion of prescriptions that included at 
least one injection (25%) than the control areas (58%). Interestingly, the authors concluded that 
the restriction of the range of drugs available in the drug ration kits probably had a greater 
influence than did training alone on improved drug use.205 
Effectiveness of interventions aimed at reducing unsafe injection practices 
Interventions aimed at reducing unsafe injection practices used communication strategies that 
included training and/or education of providers (n=3), provision of safe injection equipment 
(n=2) and education of the population (n=4). Indicators used were based upon patients' reports 
regarding the last injection received (n=2), observations of providers (n=2) and surveys of 
injection providers' practices (n=1).  
The median absolute reduction in unsafe injection practices ranged from 30 to 82% (relative 
reduction ranging from 40 to 100%). Category three studies were mainly based upon 
communication activities. The reported reduction in unsafe injection practices ranged from 40 to 
49%. Category four studies were mainly based upon provision of safe injection equipment. The 
reported relative reduction of unsafe injection practices ranged from 94 to 100%. The average 
length of follow up was 38 months (Range: 4-60). 
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Table 11: Summarized characteristics of studies assessing the effectiveness of interventions aimed reducing unsafe injection use 
   Characteristics of the intervention    Decrease in unsafe injections in 
intervention group * 
Author, 
Reference 
Country Year †  Training of 
providers 
Provision of 
injection 
equipment 
Education of the 
population 
Type of study Quality of 
evidence ‡ 
(Category) 
Indicator Relative impact Absolute impact 
Luby 60 Pakistan 2002 No No Continuous Before-after 3 Patients’ reports -40.5% -30% 
Ahmed 201 Pakistan 1999 Multiple No Yes Before-after 3 Patients’ reports -48.9% -35.9% 
Vos 199 Tanzania 1998 Once No Continuous Before-after 3 Observations §. -49.2% -32% 
Fitzner (Abstract 10) 204 Burkina Faso 2000-
2001 
No Yes No Historical 
comparison 
4 Observations -93.9% -46.7% 
CDC 64 Romania 1993- 
2001 
Continuous Yes Yes Historical 
comparison 
4 Survey of providers -100% -82% 
 
                                                 
* Proportion of injections given with used equipment, i.e. equipment reused in the absence of sterilization. 
† Year of publication. 
‡ Ranking according to type of studies, quality of data and evidence (Table 9). 
§ Checklist included: Use of a sterile syringe and needle, no touch, disinfection of vial stoppers and use of a separate needle to draw medication and give injections. 
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Discussion 
The issue of the safe and appropriate use of injections has received some attention from public 
health professionals in the last decades. Assessments were conducted,58 policy statements were 
formulated 180 and alternative technologies were developed.184 However, this interest did not 
always materialize in the form of interventions. We only identified a modest number of studies 
that included an initial assessment and a final evaluation. However, all demonstrated some degree 
of effectiveness in reducing injection use and/or unsafe injection practices. Interventions to 
reduce unsafe use of injections were more effective than interventions to reduce injection use, 
probably because they require a more modest change in behaviour (changing a type of syringe for 
another versus reducing injection use). Interestingly, the approach of the studies that examined 
the effectiveness of interventions to reduce injection use differed from the ones of those that 
examined the effectiveness of interventions to reduce unsafe use of injections (Table 12). 
Table 12: Compared characteristics of interventions aiming at decreasing injection use 
and reducing unsafe injections  
 Type of 
change 
needed 
Public health  
benefit 
Number 
of 
studies 
Scientific 
quality  
Coverage of 
intervention 
Effectiveness Key effective 
 interventions  
Interventions 
to reduce 
injection use 
Substantial  
(Behaviour 
change of 
prescribers)  
Improve 
rational use of 
injections 
20 Higher Small scale  
(Pilots selected 
districts) 
-1 to - 53% Communication 
and supervision 
with prescribers 
Interventions 
to reduce 
unsafe 
injections  
Limited  
(Replacement 
of a type of 
syringe by 
another)  
Prevent HBV, 
HCV and HIV 
infection 
5 Lower Larger scale 
(Nationwide policy 
changes)  
-30 to -82% Supplying safe 
injection 
equipment 
 
Reduction of injection use was usually addressed with well-conducted intervention studies usually 
conducted as part of interventions to improve the rational use of medicines. Improving the 
rational use of medicines is about changing the behaviour of prescribers, a highly educated target 
group. Interventions are often based upon revision of standard treatment guidelines and/or 
interactions with practitioners. Thus, a solid evidence base in the use of medicines is required to 
conduct and evaluate them. This may explain why the approach used to study the effect of 
interventions to reduce injection use has been largely academic. Compared to interventions to 
reduce unsafe use of injections, studies were available in a larger number and a higher proportion 
was of good quality (category one and two studies according to our ranking). However, 
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interventions to reduce injection use were mostly implemented on a small or pilot scale. Studies 
that attempted to influence the behaviour of the general population in addition to that of 
prescribers had a larger effect size. This suggests that patients may influence the choice of the 
medications that are prescribed to them. Among all these interventions to reduce injection use, 
interactional group discussions where prescribers were confronted with the actual lack of 
preference for injections among their patients stood out as a successful strategy that was both 
well described and well evaluated.  
In contrast to interventions to reduce the use of injections, interventions to reduce the unsafe use 
of injections were not conducted as academic studies. The public health benefit of these 
interventions consists essentially in the prevention of injection-associated infections with HBV, 
HCV and HIV. The approach used in interventions to improve injection safety was twofold. A 
number of interventions targeted the behaviour of providers and/or that of the general 
population. Others primarily focused on the provision of new single use injection equipment. 
Interventions to reduce unsafe use of injections have often been designed as policy changes. 
Thus, a smaller number have been published in peer-reviewed journals and those published were 
of lower quality (categories three and four according to our grading system). However, the 
practical rather than academic nature of interventions to reduce unsafe use of injections led to 
broader, nationwide coverage. Additional evidence supports the hypothesis that policy changes 
leading to increased availability of single use injection equipment improve injection practices. In 
Uzbekistan and in Mongolia, two countries that recently conducted injection safety assessments, 
reuse of injection equipment in the absence of sterilization was uncommon if observed at all 206 
(Abstract 16, Jean Pierre Stamm, Swiss cooperation, personal communication). In these two 
countries, no historical reference was available to compare the current injection safety situation 
with the past one. However, anecdotal evidence suggested that the recent set-up of factories that 
produced single use syringes had a major impact to (1) eliminate the use of sterilizable injection 
equipment, (2) increase the availability of injection equipment and (3) improve injection practices. 
Overall, evidence suggests that provision of sufficient quantities of new, single use injection 
equipment is effective in reducing unsafe injection practices.  
Our study suffered from four main limitations. First, we were not able to conduct a meta-
analysis, the standard method for systemic reviews. The number of studies available was too 
small and the interventions examined were heterogeneous. Because of this limitation, we were 
not able to generate a weighted average effect size and its confidence interval.  Second, the 
information provided in these studies did not allow us to estimate the quantity or the quality of 
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the resources invested in the communication activities conducted to reduce injection use or to 
reduce unsafe use of injections in these various interventions. Third, a number of studies using 
communication activities to target injection use and/or unsafe injections were conducted as pilot 
studies involving highly qualified and highly motivated staff. Thus, it is unclear what additional or 
alternative efforts would be needed to achieve similar levels of effectiveness at the national level. 
Fourth, we compared various studies using different indicators. Some of these could overestimate 
effectiveness (e.g., prescription-based indicators that do not take into account injections received 
outside of the formal health care setting).  Some others could underestimate effectiveness (e.g., 
population-based injection frequency indicators that take into account all injections received, 
including those received in settings not targeted by the intervention). However, all indicators 
tended to measure the same outcome and all studies were consistent in documenting a higher 
effectiveness of interventions to reduce unsafe use of injections than interventions to reduce 
injection use. 
While interventions to reduce injection use and to reduce the frequency of unsafe injections have 
mostly been conducted separately, they have all demonstrated some degree of effectiveness and 
they should be recommended for wider use. Conducting them together may yield additional 
benefits in terms of effectiveness. Thus, national drug policies should (1) promote rational use of 
injections through communication activities targeting providers and patients and (2) improve 
access to safe injection equipment to ensure that all injections are administered safely. Restricting 
access to unnecessary injectable medications may also contribute to the reduction of injection 
use. 205 Beyond the national drug policy, programmes for the prevention and care of HIV 
infection should communicate the risk of HIV infection associated with unsafe injections and the 
health system should manage sharps waste. Implementation of such national policies for the safe 
and appropriate use of injections will generate substantial benefits, not only in terms of rational 
use of drugs but also in terms of prevention of infection with bloodborne pathogens.  
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Chapter 5: The cost-effectiveness of the safe and appropriate use 
of injections 
 
"Jumping is the cheapest way to go to the moon. However, we don’t do it, because it does not work”. 
Mark Kane 
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Introduction 
Poor injection practices lead to infections with hepatitis B virus (HBV), hepatitis C virus (HCV) 
and human immunodeficiency virus (HIV).1 In addition, unsafe injections were an important 
vector for the introduction of HCV in some countries, including Egypt and Pakistan. 67,5,39 
However, the burden of cirrhosis, hepatocellular carcinoma and Acquired Immunodeficiency 
Syndrome (AIDS) associated with unsafe injections is delayed in time and may not be directly 
apparent. 
While injection-associated infections constitute a silent epidemic, effective interventions are 
available to reduce injection use and unsafe practices (Chapter 4). First, Information, Education 
and Communication (IEC) targeting prescribers, including patient/prescribers interactional group 
discussions, reduces injection use. Second, provision of single use injection equipment improves 
safety. 
For national stakeholders faced with competing priorities, the availability of effective 
interventions to prevent a hidden epidemic may not be sufficient to justify an investment in a 
policy for the safe and appropriate use of injections. Economic considerations also enter the 
debate. Accordingly, we set out to estimate the cost-effectiveness of policies for the safe and 
appropriate use of injections in terms of cost per Disability Adjusted Life Year (DALY) averted. 
In so doing, we adopted a broad, sectoral approach to cost-effectiveness analysis, using the 
perspective of the health system, the goal of which is maximization of health. 
Methods 
Study populations 
The six regions of the World Health Organization (WHO) were subdivided into subgroups of 
countries sharing similar rates of child and adult mortality. This gives rise to 14 Global Burden of 
Disease 2000 epidemiological sub-regions characterized by the WHO region acronym and a letter 
for the mortality stratum (Table 1). 207 Four sub-regions (AMR A, EMR B, EUR A and WPR A) 
where reuse of injection equipment in the absence of sterilization is negligible were excluded 
from the analysis. 
Effectiveness model 
We considered a theoretical cohort of the population living in the year 2000 in sub-regions where 
reuse of injection equipment is reported. We first applied a current, "do nothing" scenario where 
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persons were exposed to contaminated injections and acquired infections. Second, we applied a 
series of "counterfactual" intervention scenarios for the year 2000, taking into account the effect 
of these interventions on the incidence of infections. 
DALYs attributable to poor injection practices 
We modelled the fraction of incident HBV, HCV and HIV infections attributable to 
contaminated injections on the basis of the annual number of injections per person, the 
proportion of injections administered with equipment reused in the absence of sterilization, the 
probability of transmission following percutaneous exposure, the prevalence of active infection, 
the prevalence of immunity and the incidence (Chapter 1 and Chapter 2). The burden in DALYs 
for the years 2000-2030 because of infections in the year 2000 were estimated on the basis of the 
natural history of viral infections, background mortality, life tables 108 and the average duration 
and disability weights of acute hepatitis, cirrhosis, hepatocellular carcinoma and AIDS, the four 
sequelae of interest.99 DALYs were age-weighted and 3% discounted (Chapter 2).  
Effectiveness of interventions 
We examined interventions to decrease unsafe use of injections, interventions to reduce injection 
use and the effect of these two interventions implemented jointly. For interventions to decrease 
unsafe use of injections, we considered the effectiveness of interventions based upon provision 
of single use injection equipment (Abstract 5).204,64 Interventions to decrease injection frequency 
reported a large variation of effectiveness (1-53%) due to variable approaches and study designs. 
52,188,191,192,60,197,195,200,198,201,189,196,187,199,203,194 We used the effectiveness reported for interactional group 
discussions, an intervention developped, implemented and evaluated in Indonesia. 52 Interactional 
group discussions consist of moderated patient/prescriber discussions on the topic of injection 
use during which the prescribers are confronted with the actual absence of preference for 
injections among patients. Our disease model was based upon the number of contaminated 
injections, a direct product between the number of injections received and the proportion of 
these given with reused equipment. Thus, we assumed that the effectiveness of the combined 
interventions was a multiplication of the effect of the two. In addition, in the absence of evidence 
suggesting another scenario, we assumed that the effectiveness of the intervention was identical 
irrespective of the magnitude of the problem in the "do nothing" scenario. 
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Cost of interventions 
Quantification 
First, we identified the activities required for each intervention at the national and sub-national 
level for an implementation period of 10 years of intervention (Table 13).207 Each of these 
activities was assigned to the intervention to reduce injection use, to the intervention to reduce 
unsafe practices or to both (in the case of the latter, activities necessary in the two interventions 
were only counted once). Second, we estimated the fractions of full time-equivalent staff 
members and the material resources required to conduct these activities. Third, we estimated the 
needs of single use syringe and needle sets on the basis of the number of injections administered 
and the proportion already given with sterile injection equipment (Chapter 1).  Fourth, the 
resources required for safe sharps waste collection and management was taken into account as 
part of the intervention. 
Table 13: Activities included in interventions for the safe and appropriate use of 
injections * 
     Years 
Activities Intervention Timing Level Start-up† 1 2 3 4 5 6 7 8 9 10 
National planning workshop Appropriate 
use 
Start-up National ‡ X - - - - - - - - - - 
Development of IEC§ 
material 
Appropriate 
use 
Start-up National ‡ X - - - - - - - - - - 
Training of the trainers Appropriate 
use 
Start-up National ‡ X - - - - - - - - - - 
Training of the procurement 
officer 
Safe use 
 
Start-up National ‡ X - - - - - - - - - - 
District planning workshops  Appropriate 
use 
Start-up Sub-national ‡ X - - - - - - - - - - 
Supplying injection 
equipment ** 
Safe use 
 
Post 
start-up 
Sub-national ‡ - X X X X X X X X X X 
Annual national follow-up 
workshop 
Appropriate 
use 
Post 
start-up 
National ‡ - X X X X X X X X X X 
Interactional group 
discussions  
Appropriate 
use 
Post 
start-up 
Sub-national ‡ - X X X X X X X X X X 
Annual monitoring surveys Both †† Post 
start-up 
Sub-national ‡ - X X X X X X X X X X 
                                                 
* The analysis considered the 3% discounted average yearly cost of a 10-year intervention. Safe and appropriate use interventions were considered 
both separately and combined. 
† Included in year one. 
‡ According to WHO CHOICE methods. 207 
§ Information, Education and Communication. 
** With and without safe sharps waste management in the sensitivity analysis. 
†† This activity appears twice, once for the appropriate use and once for the safe use intervention but is counted only once in the hypothesis of the 
combined intervention. 
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Costing 
We estimated the average yearly programme cost for human resources and associated materials 
for the year 2000, based on costing studies conducted in each sub-region as part of the WHO 
CHOICE project.207 The cost of injection equipment was calculated on the basis of international 
retail prices and the cost of distribution. First, we estimated international retail market prices 
among main international wholesalers. Second, we estimated international distribution costs on a 
standardized mark-up, taking into account the average difference between international Free-On-
Board (FOB) and Cost, Insurance and Freight (CIF) prices, as well as additional trade-related 
international distribution costs.208 Third, we estimated the cost of domestic distribution on the 
basis of a hexagon-shaped sub-regional distribution model that calculated distances between the 
theoretical centre of a country with highest population densities and a periphery with lowest 
population density.209 The cost of personnel, capital and fuel was estimated from a database to 
which fuel efficiency and maintenance cost were added.210 Finally, we used costing studies 
conducted by WHO to estimate the costs, per syringe and needle set, of sharps waste collection 
and disposal through incineration (Ulla Kou and Patrick Lydon, personal communication). We 
assumed 100% coverage of all situations where injections were given in the formal public sector. 
Uncertainty analysis 
We first tested the lower and upper values of the attributable fraction of the Comparative Risk 
Assessment (Chapter 2). Second, we assumed that the effectiveness of interventions was only 7% 
for reduction of injection use (the lowest effectiveness reported for an intervention targeting 
patients and providers) and 50% for reduction of unsafe use of injections. Third, we ran the 
analysis using an upper value of the number of syringes and needle sets required. Fourth, we ran 
an analysis that did not take into account the additional cost of safe sharps waste collection and 
management. Finally, we entered total baseline costs and effects into an analytical software 
package (MCLeague) for a stochastic analysis using Monte Carlo simulation for 1 000 runs using 
a truncated normal distribution. 211 
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Results 
Effectiveness of interventions 
Burden of disease attributable to contaminated injections in 2000 
We estimated that the number of injections per person per year ranged from 1.7 in AMR B to 
11.3 in EUR C, of which a proportion ranging from 1.2% in EUR B and 75% in SEAR D was 
administered with injection equipment reused in the absence of sterilization (Table 14). Overall, 
contaminated injections caused 22 million HBV infections, two million HCV infections and 
260 000 HIV infections. These infections lead to 49 000, 24 000 and 210 000 deaths between the 
years 2000 and 2030, respectively, for a total of 9 177 679 discounted and age-weighted DALYs 
(non-discounted, unadjusted DALYs: 48 541 032). HIV infections accounted for the highest 
proportion of DALYs (63%) while HBV and HCV infections accounted for 34% and 4% of the 
total, respectively. Most of this burden is caused by early death rather than by disability. 
Burden of disease preventable through interventions 
We assumed the effectiveness on injection use of interactional group discussion to be 30%. 52 
This effectiveness translated directly into projected burden of disease reduction, since in our 
disease model the incidence of injection-associated infections was proportional to (a) the annual 
number of injections per person and (b) the proportion of injections given with reused 
equipment (Chapter 2). Implementation of interventions to reduce injection use would lead to a 
reduction of 2 753 304 DALYs. The effectiveness on the unsafe use of injections of provision of 
single use injection equipment was assumed to be 95%. Implementation of interventions to 
reduce unsafe use of injections would lead to a reduction of 8 718 795 DALYs. When combined, 
the two interventions would lead to a reduction of 8 856 461 DALYs. 
Costs of interventions 
The expected annual cost of the intervention to reduce injection use (Table 15) ranged from 
I$ 1.1 million in AMR D to I$ 26 million in WPR B (cost per capita: I$ 0.009-0.024). The cost of 
the intervention to reduce unsafe use of injections ranged from I$ 2.5 million in AMR D to I$ 
459 million in SEAR D (cost per capita: I$ 0.01-0.44). A high proportion of these costs (83-99% 
in all sub-regions other than AMR B and EUR B) consisted of injection equipment, including 
international retail price, international transport and waste management. Overall, the international 
retail price accounted for 40% of the total injection equipment costs (Figure 6). The estimated 
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yearly cost of combined interventions ranged from I$ 3 million in AMR D to I$ 466 million in 
SEAR D (cost per capita: I$ 0.03-0.45). 
Figure 6: Total unit cost of syringes and needle sets according to various cost 
components, by sub-region.  
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Cost-effectiveness of interventions 
The average cost-effectiveness ratio (CER; total costs divided by total effects) for interventions 
to reduce injection use ranged from I$7 to I$5 124 per DALY averted according to the region 
(Table 15). The average CER for interventions to reduce unsafe use of injections, including waste 
management, ranged from I$ 12 to I$1 107 par DALY averted according to the region. The 
average CER for combined interventions for the safe and appropriate use of injections, including 
waste management, ranged from I$14 to I$ 2 293 per DALY averted according to the region. 
Incremental analysis (Table 15) suggested that in the six sub-regions where the proportion of 
reuse of injection equipment exceeds 15% (Table 15), the intervention to reduce injection use 
represents the single most cost-effective strategy. In the four other sub-regions, reduction of 
unsafe use is the most efficient strategy. However, in all regions, the combined interventions 
remained under the threshold of one year of average per capita income. 
Uncertainty analysis 
Five scenarios were assessed in the sensitivity analysis (Table 16). Higher attributable fraction 
reduced the average cost per DALY averted by 19-86% compared to the base case, but removal 
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of sharps waste management costs had little additional influence on baseline results (scenarios 1 
and 2, with the latter representing the best case). Attribution of a lower fraction of injection-
related infections raised the average cost per DALY averted (scenario 3). Using the minimum 
estimates for intervention effectiveness in addition to the lower attributable fractions increased 
CER ratios further, particularly for the intervention to reduce injection use (scenario 4). Finally, a 
scenario incorporating the lower attributable fraction, minimum effectiveness and a doubled 
number of syringe and needle sets (scenario 5) resulted in a four- to ten-fold increase in the 
average cost per DALY averted, compared to initial baseline estimates. However, even under this 
worst-case scenario, the average cost-effectiveness ratio of all interventions remained below the 
threshold of average annual income per capita (Table 16). Inclusion of best- and worst-case total 
costs and effects in the stochastic uncertainty analysis showed that at very low levels of resource 
availability, reduction of injection use represents the most cost-effective strategy in most sub-
regions for a small health gain achieved at a low cost. At higher levels of resource availability, a 
combination approach would be the most efficient choice for considerably greater gains at an 
increased but still cost-effective level of investment. 
Discussion 
The average cost of a policy by which single use syringes and needles are used for all injections 
amounts to less than I$ 0.50 per person per year. This may appear an unaffordable gold standard 
where sterilizable injection equipment is still in use, particularly in view of the fact that safe 
injections yield benefits in terms of death and disability prevented far ahead in the future.212 
However, in Burkina Faso, it was estimated that purchasing injection equipment in quantities that 
match injectable medicines only increased essential drug expenditures by 2.2% (WHO 
unpublished data). Supplying sufficient quantities of single use injection equipment is cost-
effective. Implemented jointly with interventions to reduce injection use, injection safety 
interventions can prevent more death and disability while remaining a sound investment in public 
health. In addition, policies for the safe and appropriate use of injections can lead to savings on 
the cost of injectable medicines that may be redirected to finance injection equipment for those 
injectable medicines that are necessary. 
In all sub-regions analyzed here, each DALY averted through national policies for the safe and 
appropriate use of injections costs considerably less than one year of average per capita income, 
which is the threshold for an intervention being highly cost-effective proposed recently by the 
WHO Commission on Macroeconomics and Health. 213 When recently compared with other 
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strategies to reduce leading risk factors for disease, safe and appropriate use of injections leads to 
a modest reduction in DALYs but was one of the most cost-effective interventions. 207 When 
compared with other modes of HIV infection prevention in sub-Saharan Africa, the cost-
effectiveness ratio of policies for the safe and appropriate use of injections remained under the 
threshold of I$ 50 per DALY averted, in the range of the most cost-effective interventions to 
prevent HIV infection (e.g., blood safety, targeted condom distribution and treatment of sexually 
transmitted diseases).214 Policies for the safe and appropriate use of injections are a natural 
addition to universal infant vaccination against hepatitis B in a national strategy to prevent HBV 
infection. Infant immunization against hepatitis B is probably more cost-effective than the safe 
and appropriate use of injections with cost per life year saved ranging from I$ 4 to I$ 36.215 
However, when global efforts for universal vaccination of infants will have reached sufficient 
coverage for a sufficient period of time, high levels of immunity against HBV infection will 
ultimately protect populations from injection-associated HBV infection. 
A safe injection is defined as one that does not harm the recipient, the provider and the members 
of the community at large (Chapter 3).216 To take this into account, we included the costs of 
sharps waste collection and management as part of programme costs. However, we were not able 
to estimate the effect of safe sharps waste collection and management in terms of burden of 
disease prevented secondary to needle-stick injuries among health care workers or the 
community. Thus, such a policy may be more cost-effective than our results suggest. Our 
sensitivity analysis indicates that the cost per DALY averted decreased by 36% to 39% if the 
costs of safe sharps waste collection and management were excluded to match costs and effects. 
This study was not an attempt to compare various injection technologies. Our model did not 
consider the use of sterilizable injection equipment in any of the interventions. There is no data 
available to indicate that the use of sterilizable injection equipment can lead to safe injection 
practices. In fact, the use of sterilizable injection equipment has been specifically associated with 
infections with bloodborne pathogens 86,77,88,37 and health systems making use of sterilizable 
syringes have poorer practices than those making use of single use equipment.59 We did not make 
any special reference to the use of auto-disable (AD) injection equipment that inactivates itself 
after one use.184 AD syringes offer the highest level of safety and are now considered the standard 
for the administration of vaccines. However, immunization injections only account for less than 
10% of all injections (Chapter 1). Thus, introduction of AD syringes in immunization services 
will only address a small proportion of the burden of disease associated with unsafe injections. 
With respect to use of AD syringes in curative services, while single use syringes can be reused, 
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we were unable to identify effectiveness data indicating that when compared with standard single 
use syringes made available in sufficient quantities, AD syringes would be associated with safer 
injection practices. Nevertheless, AD syringes should be considered for use in settings where 
unsafe practices are common, particularly in the informal sector, specifically in South Asia.39,41 In 
such cases, the results of our analysis could be easily extrapolated to AD syringes since they are 
now available at a cost that is very close to the one of standard single use syringes. In 2002, the 
international retail price for an immunization AD syringe was five to seven US cents while 
international retail prices for single use syringes ranged from four [2 ml] to eight [5 ml] US cents. 
Our study presented a number of limitations. First, our model did not take into account any 
longer term dynamic effects that the reduction of transmission would have on the prevalence of 
infections with bloodborne pathogens. This may be a problem in the case of HCV infection as 
contaminated injections account for a high proportion of new infections. This limitation could 
also have led to an underestimation of the effect size that in turn would lead us to describe these 
interventions as less cost-effective than they really are. Second, we did not address the specific 
issues associated with working in the private sector. Provision of sufficient quantities of single 
use injection equipment and interactional group discussion may not be sufficient where the 
informal private sector accounts for a high proportion of health care services delivery. In such 
settings, demonstration projects should identify effective strategies, some of which may include 
the use of AD syringes in curative services and/or addressing financial incentives to over-
prescribing injections. Because we did not have information on the proportion of injections 
administered in the private sector, we were unable to include this factor in our sensitivity analysis. 
Third, we used interactional group discussions as a template to estimate the cost and the 
effectiveness of interventions to reduce injection use. Interactional group discussion was the best 
scenario to use as (1) they have been well evaluated and (2) they represent a substantial 
investment in human resources that could be invested in other types of interventions to reduce 
injection use.  However, interactional group discussions have only been used in Indonesia. In 
addition, they only represent one of various strategies that may be used to reduce injection use. 
Thus, the effetiveness reported in Indonesia may not be generalizable to a model that assumes 
their scaled-up implementation in other developing and transitionnal countries.  Fourth, the 
effectiveness of interventions to supply single-use injection devices was estimated on the basis of 
studies that were of lower scientific quality (e.g., before-after comparison without control groups 
and historical comparisons, Chapter 4). Thus, the estimates is subject to uncertainty and the 
lower estimate used for the worst case scenario was chosen arbitrarily.  
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Poor injection practice is not a leading cause of disability and death worldwide. However, safe 
and appropriate use of injections represents an opportunity to avert a substantial number of 
DALYs at a relatively low cost. Improved injection practice can be recommended for 
implementation worldwide, particularly in settings where reuse of injection equipment is 
common and where the HIV epidemic is generalized. Such policies can be developed through a 
better coordination of already existing programmes to facilitate implementation. Finally, in 
addition to being cost-effective, the safe and appropriate use of injections is an attainable way of 
applying the "first do no harm" principle as part of the ethics of health care service delivery. 
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Table 14: Contaminated injections in the year 2000, secondary attributable and avertable burden of disease for the period 2000-2030  
AFRICA THE 
AMERICAS 
EASTERN 
MEDI-
TERRANEAN 
EUROPE SOUTH EAST 
ASIA 
WESTERN 
PACIFIC 
  
 
AFR D 
 
AFR E 
 
AMR B 
 
AMR D 
 
EMR D 
 
EUR B
 
EUR C 
 
SEAR B 
 
SEAR D 
 
WPR B 
 
ALL 
Mortality in children high high low high high low low low high low  
Mortality in adults high very high low high high low low low high low  
Injections  
per person per year * 
2.2 2.0 1.7 1.9 4.3 5.2 11.3 2.1 4.0 2.4 3.4 
Proportion  
of reuse * 
19% 17% 1.2% 11% 70% 1.2% 11% 30% 75% 30% 39.8% 
Total burden 2000-2030 * 555 644 1 668 583 9 083 27 332 559 702 3 479 64 733 280 789 4 720 866 1 287 470 9 177 679 
Reduction of 
injection use † 
 
166 693 
 
500 575 
 
2 725 
 
8 200 
 
167 911 
 
1 044 
 
19 420 
 
84 237 
 
1 416 260 
 
386 241 
 
2 753 304 
Reduction of 
unsafe use ‡ 
 
527 862 
 
1 585 154 
 
8 629 
 
25 965 
 
531 717 
 
3 305 
 
61 496 
 
266 749 
 
4 484 823 
 
1 223 096 
 
8 718 795 
P
r
e
v
e
n
t
a
b
l
e
 
b
u
r
d
e
n
 
2
0
0
0
-
2
0
3
0
 
Combined 
interventions § 
 
536 197 
 
1 610 182 
 
8 765 
 
26 375 
 
540 112 
 
3 357 
 
62 467 
 
270 961 
 
4 555 636 
 
1 242 408 
 
8 856 461 
                                                 
* "Do nothing" scenario. 
† Interactional group discussions between patients and providers to reduce injection use. 
‡ Provision of single use, disposable syringes and needles for all injections. 
§ Safe and appropriate use of injection policies combining the two interventions above. 
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Table 15 Costs and cost-effectiveness of policies for the safe and appropriate use of injections (in international dollars (I$)), 2000 
Region AFR D AFR E AMR B AMR D EMR D EUR B EUR C SEAR B SEAR D WPR B 
Total population (million) 294 346 431 71 343 218 243 294 1,242 1,533 
Gross domestic product  
(GDP) per capita (I$) 
1,381 1,576 7,833 3,837 2,393 7,294 6,916 2,545 1,449 4,186 
Syringes /needles *   
Syringe/needle sets needed   122,924,628  117,475,114     8,791,014   14,887,078 1,031,154,040   6,553,752  93,625,680  185,105,732    3,725,419,491   1,103,711,844 
Syringe/needle costs (I$)      19,176,242    18,208,643     1,116,459      2,084,191    148,486,182       773,343    11,422,333   25,544,591       454,501,178      144,586,252 
Programme costs (I$) †   
Reduction of injection use       2,738,289     3,308,975   10,524,021      1,080,717        3,876,085    5,349,039     5,298,743      3,568,129         10,599,413       25,579,948 
Reduction of unsafe use        1,602,096      1,391,325     3,189,442        434,498        1,542,952   2,884,373      1,692,560      1,218,867            4,402,415          8,452,776 
Combination       3,553,983      3,711,160   11,020,206      1,205,776        4,234,537   6,922,989     5,554,346      3,757,891         11,812,493        27,164,652 
Total cost per year (I$)   
Reduction of injection use       2,738,289     3,308,975   10,524,021      1,080,717        3,876,085   5,349,039     5,298,743      3,568,129         10,599,413       25,579,948 
Reduction of unsafe use    20,778,338    19,601,204     4,305,901      2,518,893    150,029,134    3,657,716    13,114,893  26,763,458      458,903,593      153,039,028 
Combination    22,730,225    21,922,514   12,136,665     3,290,463    152,720,719   7,696,332   16,976,679  29,302,482       466,313,671      171,750,904 
Average CER  
(I$ per DALY averted)  
  
Reduction of injection use 16 7 3,862 132 23 5,124 273 42 7 66 
Reduction of unsafe use 39 12 499 97 282 1,107 213 100 102 125 
Combination  42 14 1,385 125 283 2,293 272 108 102 138 
Incremental CER  
(I$ per DALY averted) ‡ 
  
Reduction of injection use 16 7 - - 23 - - 42 7 66 
Reduction of unsafe use 50 15 499 97 - 1,107 213 127 - 152 
Combination  234 93 57,579 1,882 400 77,666 3,977 603 145 969 
                                                 
* Syringes and needle costs include the international retail price, international transport and waste management (domestic transport included under programme costs). Not applicable to interventions to reduce injection use. 
† Programme costs include personnel, transport, equipment and supplies but exclude syringes and needles sets. 
‡ Lowest value represents most cost-effective option relative to doing nothing; next lowest value represents next most cost-effective option. 
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Table 16: Sensitivity analyses for the estimate of the average cost-effectiveness ratios of interventions for the safe and appropriate use of 
injections (expressed in international dollars (I$)) per DALY averted * 
Sensitivity scenario AFR D AFR E AMR B AMR D EMR D EUR B EUR C SEAR B SEAR D WPR B 
1. Higher attributable fraction †    
Reduction of injection use 13 5 523 44 17 1,394 140 33 6 28 
Reduction of unsafe use 32 10 68 33 210 301 109 79 78 53 
Combination 34 11 187 42 210 624 139 85 78 59 
2. Higher attributable fraction, no sharps waste 
management 
          
Reduction of injection use 13 5 523 44 17 1,394 140 33 6 28 
Reduction of unsafe use 20 6 61 22 127 276 71 49 47 33 
Combination 23 7 181 31 129 599 102 55 48 39 
3 Lower attributable fraction            
Reduction of injection use 22 9 N/A N/A 45 N/A 970 57 11 N/A 
Reduction of unsafe use 52 16 N/A N/A 544 N/A 758 136 156 N/A 
Combination 56 18 N/A N/A 546 N/A 967 146 156 N/A 
4. Lower attributable fraction, minimum effectiveness           
Reduction of injection use 93 37 N/A N/A 191 N/A 4,159 245 49 N/A 
Reduction of unsafe use 99 31 N/A N/A 1,035 N/A 1,441 258 296 N/A 
Combination  106 34 N/A N/A 1,038 N/A 1,838 278 296 N/A 
5. Lower attributable fraction, minimum effect, double 
injection sets 
          
Reduction of injection use 93 37 N/A N/A 191 N/A 4,159 245 49 N/A 
Reduction of unsafe use 190 60 N/A N/A 2,058 N/A 2,696 504 589 N/A 
Combination  196 62 N/A N/A 2,046 N/A 3,074 520 585 N/A 
                                                 
* Not applicable (N/A) refers to lower attributable fraction equals to zero; CER cannot therefore be calculated. 
† Attributable fraction refers to the fraction of new HBV, HCV and HIV infections attributable to contaminated injections. 
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Conclusion 
1. Context of this work and main objectives 
In 1999, a review of the literature suggested that poor injection practices required more attention 
from public health policy-makers.1 This review drew three main conclusions. First, high rates of 
injection use were reported from many developing and transitional countries. Second, a 
substantial proportion of these injections was administered under non-sterile circumstances. 
Third, epidemiological studies conducted in selected countries suggested that receiving health 
care injections could transmit HBV and HCV on a large scale and was associated with HIV 
infection. However, a number of elements were missing. No regional estimates were available for 
the frequency of injections and the proportion of injections given with injection equipment 
reused in the absence of sterilization. The proportion of new HBV, HCV and HIV infections 
attributable to contaminated health care injections was not estimated. There was no evidence-
based international consensus over what constituted a safe injection. More importantly, it was 
unclear what strategies were effective at reducing injection use or the unsafe use of injections. 
Finally, no economic analysis was available to determine whether investing in the safe and 
appropriate use of injections was a cost-effective use of financial resources in countries where 
poor injection practices occur. 
The goal of this work was to constitute an evidence base that would support national policies for 
the safe and appropriate use of injections. First, we estimated the annual number of injections per 
person and the proportion of injections given with a syringe and or a needle reused in the 
absence of sterilization in selected regions of the world (Chapter 1). Second, we participated in 
the Comparative Risk Assessment component of the 2000 update of the Global Burden of 
Disease study and used mathematical models to estimate the proportion of HBV, HCV and HIV 
infections that were attributable to contaminated health care injections in the year 2000 (Chapter 
2).94 Third, we reviewed the evidence available on infection control practices with respect to 
administering injections to formulate evidence-based best infection control practices for 
intradermal, subcutaneous and intramuscular injections using the new WHO proposed 
framework to formulate evidence-based guidelines (Chapter 3). Fourth, we reviewed evidence 
available on the effectiveness of interventions to reduce injection use and to achieve safe 
injection practices to estimate their effectiveness and identify successful prevention strategies 
(Chapter 4). Finally, we participated in the WHO CHOICE project to estimate the cost-
effectiveness of national policies for the safe and appropriate use of injections in terms of cost 
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per DALY averted (Chapter 5). None of these studies provide a final answer to the research 
questions that they tried to address and uncertainty remains. However, our conclusions 
summarized below allow us to propose a conceptual framework to benchmark, assess, plan, 
implement and evaluate national policies for the safe and appropriate use of injections (Appendix 
1). 
2. Key conclusion points 
2a) In developing and transitional countries, 16 thousand million injections are 
administered each year for a ratio of 3.4 injections per person that suggests a gross 
overuse of injections 
In the 10 of the 14 global burden of disease regions included in our study, over 16 thousand 
million injections are administered each year, for an average of 3.4 injections per person (Chapter 
1). However, we were unable to estimate the distribution of these injections received between 
various injection providers, indications and health care settings. The heterogeneity of injection 
frequency across regions and the high number of injections per person suggest that injections are 
grossly overused in most developing and transitional countries. However, studies were not 
available in sufficient numbers to allow the estimation of the proportion of these injections that 
are unnecessary. Unnecessary injections represent a major wastage of health care resources. This 
wastage is distributed among four expenses. First, the cost of injectable medications (the median 
international retail price of the injectable medications on the WHO model essential drugs list is 
US$ 0.5 per dose). Second, the cost of injection equipment (the average international retail price 
of a new syringe and needle set is US$ 0.05). Third, the prescriber's fee for service. Fourth, the 
injection provider’s labour. These expenses that are often incurred out of patients' pockets 
probably sustain injection overuse through provision of a financial incentive to physicians, 
pharmacists and nurses to prescribe, dispense and administer injectable medicines. Injection 
overuse is commonly attributed to the preference for injections among patients. Qualitative 
assessments and Knowledge, Attitude and Practices (KAP) studies conducted among patients 
and health care providers suggest that while perceptions that injectable medicines are more 
effective or work faster are prevalent in general populations,3 most patients do not prefer 
injectable medications for the treatment of common ailments (Abstract 4, Abstract 13).217,27,28 In 
fact, health care providers overestimate patients' preference for injections (Abstract 3).55,52 Thus, 
in contrast to what many public health specialists may think, injection overuse is driven to a large 
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extent by health care providers on the basis of financial incentives and inaccurate perceptions of 
their patients' preferences.52 
2b) In developing and transitional countries, approximately one third of all injections are 
administered with injection equipment reused in the absence of sterilization 
Reducing injection overuse would only be a matter of promoting rational use of essential 
medicines if injections were administered safely. However, the results of our analysis indicate that 
injections are given in a way that may harm the injection recipient. Overall, the proportion of 
injections administered with equipment reused in the absence of sterilization was 39.3%, ranging 
from 1.2% in Latin America to 75% in South Asia (Chapter 1). Determinants of these unsafe 
injection practices include the lack of supplies of new, single use injection equipment, the lack of 
awareness among patients and providers regarding the risks associated with unsafe practices and 
the absence of an efficient sharps waste management system to prevent illegal re-processing for 
re-packaging of used injection equipment.  
2c) In the year 2000, the combination of injection overuse and unsafe practices may have 
accounted for one third of new HBV infections, 40% of new HCV infections and 5% of 
new HIV infections 
In the year 2000, four decades after the widespread availability of single use injection equipment 
and two decades into the HIV pandemic, contaminated injections may still account for close to 
one third of new HBV infections, 40% of new HCV infections and five percent of new HIV 
infections. Injection-associated HBV, HCV and HIV infections acquired in the year 2000 will 
translate into 9 177 679 discounted and age-adjusted disability-adjusted life years (DALYs) 
between 2000 and 2030 because of fulminant hepatitis, AIDS, hepatocellular carcinoma and end-
stage liver disease (Chapter 2). This burden of disease accounts for less than one percent of the 
total burden attributable to 20 main risk factors to health that are avoidable.94 Thus, 
contaminated injections in health care settings are not a leading cause of death and disability 
worldwide. However, in contrast to some other risk factors responsible for a higher burden of 
disease (e.g., tobacco use, hypertension), interventions to achieve the safe and appropriate use of 
injections may be simpler to conduct and more effective. A majority of the burden of disease 
associated with contaminated health care injections (63%) is secondary to injection-associated 
HIV infections (Chapter 2). Thus, the fraction of HIV infections attributable to contaminated 
health care injections and the uncertainty around its estimate is a key element in apprehending the 
burden of disease secondary to this public health problem. 
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2d) Best infection control practices could make injections safer for the recipient, the 
health care worker and the community 
The proportion of injections administered with a syringe and or a needle reused in the absence of 
sterilization was a key input parameter in our burden of disease model (Chapter 2) and is used as 
a critical indicator of injection safety.20 Reuse of injection equipment is the focus of much 
attention as it leads to more burden of disease (260 000 HIV infections worldwide annually, 
Chapter 2) than needle-stick injuries among injection providers (1 000 HIV infections worldwide 
annually).179 However, a safe injection is one that should be completely safe to the patient, the 
health care worker and the community. Thus, in addition to using new, single use injection 
equipment, additional infection control steps are needed to make injections safe for the recipient 
and to prevent needle-stick injuries. Eliminating unnecessary injections is the highest priority 
towards preventing injection-associated infections (Chapter 3). However, when injections are 
medically indicated, evidence-based best infection control practices for intradermal, subcutaneous 
or intramuscular injections include (1) the use of sterile injection equipment, (2) the prevention of 
contamination of injection equipment and medication, (3) the prevention of needle-stick injuries 
to the provider and (4) the prevention of access to used needles (Chapter 3). These best practices 
may be achieved if injection providers are trained in these safe techniques and if sufficient 
quantities of injection equipment (i.e., single use syringe and needle sets) and infection control 
supplies (i.e., puncture- and liquid- proof containers for the collection of sharps waste) are made 
available. Engineered technologies have been developed to support safer injection practices. 
These include auto-disable syringes that make the reuse of injection equipment difficult or 
impossible through plunger blocking, plunger breaking or needle retraction and safety syringes 
that prevent needle-stick injuries. 
2e) Effective interventions are available to reduce injection use and to achieve a safe use 
of injections 
While the danger of injection overuse and unsafe practices has been underlined for a few 
decades, the safe and appropriate use of injections remains elusive. This lead to a widespread 
perception among public health policy makers that poor injection practices are a chronic plague 
of health systems and that no effective interventions are available. The data does not support that 
complacency. In our review of studies that allowed the estimation of the effectiveness of 
interventions to reduce injection use and achieve safe practices, all studies demonstrated some 
degree of effectiveness. The effectiveness of interventions to reduce injection use ranged from 
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1% to 53% (Chapter 4). While interventions targeting providers are keys to change prescribing 
practices, interventions that targeted providers and the general population achieved a higher 
median effectiveness than interventions targeting providers alone. Among all these interventions, 
patient/provider interactional group discussions (IGD) to change prescribing behaviours stood 
out as a successful strategy that was well described and well evaluated.52 The effectiveness of 
interventions to reduce unsafe use of injections ranged between 30% and 82% (Chapter 4). 
Among the interventions to improve injection safety, provision of sufficient quantities of new, 
single use injection equipment was highly effective in reducing unsafe injection practices. 
Interventions to reduce injection use and to reduce the frequency of unsafe injections can be 
recommended for wider use. Implementing them as a joint safe and appropriate use of injection 
strategy may generate opportunities for synergy and reinforce messages to yield additional 
effectiveness benefits.  
2f) Interventions for the safe and appropriate use of injections can be considered very 
cost-effective on the basis of a cost per DALY averted that is below one year of average 
per capita income 
We evaluated the cost-effectiveness of interventions for the safe (i.e., provision of new, single use 
injection equipment) and appropriate use of injections (i.e., interactive, patient-provider group 
discussions) separately and in combination in the regions where the burden from unsafe 
injections is substantial. Reducing unnecessary use of injections will have a lower total impact on 
population health than reducing reuse of injection equipment without sterilization (Chapter 5). 
The effect of doing both at the same time is less than additive, although doing both together does 
improve population health to a greater extent than doing simply one. In approximately half the 
sub-regions, reducing reuse is also the most cost-effective option. However, in the other regions, 
behavioural interventions to reduce overuse are more cost-effective than interventions to reduce 
reuse, which require large quantities of injection equipment. In all regions, combined 
interventions for the safe and appropriate use of injections had a cost-effectiveness ratio well 
below the cut-off point of one gross domestic product per capita for each DALY averted 
(Chapter 5). On that basis and according to the criteria proposed by the WHO report of the 
commission on macroeconomics and health,213 the safe and appropriate use of injections may be 
considered a very cost-effective intervention. 
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3. Remaining areas of uncertainty 
The relative frequency of injection use can be compared across world regions. Similarly, injection 
safety assessments provide a good understanding of the worldwide distribution of reuse of 
injection equipment in the absence of sterilization. Best infection control practices for 
intradermal, subcutaneous and intramuscular injections are well characterized. Interventions that 
are successful in decreasing injection use or unsafe use injection are identified and economic 
evaluations suggest that these constitute a very cost-effective use of health care resources. 
However, uncertainty remains in the understanding of unsafe injection practices, their 
determinants and their consequences. First, injection frequency estimates do not translate easily 
into figures that can be used to forecast needs in injection equipment. Second, breaks in infection 
control practices other than reuse of injection equipment are not well described. Third, the 
proportion of HIV infection attributable to contaminated health care injections is uncertain. 
Fourth, the role of engineered technologies in interventions to achieve injection safety is unclear. 
Fifth, experience is limited in scaling up interventions for the safe and appropriate use of 
injections. Finally, cost-effectiveness models need to be validated through real-size economic 
analysis of in-country interventions. We will now review these areas of uncertainty. 
3a) Routine methods are needed to describe injection use and quantify needs of injection 
equipment  
The population-based surveys and the prescription reviews that we used allowed the generation 
of estimates of the annual number of injections per person and per year. This indicator can be 
used to document high levels of injection use, suggest injection overuse and compare injection 
frequency across regions. However, it is unclear whether the mean number of injections per 
person and per year obtained using our methods can be used to forecast needs in injection 
equipment. Within a population, the frequency distribution of the number of injections received 
is heterogeneous. There is a small proportion of the population in which injection use is clustered 
and where the number of injections received is high (e.g., diabetics, patients hospitalized in 
surgery or in intensive care). The studies that we reviewed may have had too small a sample size 
to include these rare individuals in sufficiently large numbers to describe injection practices 
among them. Thus, the results of our analysis may underestimate the total number of injections 
received in the population. To account for this uncertainty, we ran a sensitivity analysis in our 
cost-effectiveness model where we multiplied by two the number of syringe and needle sets 
needed (Chapter 5). In practice, for supply management purposes, two approaches have been 
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used to estimate injection equipment needs. First, epidemiologists who tend to be population-
focused have conducted population-based injection frequency surveys based upon the self-
reported number of injections received. However, this approach does not capture well the high 
level of injection use that is clustered in specific settings. Second, marketing specialists who tend 
to be device-focused have studied the number of syringes and needles sold in a country.  
However, this approach does not capture well the number of times that a syringe and needle set 
may be reused. These two types of approaches should be combined to ensure appropriate 
forecasting of injection equipment needs. Studies could compare (1) population-based injection 
frequency estimates with (2) market data on the consumption of injection equipment, which 
could include specific consumption surveys in programmes and settings where injection use is 
particularly high. Collaboration between the private and the public sector may be useful in that 
regard. Procurement units in Ministries of Health could benefit from these accurate forecasting 
methods to provide injection equipment in quantities that are sufficient to prevent shortages. 227 
3b) Unsafe injection practices need to be described in greater detail to prevent all 
opportunities of bloodborne pathogen transmission   
The reuse of injection equipment in the absence of sterilization is an indicator that is somewhat 
arbitrary and that does not reflect the variety of breaks in infection control practices that may 
occur in health care settings. These include the immediate reuse of a syringe and needle set on a 
second patient, the reuse of a syringe and needle set on multiple patients, the reuse of a syringe 
although the needle has been changed, the reuse of injection equipment after rinsing in a pot of 
tepid water, the reuse of injection equipment after an inappropriate or incomplete sterilization 
procedure (e.g., boiling), the reuse of injection equipment on a same patient in combination with 
the use of a multi-dose medication vial, the preparation of injections in areas potentially 
contaminated with blood and body fluids and the reuse of injection equipment to administer 
intravenous medications to hospitalized patients in intravenous catheters in which reflux may 
occur. Thus, tools developed to assess 20 or to supervise 218 injection practices should use the 
checklist proposed by the best infection control practices for intradermal, subcutaneous and 
intramuscular injections (Chapter 3) to ensure that all breaks of infection control practices are 
identified, quantified and prevented. 
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3c) Better estimates of the proportion of HIV infections that may be attributed to unsafe 
health care injections are needed 
In the case of HBV and HCV infection, epidemiological studies assessing the association 
between injections and infections are available to validate the results of our estimates of the 
proportion of HBV and HCV infections attributable to injections. In contrast, in the case of 
HIV, epidemiological studies are limited to sub-Saharan Africa where they suggest that our 
estimate is conservative. In Asia, our high attributable fractions are not validated by 
epidemiological studies and may be overestimated. At the end of the 1980s, the consensus among 
public health officials involved in the prevention of HIV infection evolved towards the concept 
that unsafe health care injections only account for a small proportion of all HIV infections.219 
Since then, the achievement of safe health care injections has not received a high level of 
attention in HIV prevention and care programmes,220 often because of a fear of “diluting the 
message” that sex is the main driver of the HIV epidemic. In addition, most epidemiological 
studies estimating the relative importance of various potential sources of HIV infection in 
developing and transitional countries have not fully examined the role of health care injections in 
HIV transmission. Questionnaire items were either missing or not adapted. When data were 
collected, they were often not analyzed or not reported. Today, the uncertainty around the 
proportion of HIV infections attributable to unsafe health care injections has generated a 
controversy.95 Researchers reviewed prevalent and incident analytical epidemiological studies to 
suggest that the fraction of HIV infection attributable to health care injections could be as high as 
20-40% in sub-Saharan Africa.95 Others argue that reverse causation is possible as most of the 
evidence available is based upon cross-sectional studies that do not disentangle health care 
injections as an exposure from a variety of confounding factors, including sexually transmitted 
infections that may lead to health care visits. This unresolved issue will have to be addressed 
through prospective case control and cohort studies examining the risk of HIV infection 
associated with health care exposure in a way that allows for the control of confounding factors. 
In the meantime, progress has been achieved in that irrespective of the fraction of HIV 
attributable to unsafe health care injections, it is considered that unsafe health care injections 
should not occur. Communication of the results of the Global Burden of Disease study within 
WHO has led the department of HIV/AIDS to make a number of key decisions. First, the safe 
and appropriate use of injections is now considered one of the 10 key elements of a national 
strategy for the prevention and care of HIV infection along with health care worker protection.221 
Second, a time-bound milestone now proposes that by 2005, all supplies of injectable substances, 
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including vaccines and essential medicines should be delivered with matching quantities of single 
use injection equipment.222 Third, a meeting of consultants held at WHO on 13 March 2003 
reviewed all data available regarding the proportion of HIV infections that may be attributable to 
unsafe health care injections. While the majority of HIV infections in sub-Saharan Africa are 
clearly attributable to unsafe sex, strategies to prevent HIV infection should include strategies to 
achieve the safe and the appropriate use of injections and adapted epidemiological methods 
should monitor injection practices as part of HIV prevention indicators.223 
3d) The role of engineered technologies in policies to achieve injection safety is unclear 
The best infection control practices for intradermal, subcutaneous and intramuscular injections as 
we defined them do not address the use of specific safety injection devices, allowing the 
development group to avoid issues that could lead to actual or perceived conflicts of interest. 
Newer technologies supporting a safer use of injections have been developed.184 Auto-Disable 
(AD) syringes are engineered to inactivate themselves by plunger blocking, plunger breaking or 
needle retraction to prevent reuse of injection equipment. Other safety mechanisms have been 
engineered to prevent needle-stick injuries among health care workers (Chapter 3). WHO, 
UNICEF and UNFPA formulated a policy statement in 1999 to recommend the exclusive use of 
auto-disable injection equipment in immunization services by the end of 2003. 180 However, in 
curative services, the effectiveness of these engineered technologies in preventing specific unsafe 
practices is unknown. In the absence of evidence, a policy statement cannot be formulated to 
recommend their wide-scale use. Well-monitored comparative field studies will need to determine 
whether auto-disable syringes lead to safer injection practices than single use syringes provided in 
sufficient quantities. Such field studies will need to be conducted in a variety of geographical 
settings and health systems, including the informal private sector. Identification of independent 
funding sources may help prevent actual or perceived conflicts of interest in the financing of such 
studies. In practice, to ensure that such studies are conducted, as the results of our research 
suggest they should be, the industry needs the expression of a sufficient level of interest in 
curative-size auto-disable syringes to develop products and make them available for evaluation. 
Thus, to facilitate research and development, open a market for the industry and make products 
available for broader assessment in curative health care services, WHO made the strategic choice 
to recommend the use of curative size auto-disable syringes in selected donor- or lender-
supported programmes making use of injections (e.g., tuberculosis treatment with streptomycin 
in the context of the Global TB Drug Facility of the Stop TB alliance). This initial support to the 
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introduction of auto-disable syringes through programmes funded through donors and lenders 
will provide opportunities to recover experience associated with the use of auto-disable syringes 
in curative services through systematic assessments. This experience will ultimately generate the 
body of evidence upon which a future policy decision will be based. 
3e) More experience is needed in the scaling-up of successful interventions to reduce 
injection use and achieve safe injection practices 
WHO proposes that national policies for the safe and appropriate use of injections be based 
upon (1) behaviour change among patients and health care workers to decrease injection overuse 
and achieve safe injection practices, (2) provision of sufficient quantities of injection equipment 
and infection control supplies and (3) sharps waste management.65 The three interventions 
recommended as components of this strategy have been conducted individually or on a pilot 
level. However, limited experience is available on the implementation of multidisciplinary 
national strategies for the safe and appropriate use of injections that include these three elements. 
Interventions to reduce injection use, including interactional group discussions, have mostly been 
conducted as well-evaluated, pilot research projects but have rarely been scaled up as national 
policies (Chapter 4). In contrast, provision of sufficient quantities of single use injection 
equipment to improve injection safety has mostly been implemented as national policies that 
have not always been evaluated prospectively (Chapter 4). There are two challenges to overcome 
to successfully scale up national policies for the safe and appropriate use of injections. First, 
cross-departmental collaborations within the Ministry of Health need to integrate the 
multidisciplinary interventions required in the routine of health care service delivery. While a 
national strategy for the safe and appropriate use of injections should not be implemented as a 
separate programme, let alone a vertical one, integration raises additional difficulties as tasks and 
responsibilities need to be distributed, coordinated and evaluated across health programmes and 
services. Second, there is a need to address the overuse and unsafe use of injections in the 
informal, private sector, particularly in South Asia 39,41 where these providers account for a high 
proportion of health care services delivery. Interventions in the informal, private sector may 
require specific strategies, including mechanisms to address the financial incentives for injection 
overuse and the introduction of auto-disable syringes. Scaled-up national demonstration projects 
in selected countries in various regions of the world would assist in overcoming these two 
challenges. Such demonstration projects would generate an experience that could be recovered to 
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offer practical guidance to other countries regarding the steps and processes to follow for a 
successful scale-up. 
3f) Cost-effectiveness assessment of scaled-up national interventions are needed to 
validate the results of our cost-effectiveness estimates 
We generated our cost-effectiveness estimates using mathematical models based upon a number 
of assumptions, including the proportion of HIV infections attributable to unsafe health care 
injections, the assumed effectiveness of selected interventions and the theoretical costing 
exercises that WHO conducted as part of the CHOICE project.207 This approach remains subject 
to a number of limitations (Chapter 5). A stronger confidence in the cost-effectiveness of 
national policies for the safe and appropriate use of injections may be obtained through a cost-
effectiveness analysis conducted on the basis of the evaluation of a scaled-up national 
demonstration project. As a practical next step, implementation of this approach on scale in a 
single high-burden country in a region where the model generated a high cost-effectiveness ratio 
would allow to evaluate the assumptions of this model. To achieve this, costs and effects will 
need to be closely monitored throughout a study design that will have to be integrated into the 
intervention itself. Thus, better cost-effectiveness estimates will be both a direct consequence of 
the first scaled-up national interventions and the condition for implementation of similar policies 
in additional countries. 
4. Recommendations for prevention strategies 
From evidence to policy   
Throughout our work, we provided evidence indicating that the combination of injection overuse 
and unsafe practices transmit HBV, HCV and HIV on a large scale worldwide, causing 
substantial death and disability. To prevent the consequences of unsafe injections, we formulated 
best practices, identified the interventions that are successful in implementing them and 
estimated the cost-effectiveness of these prevention strategies. Evidence and information need to 
translate into public health action that may be implemented more effectively if it is seen as a 
quality cycle.  
The injection safety planner   
A national policy for the safe and appropriate use of injections should not be seen as a static 
document. Rather, it is a process by which a standard is developed, the current situation is 
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assessed, a plan is made, actions are implemented and an evaluation measures progress. This 
"quality cycle" that includes five steps is outlined below and developed further in the injection 
safety planner ("Managing an injection safety policy", see Figure 7, Appendix 1). 
Setting a national standard ("Benchmarking") 
Benchmarking defines the ideal system and its indicators. WHO best infection control practices 
for intradermal, subcutaneous and intramuscular injections may be used as a template for a 
national standard that can be defined through an involvement of all stakeholders. 
Assessing practices 
Assessment will determine how the current system differs from the ideal one on the basis of 
selected indicators (Abstract 10). A set of input, process and outcome indicators identified as key 
to estimating the burden of disease associated with unsafe injections were developed together 
with rapid assessment tools to collect them (See Table 17 in Appendix 1).  
Planning for change 
A planning process will set the objectives and targets to reach the ideal system. Ideally, a template 
plan should include five key elements: 
1. HIV prevention and care programme to communicate the risk of HIV infection associated 
with poor injection practices; 
2. National drug policy to prevent injection overuse; 
3. Essential drug system supplies to make syringes and sharps boxes available in every health 
care facility; 
4. Immunization and family planning to deliver injectable substances with auto-disable syringes 
and sharps boxes; 
5. Health care system to manage sharps waste. 
Implementing multidisciplinary interventions 
Implementation will conduct interventions to reach the targets and improve the system. 
Evaluating impact 
Evaluation will measure progress towards the objectives and targets. A supervision process based 
upon the best practices will facilitate evaluation and provide guidance through reinforcing good 
practices and proposing strategies to improve weak ones. 
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Convincing finance committees to invest in injection safety  
The approach proposed in the injection safety planner has never been attempted in real size at 
country level. This lack of experience is a substantial barrier to securing funds for 
implementation. A national programme would require a specific budget to cover the various 
components of the recommended multidisciplinary approach. Governments of low income 
country have several budgetary constraints, including a limited capacity to collect revenues and 
extreme competition for resources. Cost-effectiveness estimates are unlikely to be sufficient to 
convince finance committees of the need to invest in an intervention that addresses less than one 
percent of the burden of disease. While international donors and lenders might have some 
interest in this issue because of the cost-effectiveness ratio, external ongoing support for these 
initiatives in priority countries is unlikely. Thus, the remaining challenge is to acquire practical 
experience in the mechanisms that would reduce the costs of the intervention (e.g., financing 
single-use injection devices through a cut in purchases of unnecessary injectable medicines) and 
that would break down these costs into smaller manageable pieces that could be spread over 
essential components of various routine programmes (e.g., Behaviour change campaigns of 
HIV/AIDS prevention and care programmes, essential medicines procurement, training and 
supervision in immunization services and health care waste management within health care 
services delivery). 
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The elephant, the mouse and the wise old owl 
The elephant and the mouse who had wanted to get married in spite of the resentment of their 
families had been most happy with the advice from the wise old owl of the forest a year 
beforehand. At that time, she suggested that they listen to their hearts to move forward with 
what, to the best of their awareness, was a good move. When they went to see her again in the 
forest the following year looking for more words of wisdom to build a family, she replied with 
the most humble tone:  
- "Uh-Oh! I am sorry, I am an expert in policy, but not in implementation." 
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Appendix 1: Managing an injection safety policy 
A framework to benchmark, assess, plan, implement and evaluate a national strategy for the safe 
and appropriate use of injections  
Introduction  
Rationale  
Unsafe injection practices are common worldwide (see Chapter 1).1 Due to the overuse of 
injections in many countries, unsafe injections cause a substantial proportion of infection with 
bloodborne pathogens.16  At risk of infection are injection recipients and health care workers 
through contaminated needles and syringes and the community at large through exposure to 
contaminated sharps waste. A mathematical model has been used to estimate the burden of 
disease from unsafe injections in various regions (see Chapter 2). According to its estimates, 
unsafe injections accounted for 32% of hepatitis B virus infection, 40% of hepatitis C virus 
infection, 28% of liver cancer, 24% of cirrhosis and 5% of HIV infections in the year 2000 
(Chapter 2). Overall, about 500 000 deaths per year are attributable to contaminated injections in 
health care settings worldwide (Chapter 2). 
What is the objective of this document? 
This guide is designed to assist in benchmarking, assessing, planning, implementing and 
evaluating a national strategy for the safe and appropriate use of injections. 
Who should use this document? 
This framework is to be used – and adapted – by national public health managers and their 
national and international partners. 
Elements of a national strategy for the safe and appropriate use of injections 
A national strategy for the safe and appropriate use of injections should be viewed as a process 
by which a national standard is developed, the current situation is assessed, a plan is made, 
actions are implemented under continuous monitoring and an evaluation is done to measure 
progress. In fact, public health strategies can be seen as a "quality cycle" that includes five steps 
(Figure 7): 
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Figure 7: The quality cycle 
Standard setting (benchmarking) 
Benchmarking defines and re-defines the standard (the ideal system) and its indicators. 
Assessing 
Assessing consists of determining how the current system differs from the ideal one on the basis 
of selected indicators. 
Planning 
Planning allows the setting of objectives and targets to reach the ideal system. 
Implementing  
Implementing is about conducting interventions to reach the targets and improve the system. 
Evaluating 
Evaluating is done through measuring progress towards the objectives and targets. 
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1. Setting a national standard ("Benchmarking") 
Rationale 
Before engaging on an assessment of injection practices, it is useful to set a national standard. 
Injection practices may be described using a set of key indicators. Each of these indicators has an 
ideal value (see Table 17). The national standard will define a target value and the assessment 
determines how much the current situation differs from this target. 
Objective 
A national standard for injection practices is defined that addresses (1) injection overuse, (2) 
injection safety, (3) the type of injection equipment to be used and (4) safe sharps waste 
management. 
Who should set the national standard? 
Setting a national standard requires the participation of all stakeholders,224 including professional 
associations of health care workers (who prescribe and give injections, e.g., physicians and 
nurses), infection control practitioners (who define infection control standards), health system 
managers (who define standards of care) and procurement units (who purchase necessary 
equipment and supplies).  
How to make it happen? 
Injection use 
National standard treatment guidelines may be used to define the clinical situations for which 
injections are justified. 
Injection safety 
The best practices may be used as a basis to describe the steps that make an injection safe or 
unsafe (Chapter 3). 
Injection equipment to be used 
The choice of injection equipment to be recommended (sterilizable, single use or auto-disable) 
may be an issue for which consensus is difficult to reach. Two elements should be taken into 
consideration. First, WHO best practices recommend single use injection equipment (standard or 
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auto-disable) for all injections (Chapter 3). Second, WHO, UNICEF, UNFPA and IFRC 
recommend that immunization services should exclusively use auto-disable injection equipment 
by the end of 2003. 180 Sterilizable injection equipment should only be considered if (1) sufficient 
quantities of single use injection equipment cannot be made available and (2) if the quality of the 
sterilization is documented in registers with Time, Steam and Temperature (TST) spot indicators 
for all injections. Experience in many developing and transitional countries indicates that the 
latter condition is rarely met and that only single use injection equipment made available in 
sufficient quantities can ensure the safety of injections. 
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Table 17: Key indicators to describe injection practices in a country * 
PROGRAMME INDICATORS (INPUT) IDEAL VALUE TARGET VALUE  
I.1. HIV/AIDS prevention and care programme communicating the risk of HIV infection 
associated with injections 
Yes  
I.2. National drug policy discouraging injection overuse  Yes  
I.3. Number of injectable medications on the national essential drug list  Lowest possible †  
I.4. Essential drugs programme supplying syringes, needles, diluent and safety boxes in quantities 
matching supplies of injectable medications  
Yes  
I.5. Donor or lender-funded programmes such as immunization or family planning services 
supplying AD syringes and needles in quantities matching supplies of injectables  
Yes  
I.6. Health care waste management plan established within the health care system Yes  
DETERMINANTS OF INJECTION PRACTICES (PROCESS) IDEAL VALUE  TARGET VALUE  
Injection Use 
P.1. Proportion of the population reporting a preference for injections in the case of fever < 15 %  
P.2. Proportion of prescribers reporting a preference for injections among patients in the case of 
fever 
< 15% ‡  
P.3. Proportion of the population recalling that the last injection received has been given at home < 10%  
Injection Safety  
P.4. Proportion of the population spontaneously reporting the risk of HIV infection associated with 
unsafe injections  
100%  
P.5. Proportion of prescribers spontaneously reporting the risk of hepatitis C virus infection 
associated with unsafe injections  
100%  
P.6. Proportion of health care facilities using sterilizable injection equipment 0%  
P.7. Proportion of health care facilities using single use injection equipment  100%  
P.8. Proportion of health care facilities using auto-disable injection equipment 100%   
P.9. Proportion of health care facilities with sufficient stocks of single use injection equipment (in 
the facility or in a nearby public or community pharmacy) 
100%  
P.10. Proportion of injections administered by unqualified or family providers  0%  
INJECTION PRACTICES (OUTCOME)§ IDEAL VALUE  TARGET VALUE  
Injection Use 
O.1. Proportion of prescriptions including at least one injection ** Lowest possible †  
O.2. Average number of injections per prescription (for prescriptions containing at least one 
injectable medication) 
Variable †  
O.3. Average number of injections per person and year < 1  
Injection Safety  
O.4. Proportion of health care facilities where injections are always given with a sterile syringe and 
needle 
100%  
O.5. Proportion of health care facilities where used injection equipment can be observed in places 
where they expose health care workers to needle-stick injuries 
0%  
O.6. Annual number of needle-stick injuries per injection provider 0  
O.7. Proportion of health care facilities where used injection equipment can be seen in the 
surrounding environment 
0%  
                                                 
* The difference between the national target value and the observed value from the assessment will determine the objectives of the national 
injection safety strategy. 
† Will vary according to many factors including health care settings, standard treatment guidelines, severity of illnesses when patients seek care. 
‡ The value of P.2 should not exceed the value of P.1.  
§ Estimation of the incidence of infection-associated infections as outcome indicator of a strategy for the safe and appropriate use of injections 
requires substantial epidemiological expertise and resources. 
** Also referred to as "OT8 indicator" to monitor essential medicine policies. 
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2. Assessing practices 
Rationale 
A base of evidence is needed to define the most common and important problems related to 
injection practices so that the plan of action can be developed and adapted to the local situation. 
Objective 
Stakeholders are engaged in a process by which they describe injection practices on the basis of 
up-to-date evidence.  
Who should conduct the assessment? 
Stakeholders' involvement in all steps of the assessment process will facilitate planning. However, 
the data collection step requires expertise in the design, implementation, analysis and 
interpretation of surveys. 
How to make it happen? 
Key indicators (Table 17) include programme indicators (input), determinants of injection 
practices (process) and indicators of injection practices (outcome). Two main tools are available 
to obtain information on these indicators: The "Rapid assessment and response guide" and the 
"Tool for the assessment of injection safety" (see Table 18). The methods they propose may be 
combined. 
 
The rapid assessment guide for injection practices 66 aims at engaging stakeholders in 
launching a planning process through the provision of a simple description of injection practices, 
their determinants and their consequences. It is based upon combined sampling of injection 
prescribers, injection providers and the general population. It offers a range of sampling 
strategies according to the level of precision required and resources available (Abstract 16). 
The WHO tool to assess injection safety 20 aims at estimating the proportion of health care 
facilities engaging in safe injection practices in a standardized way. It is based on a cluster sample 
of 80 health care facilities and provides representative data on injection practices predominantly 
in immunization and curative public health care services (Abstract 10, Abstract 11). 
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Table 18: Compared characteristics of the two WHO assessment tools available 
 Rapid assessment  
and response guide 
Tool for the assessment  
of injection safety  
Aim • Engage stakeholders to launch a planning process • Estimate the proportion of safe injections as the 
basis for planning  
Focus • Injection frequency 
• Injection safety 
• Injection safety 
Groups surveyed • General population  
• Injection prescribers (e.g., physicians) 
• Injection providers (e.g., nurses) 
• Formal health care facilities, most often in the 
public sector 
Precision • According to sampling strategy  • ± 10% around the estimate 
Representativity  • According to sampling strategy • Good 
Qualitative component  • More qualitative  • More quantitative  
Potential users • National essential medicine policy-makers 
• Injection safety committee  
• Expanded Programme on Immunization 
• Injection safety committee 
Cost • Around US$ 10 000 • Around US$ 20 000 
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3. Planning for change 
Rationale 
A successful strategy to achieve safe injection practices requires making deliberate efforts to 
engage all national programmes and services involving injections. Such a strategy will contain 
three elements (See “Aide mémoire” for a national safe and appropriate use of injection policy 65): 
1. Behaviour change among patients and health care workers to reduce unnecessary injections 
and achieve safe practices (e.g., through interactional patient-provider group discussions); 
2. Equipment and supplies: Provision of sufficient quantities of new, single use injection 
equipment and infection control supplies; 
3. Sharps waste management: Safe collection and management of sharps waste.  
Objective 
Different national programme areas establish plans of action based on the assessment results in 
which they incorporate the three elements of the strategy for the safe and appropriate use of 
injections. These plans form the blueprint for the implementation of interventions. 
Who should formulate the national plan? 
Key Ministry of Health departments (including HIV prevention and care, essential medicines, 
immunization, family planning and health care system) and partners can gather in an initial 
national workshop. Its participants can then establish a multidisciplinary national committee on 
injection safety that meets regularly to follow up on the national policy and its implementation 
through the plan of action. 
How to make it happen? 
Template agenda for the national workshop 
The national workshop can set priorities and define a plan of action on the basis of the 
assessment results. 
Template national plan 
A template may be used to generate a national plan of action (see Table 20). The proposed 
outline makes reference to specific programmes implementing specific activities. Behaviour 
change activities may be best conducted by the programmes on HIV prevention and care and the 
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programme on essential medicines. Equipment and supplies may be best provided through the 
programme on essential medicines and the immunization and family planning programmes. 
Sharps waste management may be best implemented within the broader health care system. 
National blood transfusion services will monitor the prevalence of hepatitis B and C viruses and 
of HIV infection and ensure safe blood donations. Other potential entry points include 
legislation, regulation and financing of health care services, quality management programmes, 
human resources training and health promotion. In practice, the actual distribution of tasks may 
differ according to the organizational chart of the Ministry of Health and the local situation. 
What matters is that all these activities are conducted regardless of who takes the lead in 
implementation so that health care workers and the general public receive consistent messages 
from all programmes. 
Setting a timeline 
Once a plan is formulated, setting a timeline with designated, time-bound milestones for progress 
will assist in implementation and monitoring. 
Costing, budgeting and financing 
Cost estimates for each area of work will facilitate the inclusion of the required elements in the 
budgets of the various ministries (such as Ministries of Health, Education, Law, Environment) 
and programmes (e.g., HIV, essential medicines, immunization and health care services). Proper 
costing (Table 19) and budgeting will also help in identifying sources of funds. 
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Table 19: Costing elements of a plan of action for the safe and appropriate use of 
injections 
Activities 
Behaviour change Supplies Waste management 
INPUT 
US$ % total US$ % total US$ % total 
Capital costs        
Information, education and communication material 
development 
      
Curriculum development of training materials       
Good manufacturing practices and technology transfer to local 
producers of injection equipment and safety boxes 
      
Equipment for waste treatment (e.g. incineration) and waste 
disposal 
      
Total capital costs        
Recurrent costs       
Capacity building to use new equipment through pre-service and 
in-service training  
      
Revision of standard treatment guidelines and the essential drug 
list 
      
Appropriate injection equipment and safety boxes       
Supervision and in-service training on updating skills       
Transport for delivery of supplies and collection of waste       
Contracts for treatment and disposal of contaminated waste       
Fuel and supplies for incinerators       
Information, education, communication and mass media 
activities 
      
Interactional group discussions between patients and health care 
providers 
      
Total recurrent costs        
TOTAL COSTS        
 
For calculation of costs of injection equipment and injection control supplies refer to “Procuring 
single use injection equipment and safety boxes: a practical guide”. In countries not yet providing 
safe injection equipment to all programmes and services, costs for equipment will likely be the 
major cost elements of a plan of action for the safe and appropriate use of injections. 
Option appraisal 
A comprehensive option appraisal should present both quantified and non-quantified costs and 
benefits. Besides the financial implications of a plan of action, other issues to be considered 
include the technical feasibility, the legal and administrative constraints and the long-term 
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sustainability in terms of managerial and financial resources. Wider effects of an intended change 
on the traditional, social or power structure of communities, on employment, equity and gender 
as well as possible environmental effects need to be equally appraised.  
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Table 20: Template for a plan of action for the implementation of the national policy for the safe and appropriate use of injections 
1. BEHAVIOUR CHANGE 
HIV PREVENTION AND CARE PROGRAMME TO COMMUNICATE THE RISK OF HIV INFECTION ASSOCIATED WITH POOR INJECTION PRACTICES 
Objectives Core interventions Beneficiaries/ 
Target groups 
Indicators 
Create consumer demand for new, single use injection 
equipment 
• Education materials 
• Mass media 
• Patients • Proportion of the population spontaneously reporting the 
risk of HIV infection associated with unsafe injections 
(Indicator P.4) 
Ensure use of new, single use injection equipment 
• Pre-service and in-service training  
• Injection providers 
(e.g., nurses) 
• Proportion of health care facilities where injections are 
always given with a sterile syringe and needle (Indicator 
O.4) 
Achieve safe injection practices 
Protect health care workers from needle-stick injuries 
• Endorsement of best practices by medical and nursing 
association 
• Pre-service and in-service training 
• Injection providers 
(e.g., nurses) 
• Proportion of health care facilities where used injection 
equipment can be observed in places where they expose 
health care workers to needle-stick injuries (Indicator O.5) 
NATIONAL DRUG POLICY TO PREVENT INJECTION OVERUSE 
Objectives Core interventions Beneficiaries/ 
Target groups 
Indicators 
Promote oral medication 
• Education materials 
• Mass media 
• Patients • Proportion of the population reporting a preference for 
injections in the case of fever 
(Indicator P.1) 
Reduce prescription of injectable medications  
• Standard treatment guidelines 
• Policy statement from medical association 
• Interactional group discussions 
• Reduce financial incentive to provide injections  
• Injection prescribers  
(e.g., physicians, medical 
assistants, including in the private 
sector) 
• Proportion of prescriptions including at least one injection 
(Indicator O.1. also referred to as OT8) 
Reduce injection overuse 
Reduce access to injectable medications 
• Remove unnecessary injectable medications from the 
essential drug list 
• Health facilities, pharmacies and 
depots 
• Number of injectable medications on the essential drug list 
(Indicator I.3) 
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2. EQUIPMENT AND SUPPLIES 
ESSENTIAL MEDICINE PROGRAMME TO MAKE SYRINGES AND SHARPS BOXES AVAILABLE IN EVERY HEALTH CARE FACILITY  
Objectives Core interventions Beneficiaries/ 
Target groups 
Indicators 
Ensure universal access to safe injection 
equipment and safety boxes 
Deliver injectable medications with matching quantities of 
injection equipment and injection control supplies when 
procuring and distributing essential drugs  
• Procure syringes, needles, diluents and safety boxes for the 
collection of sharps 
• Strengthen the national regulatory authority to ensure the 
quality of injection equipment 
• Public and private health care 
facilities 
• Proportion of health care facilities with sufficient stocks of 
single use injection equipment (in the facility or in a nearby 
public or community pharmacy) (Indicator P.9) 
IMMUNIZATION AND FAMILY PLANNING PROGRAMMES TO DELIVER INJECTABLES WITH AUTO-DISABLE SYRINGES AND SAFETY BOXES 
Objectives Core interventions Beneficiaries/ 
Target groups 
Indicators 
Make all injectable vaccines and 
contraceptives available with matching 
quantities of injection equipment and safety 
boxes 
“Bundle” injectable vaccines and contraceptives procured 
by donors and lenders with essential injection equipment 
and supplies, including:  
• Auto-disable syringes and needles 
• Appropriate diluents 
• Safety boxes 
? Immunization services  
(EPI programme) 
? Family planning services  
• Donor or lender-funded programmes such as 
immunization or family planning services supplying AD 
syringes and needles in quantities matching supplies of 
injectables (vaccines or contraceptives) (Indicator I.5) 
3. SHARPS WASTE MANAGEMENT 
HEALTH CARE SYSTEM TO PROPERLY MANAGE SHARPS WASTE 
Objectives Core interventions Beneficiaries/ 
Target groups 
Indicators 
Integrate sharps waste management into a 
comprehensive national health care waste 
management plan 
National health care waste management plan 
• National policy with regulatory framework 
• Plan from waste production to disposal 
• Training at all levels 
• Procurement of waste treatment options 
• Health care facilities 
• Injection providers 
• Communities 
• Proportion of health care facilities where used injection 
equipment can be seen in the surrounding environment 
(Indicator O.7) 
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4. Implementing multidisciplinary interventions 
Rationale  
Interventions to decrease both the unnecessary use (i.e., through patient-providers interactional 
group discussions) and the reuse (i.e., through provision of single use equipment) of injections 
have been shown to be a very cost-effective investment in health (cost-effectiveness less than the 
annual gross domestic product per capita, Chapter 5). Implementation of the strategy for the safe 
and appropriate use of injections across all programmes or services involved in injections will 
achieve the required consistency in the practices of health care workers. 
Objective 
Positive changes towards the safe and appropriate use of injections are brought about through (a) 
effective communication and behaviour change interventions, (b) the sufficient and continuous 
provision of injection equipment and infection control supplies and (c) an appropriate sharps 
waste management that eliminates contaminated sharps from the environment. 
Who can assist in implementation? 
1. Communication and behaviour change will require communication experts to formulate a 
communication strategy, photographers, graphic designers, writers and other public relations 
experts to design information, education and communication materials; 
2. Provision of supplies will require pharmacists or administrators familiar with procurement 
procedures; 
3. Sharps waste management will require health system specialists to manage the plan, engineers 
for the construction of the waste treatment options and logisticians for implementation. 
How to make it happen? 
1- Communication and behaviour change strategy 
WHO designed a template communication and behavioural change strategy for the safe and 
appropriate use of injections. This strategy proposes to develop six essential behaviours among 
patients, prescribers and injection providers (see  
Table 21). Further tools and details to implement the proposed communication strategy may be 
found in the “Communication strategy for the safe and appropriate use of injections”. 225  
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Table 21: Communication strategy for the safe and appropriate use of injections 
 
Four problems 
 
Three participant groups 
 
Six key actions 
 
 
PRESCRIBERS  
 
 
1. Prescribe oral medications wherever possible 
 
THERAPEUTIC 
INJECTION OVERUSE 
2. If prescribed an injection, ask if medication can be given orally 
instead 
 
PATIENTS  
3. Demand that a syringe and needle be taken from a new, sealed 
and undamaged package 
REUSE OF INJECTION 
EQUIPMENT WITHOUT 
STERILIZATION 4. Use a syringe and needle from a new, sealed and undamaged 
package for every injection 
UNSAFE SHARPS 
COLLECTION 
5. Without recapping, place syringes and needles in a safety box 
immediately after use 
UNSAFE MANAGEMENT OF 
INJECTION WASTE 
 
 
INJECTION PROVIDERS  
(Health Care Workers) 
 6. Manage injection waste safely and appropriately 
2- Provision of equipment and supplies 
a) Curative health care system 
Since a lack of supplies of injection equipment leads to unsafe practices,58 the WHO expert 
committee for essential medicines recommended that "those who supply injectable medications 
should also procure the equipment to administer them safely"(Abstract 14) .226 Thus, national 
procurement officers purchasing pharmaceuticals should ensure that orders and deliveries of 
injectable substances also include matching quantities of (1) single use syringes and needles, (2) 
single-dose vials of diluents and (3) safety boxes for the collection of sharps waste. In some 
settings characterized by a high level of reuse of injection equipment, auto-disable syringes may 
be required instead of standard, single use syringes. Key steps to facilitate the procurement of 
equipment and supplies required to ensure injection safety are summarized in  
Table 22 and described in more detail in “Procurement single use injection equipment: A 
practical guide”. 227 
b) Immunization, family planning and other donor- and lender-supported programmes 
In the immunization field, the "bundling"* policy statement recommends that donors and lenders 
who supply injectable vaccines should also supply auto-disable syringes and safety boxes for the 
collection of sharps. Family planning services, tuberculosis control and other donor- and lender-
supported programmes making use of injections should also procure the equipment to administer 
                                                 
* "Bundling" refers to the inclusion of the costs of auto-disable syringes and safety boxes in the costs of good quality vaccines provided by donors 
and lenders as described in the WHO/UNICEF/UNFPA/IFRC 1999 policy statement [5]. "Bundling" has no physical connotation and does not 
imply that items must be "packaged" together. 
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injections safely. These programmes can use the immunization "bundling" policy statement as a 
template for the formulation of their own injection safety policy. 180 
Table 22: Steps to follow to procure injection equipment and safety boxes at country level 
Step Objective Tasks 
Step1 Select products Select the type of injection equipment and safety boxes required to be procured according to 
the purpose of use 
Step 2 Estimate injection equipment 
needs 
• Estimate needs of injection equipment and sharps boxes in preventive and curative 
services 
• Calculate costs and funds required 
Step 3 Prepare for procurement • Define procurement or tender specifications 
• Establish injection equipment specifications 
• Prepare bidding documents 
• Select potential suppliers 
Step 4 Process tender  • Choose a tender format  
• Prepare bidding documents for selective tender   
• Solicit and receive offers for selective tender 
• Select suppliers  
• Issue contract  
• Assess contract performance 
• Evaluate product performance 
3- Sharps waste management 
While sharps waste constitutes a small proportion of all health care waste, it is associated with 
one of the highest hazards. Management of sharps waste within the broader context of health 
care waste management, as described in the “Aide mémoire” for safe health care waste 
management 228 improves effectiveness and sustainability. The key to success is the locally 
adapted combination of the managerial (see Table 23 and technology aspects (see  
Table 24). 
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Table 23: Key elements of safe health care waste management  
National policy for safe health care waste management  
• Designation of responsible authority 
• Regulatory framework and guidelines  
• Initial assessment 
• Integration into overall waste management plan  
• Monitoring and evaluation 
Comprehensive system of health care waste management 
• Assignment of waste management responsibilities to personnel 
• Allocation of resources 
• Minimization of waste 
• Segregation of waste 
• Safe collection, handling and storage 
• Safe treatment and disposal 
Awareness and training 
• Inclusion of waste management in the curricula of health care personnel  
• National training package 
• Train the trainers programme 
• Education on health risks  
• Education on safe practices 
Selection of options for the management of health care waste 
• Review of available options (see Table 8) 
• Checks of safety and environment-friendliness 
• Ensure workers’ safety 
• Evaluation of sustainability 
• Assessment of acceptability 
• Monitoring of safety and efficiency 
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Table 24: Comparison of various methods for processing/disposal of sharps waste 
Method Strengths Weaknesses 
Waste burial pit or encapsulation  • Simple 
• Inexpensive 
• Low tech 
• Prevents sharps-related infections/injuries to 
waste handlers/scavengers 
• Potential of being unburied 
• No volume reduction  
• No disinfection of wastes 
• Pit may fill quickly  
• Not adapted for non-sharp infectious wastes 
• Presents a danger to community if not properly 
buried 
• Inappropriate in areas of heavy rain or if water 
table is near the surface 
Burning (< 400oC), including: 
 
Brick oven burners  
Drum burners  
Pit burning 
• Relatively inexpensive 
• Minimum training required 
• Reduction in waste volume 
• Reduction in infectious material 
• Incomplete combustion 
• May not completely sterilize 
• Results in heavy smoke 
• May require fuel or dry waste to start burning 
• High potential for toxic emissions (e.g., dioxins 
and furans), if waste stream is not properly 
managed 
Incineration (≥ 800oC) • Almost complete combustion and sterilization of 
used injection equipment 
• Reduces risk of toxic emissions 
• Greatly reduces volume of sharps waste 
• Greater compliance with  
local environmental laws 
• Relatively expensive to build, operate and 
maintain 
• Requires trained personnel to operate 
• May require fuel or dry waste to start burning 
• Some potential for toxic emissions (e.g., dioxins 
and furans) if waste stream is not properly 
managed. 
Needle removal/ 
Needle destruction 
• Reduces occupational risks to waste handlers and 
scavengers 
• Plastic and steel may be  
safely recycled for other uses 
after treatment 
• Manual technologies available 
• Potential risk of needle-stick injuries 
• Fluid splash back may create opportunities for 
bloodborne pathogen transmission  
• Used needles/syringes need further treatment for 
disposal 
• Safety profile is not conclusively established 
Plastic recycling • Environmentally friendly 
• Makes use of prevailing market mechanisms  
• Provides revenue to local private sector (e.g., 
production of buckets and coat hangers) 
• Needs to be preceded by use of a safe needle 
removal system  
• Potential risk of needle-stick injuries during 
processing 
• Requires estimation of financial viability under 
different scenarios and contexts 
Melting in industrial ovens • Greatly reduces volume of sharps waste • Expensive 
• Requires electricity 
Autoclave steam sterilization 
followed by shredding 
• Sterilizes used injection equipment 
• Environmentally friendly  
• May reduce waste volume 
• High capital and operational costs 
• Requires electricity 
• High maintenance requirements 
• Less volume reduction than incineration 
 
Further information on sharps waste management is available at 
http://www.healthcarewaste.org. 
5. Monitoring and evaluating impact 
Rationale 
Monitoring and evaluation are required to document progress towards the targets laid out in the 
national standard for injection practices and to adapt implementation of interventions 
accordingly. 
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Objective 
The implementation of the national plan for the safe and appropriate use of injections is regularly 
monitored and intermittently evaluated using a combination of input, process and outcome 
indicators to obtain evidence of the progress achieved and a basis for the new planning process. 
Who should conduct monitoring and evaluation? 
The easiest way to ensure monitoring and evaluation is to incorporate injection practice 
indicators into sets of indicators routinely used to monitor the technical quality of health systems. 
How to make it happen? 
Indicators  
The indicators to be used for evaluation are identical to the ones used for the initial assessment 
(see Table 17). The subset of indicators mentioned in the plan of action (see Table 20) are 
particularly suitable for monitoring purposes. 
Input indicators 
Input indicators reflect the human and financial and planning resources invested in the national 
strategy for the safe and appropriate use of injections. 
Process indicators 
Process indicators reflect the status of implementation of the various action points proposed in 
the national strategy for the safe and appropriate use of injections. 
Outcome indicators 
Outcome indicators reflect the evolution of injection practices in terms of frequency and safety 
following the implementation of the national strategy for the safe and appropriate use of 
injections. 
Data collection  
Data regarding these indicators may be collected regularly in the Ministry of Health and in 
different programme offices, during supervisory visits in health care facilities, in separate surveys 
and/or as part of the process of accreditation of health care facilities. In the latter case, the 
proposed indicators may be adapted. Additional resources regarding the use of supervision visits 
to monitor injection practices are available in the “Guide to supervising injection providers”. 218  
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Appendix 2: Abstracts of other publications and presentations on 
injection safety 
Abstract 1: Transmission of Hepatitis C Virus Infection Associated with 
Home Infusion Therapy for Hemophilia 
CDC publication with primary responsibility. Morb Mortal Wkly Rep 1997; 46:597-9. 
Report 
Transmission of hepatitis C virus (HCV) and other bloodborne viruses between household 
members who are not sex partners presumably results from unapparent percutaneous or 
permucosal exposures, such as sharing articles that may be contaminated with microscopic 
quantities of blood. The risk for nonsexual household transmission is extremely low, and no 
cases of such transmission have been documented (1); direct percutaneous exposures (e.g., 
injecting drugs) have been identified as the major risk factor for infection (1). This report 
summarizes the investigation of a newly acquired case of HCV infection in a child with 
hemophilia, after a preliminary investigation identified several household members with HCV 
infection. The findings suggest the child-acquired infection through percutaneous exposure to the 
mother's HCV-infected blood during infusion of clotting-factor concentrate.  
On September 12, 1996, a case of seroconversion of antibody to HCV (anti-HCV) in a 4-year-old 
child with moderate factor VIII deficiency was reported to the Seroconversion Surveillance 
Project, a surveillance system maintained jointly by the Food and Drug Administration, CDC, 
and the National Hemophilia Foundation. The child tested positive for anti-HCV on August 29, 
1996, after testing negative in June 1994 and August 1995. Serum drawn on the same day (August 
29) tested negative for human immunodeficiency virus (HIV) antibody. With the exception of the 
14 days after birth, the child had always received recombinant clotting-factor concentrate for 
treatment of bleeding episodes.  
Testing of serum samples from six household members indicated that three were anti-HCV-
positive, including the patient's mother, an older sibling, and an aunt who had stayed in the 
household for 6 weeks during September-October 1995. The mother and aunt had histories of 
having injected illicit drugs but had not been tested previously for anti-HCV. The sibling, aged 11 
years, had moderate factor VIII deficiency and was anti-HCV-positive when first tested in 1992.  
Until November 1994, the child was treated for bleeding episodes at a local emergency 
department with recombinant clotting-factor concentrate brought from home. Beginning in 
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November 1994, the patient's mother administered clotting-factor concentrate to him at home 
after receiving training from a nurse employed by a home health care company. Follow-up 
consisted of an annual visit to a hemophilia treatment center. During February 1995-June 1996, 
the period during which the child probably became infected, the patient's mother administered 
factor VIII concentrate to him on 13 occasions. She reported that, until May 1996, three other 
persons were required to restrain the child during infusions because the child was combative and 
resistant. Infusions usually were administered through a vein in the foot because of reported 
difficulties in accessing a vein in the upper arm, and up to 3 hours were required for infusion. 
The mother recalled that, on at least two occasions, she pricked her finger with the needle while 
attempting an infusion and drew a visible quantity of blood, but she could not remember whether 
she continued to use the same needle for the infusion. Before learning in September 1996 that 
she was infected with HCV, she did not use gloves when infusing clotting-factor concentrate. No 
other family members assisted in administering factor concentrates.  
The child and the mother shared a bed. Although each household member had his or her own 
toothbrush, bath towels were shared. All household members were negative for or denied recent 
histories of dermatitis, open wounds, injury, or external bleeding episodes. Sequence analysis of 
the HCV strains of the child and the HCV-infected family members indicated that the strain 
isolated from the mother and the child was identical in a sequence of 220 nucleotides in the 
NS5b region of the genome. Viral sequences in this region isolated from the aunt and brother 
differed by four and 10 nucleotides, respectively, from the child's strain.  
Reported by: L Finelli, PhD, Acting State Epidemiologist, EA Gursky, ScD, Senior Assistant 
Commissioner, New Jersey Dept of Health and Senior Svcs. Hematologic Diseases Br, Div of 
AIDS, STD, and TB Laboratory Research, and Hepatitis Br, Div of Viral and Rickettsial 
Diseases, National Center for Infectious Diseases, CDC.  
Editorial Note 
Editorial Note: The results of the investigation described in this report suggest that the child 
acquired HCV infection through percutaneous exposure to the mother's HCV-infected blood 
during infusion of clotting-factor concentrate. The mother was responsible for infusing factor 
concentrate and reported incurring needle-sticks during some of these infusions. Therefore, 
blood-to-blood contact may have resulted either from use of a contaminated needle to administer 
an infusion or by contamination of the infusion site. In addition, analysis of the sequences of the 
segments of HCV strains isolated from the mother and child indicated the strains were closely 
Evidence and information for injection safety policies 135
related. Because the time of initial infection of the mother could not be documented, the 
possibility that the child acquired infection from another unrecognized source and was the 
subsequent source of infection for the mother cannot be excluded. However, the mother had 
been a long-term injecting-drug user before birth of the child and may have acquired HCV 
infection through sharing needles and syringes. Surveys indicate that up to 90% of long-term 
injecting-drug users test positive for anti-HCV (1).  
Among persons with hemophilia who were heavily infused with clotting-factor concentrates 
before the development of viral inactivation methods, the prevalence of anti-HCV exceeds 90% 
(1). The safety of plasma-derived clotting-factor concentrates has been improved by instituting 
measures that include screening for serologic markers of bloodborne pathogens in donated 
plasma used in the manufacture of these products and the incorporation of viral inactivation 
steps (e.g., dry heating, pasteurization, and solvent detergent treatment) (2). Transmission of 
HCV or other viral agents has not been reported in association with receipt of genetically 
engineered factor concentrates or of albumin, the only human plasma-derived material present in 
these recombinant products (3,4). Based on these considerations, clotting-factor concentrate was 
an unlikely source of infection in the case described in this report because the child had received 
only recombinant product during the period in which infection was likely to have been acquired.  
Home infusion therapy is a convenient and cost-effective alternative to treatment of hemophilia 
in the health care setting (5). However, if proper infection control procedures are not followed, 
patients and household members may be at risk for exposure to bloodborne pathogens during 
home infusion therapy. In one study, 18% of household members who assisted HIV-infected 
hemophilia patients with the infusion process reported having sustained at least one needle-stick 
injury (6), and HIV infection has been acquired through percutaneous exposure during home 
treatment of acquired immunodeficiency syndrome (7) and hemophilia (8).  
CDC recommends that patients and families who are eligible for home infusion therapy be 
informed of the potential risks for infection with bloodborne pathogens and be assessed for their 
ability to use adequate infection-control practices consistently. Patients and families should 
receive training with a standardized curriculum that includes appropriate infection-control 
procedures before initiation of home infusion therapy, and infection-control practices should be 
regularly evaluated at home through follow-up visits by health care professionals with specific 
training in such practices. Routine testing of caregivers for bloodborne pathogens is not 
recommended; all caregivers should follow the universal precautions recommended for all 
persons who infuse blood products. Gloves should be worn by persons who prepare or infuse 
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blood products and during disposal of infusion equipment and waste. A needle that has broken 
the skin should not be reused, and used needles should never be recapped. Used needles should 
be placed in a sharps container in a location inaccessible to children. Needle-stick incidents 
occurring during home infusion therapy should be reported to the health care professionals 
supervising home treatment. All household and sexual contacts of patients with chronic hepatitis 
B virus infection should receive hepatitis B vaccine.  
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Abstract 2: Using Surveillance Data to Monitor Key Aspects of the 
Epidemiology of Hepatitis B Virus (HBV) Infection in Romania 
Y. J. F. Hutin*, D. Craciun, N. Ion-Neldelcu, E. E. Mast, M.J. Alter, H. S. Margolis. Abstract 
presented at the annual meeting of the Infectious Diseases Society of America, Denver, CO, 
November 1998. 
Early childhood transmission and unsafe injection practices are major determinants of high levels 
of HBV transmission in Romania. Universal childhood hepatitis B (HB) vaccination was 
implemented in October 1995, and surveillance for acute viral hepatitis in children under five 
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years old was initiated in July 1997. Patients identified with physician-diagnosed acute hepatitis 
were tested for HB surface antigen (HBsAg), IgM antibody to HB core antigen, and IgM 
antibody to hepatitis A virus. Potential exposures and HB vaccine doses received were 
ascertained for all cases. To measure HB vaccine efficacy among children born after October 
1995, the vaccination status of HBsAg-positive children who had acute hepatitis was compared 
with that of HBsAg negative children who had hepatitis A. To measure the association between 
acute HB and injections among children who had received fewer than three doses of HB vaccine, 
the injection history in children who had acute HB was compared with that of HBsAg-negative 
children who had hepatitis A. Of 10 HBsAg-positive children, four (40%) had received three 
doses of vaccine, compared with 57 (92%) of the 62 controls (vaccine efficacy = 94%, 95% 
confidence interval [CI]: 65-99). Of 32 children with acute HB, 15 (47%) received an injection, 
compared with 33 (11%) of the 288 controls (odds ratio = 6.8, 95% CI: 2.8-16, population 
attributable risk = 40%). In Romania, HB vaccine efficacy and the association between HB and 
injections can be estimated using acute hepatitis surveillance data in children under five years of 
age, providing an opportunity to monitor essential prevention programmes. 
Abstract 3: Attitudes of Physicians Regarding the Use of Therapeutic 
Injections, Arges District, Romania 
A. Stoica, Y.J.F. Hutin, M. Paun, E.E. Mast, H.S. Margolis. Abstract presented at the annual 
meeting of SHEA, San Francisco, April 1999. 
Background: 
In Romania, a high proportion of the population receives therapeutic injections every year, unsafe 
injection practices have been reported, and studies indicate an association between acute hepatitis B and 
recent injections. Although anecdotal reports suggest a preference for injections among patients, no 
information is available regarding physicians’ prescribing practices.  
Methods:  
A simple random sample of 200 clinically active physicians in Arges District was selected using the 
physician association list. Data regarding demographic characteristics and attitudes regarding therapeutic 
injections were collected on a standardized questionnaire.  
Results:  
Of the 200 physicians recruited, 26% were male; 18% were < 35 years old, 45% were 35 to 44 years old, 
33% were 45 to 59 years old, and 4% were > 60 years old. The majority (69%) was involved in outpatient 
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care. Most physicians (64%) accurately perceived that injections were more frequently used in Romania 
than in Western Europe, but 40% reported that the use of injections was not excessive in Romania. 
Criteria reported as frequent reasons for choosing injections to administer medications included inability 
of the patient to take oral medications (72%), more rapid effect of injected medications (72%), poor 
intestinal absorption of the drug (72%), stronger effect of injected medications (64%), desire to directly 
observe therapy (60%), and observance of recommendations from university professors (50%).  
Conclusion:  
Physicians’ attitudes may be an important determinant of injection overuse in Romania. Initiatives to 
prevent injection-associated transmission of bloodborne pathogens should include education programmes 
to reduce the use of therapeutic injections by physicians  
Abstract 4: Therapeutic Injections in Romania: A Population Survey in 
Four Districts 
C. M. Dentinger, Y.J.F. Hutin, S. A. Fisher-Owens, E. E. Mast, H.S. Margolis, N. Ion-Nedelcu. Poster 
presented at the SHEA annual meeting, April 1999, San Francisco. 
Background:  
Acute hepatitis B is one of the most common reportable diseases in Romania and the prevalence 
of chronic hepatitis B virus (HBV) infection is high.  Recent analysis of surveillance data 
demonstrates that therapeutic injections are associated with acute hepatitis B among 
unimmunized children under 5 years old.  Anecdotal reports suggest that patients request 
injectable medications from physicians; however, little is known about injection frequency or the 
determinants of injection use.   
Methods:  
We conducted a population-based survey of 300 households in each of four selected districts.  
Information was collected from each household member on the number of therapeutic injections 
received in the last 12 months.  Knowledge and attitudes regarding the use of injections were 
assessed from one randomly selected adult in each household.  
Results:  
An estimated 50%, 32%, 36%, and 33% of the population in the districts of Hunedoara (n = 
904), Iasi (n = 964), Mures (n = 879), and Prahova (n = 932 ), respectively,  reported receiving at 
least one therapeutic injection in the last 12 months.  Among those who received injections, the 
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median number received was 10, seven, six, and five in the four districts, respectively.  Of 1,200 
adults interviewed, 75% reported that injectable medications were stronger than oral medications; 
however, a lower proportion indicated a preference for injections for the treatment of diarrhea 
(18%), fever (28%), upper respiratory infections (29%), or for vitamin supplementation (42%).   
Conclusions:  
A high proportion of the Romanian population receives injections each year; however, a minority 
of patients indicated a preference for injected medications for common medical conditions.  
Additional information regarding prescribing practices of physicians is needed to develop a 
programme to reduce injection use. 
Abstract 5: Injection Practices in Romania: Progress and Challenges  
C. Dentinger, L. Pasat, M. Popa, Y.J.F. Hutin, EE Mast. Infect Cont Hosp Epidemiol 2004; 
25:30-35. 
Background:  
In Romania, a high proportion of the population receive therapeutic injections each year, and 
studies indicate an association between recent injections and acute hepatitis B.  However, no 
information is available on nursing infection-control practices that might lead to hepatitis B virus 
(HBV) transmission through injections.   
Methods: 
We surveyed a systematic sample (n=180) of the 1,906 nurses in Vilcea District, Romania.  
Interviewers used standardized questionnaires to collect information on nurses’ knowledge and 
practices regarding injection use and adherence to Universal Precautions (UP) for the prevention 
of transmission of bloodborne pathogens.  
Results:  
The median age of the 180 nurses was 44 years, 91% were female, the median years of practice 
was 22, 94% worked full-time, and 91% (95% Confidence Interval [CI] = 86-95%) reported UP 
training.  A total of 38% (95% CI = 31-45%) of nurses accurately reported that HBV remains 
infectious for as long as 1 week in the environment, and 4% (95%CI=1-8%) knew that HBV is 
transmitted percutaneously more efficiently than human immunodeficiency virus.  No nurse 
reported reuse of syringes or needles on different patients, but 2% (95% CI = 0.6-6%) reported 
they would reuse a syringe or needle on the same patient in an emergency.  Almost half (47% 
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[95%CI =39-66%]) of nurses reported preparing injections where blood-contaminated items 
were also handled.  Infection-control supply shortages, including sharps containers, disinfecting 
solutions, and gloves, were reported by 72% (95%CI =  65-79%), 53% (95% CI = 45-60%), and  
60% (95% CI = 51-68%) of respondents, respectively.   
Conclusions:  
Most nurses in Vilcea were trained in UP,  and none reported needle or syringe reuse; however,  
knowledge deficiencies, unsafe practices, and infection-control supply shortages exist and might 
facilitate injection-associated HBV transmission.  
Abstract 6: Identifying Target Groups for a Potential Vaccination 
Programme during a Hepatitis A Communitywide Outbreak 
Y.J. Hutin, B.P. Bell, K.L. Marshall, C.P. Schaben, M. Dart M, M.P. Quinlisk, C.N. Shapiro. 
Am J Pub Health 1999; 89:918-21. 
Objectives:  
This study sought to identify groups for targeted vaccination during a communitywide hepatitis A 
outbreak in 1996.  
Methods:  
Residents of the Sioux City, Iowa, metropolitan area reported with hepatitis A between 
September 1995 and August 1996 were sampled and compared with population-based controls.  
Results:  
In comparison with 51 controls, the 40 case patients were more likely to inject 
methamphetamine, to attend emergency rooms more often than other health care facilities, and 
to have a family member who used the Special Supplemental Nutrition Programme for Women, 
Infants, and Children.  
Conclusions:  
Groups at increased risk of hepatitis A can be identified that might be accessed for vaccination 
during communitywide outbreaks. 
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Abstract 7: Injections Given in Healthcare Settings as a Major Source of 
Acute Hepatitis B in Moldova 
Y.J. Hutin, R. Harpaz, J. Drobeniuc, A. Melnic, C. Ray, M. Favorov, P. Iarovoi, C.N. Shapiro, 
B.A. Woodruff. Int J Epidemiol 1999; 28:782-6. 
Background:  
Reported rates of acute hepatitis B are high in many former Soviet Union republics and modes of 
transmission are not well defined.  
Methods:  
Two case-control studies were undertaken in Moldova to identify risk factors for acute hepatitis 
B in people aged 2-15 years (children) and > or =15 years (adults). Serologically confirmed acute 
hepatitis B cases occurring between 1 January 1994 and 30 August 30 1995, were matched on age, 
sex, and district of residence to three potential controls who were tested for hepatitis B markers 
to exclude the immune. Stratified odds ratios (SOR) were calculated using bivariate and 
multivariate methods.  
Results:  
In multivariate analysis, compared with the 175 controls, the 70 adult cases (mean age 25 years, 
66% male) were more likely to report receiving injections in the 6 months before illness during a 
dental visit (SOR = 21; 95% CI: 3.7-120), a hospital visit (SOR = 35; 95% CI: 7.2-170), or a visit 
to the polyclinic (SOR = 13; 95% CI: 2.4-74). Among children, receiving injections during a 
hospital visit (SOR = 5.2; 95% CI: 1.2-23) was the only exposure reported significantly more 
often by the 19 cases (mean age 8 years, 68% male) compared with the 81 controls.  
Conclusion:  
These results, along with reported unsafe injection practices in Moldova, suggest that injections 
are a major source of hepatitis B virus transmission and highlight the importance of proper 
infection-control procedures in preventing transmission of bloodborne infections. 
Abstract 8: An Outbreak of Hospital-Acquired Hepatitis B Virus Infection 
among Patients Receiving Chronic Hemodialysis 
Y. J. Hutin, S.T. Goldstein, J.K. Varma, J.B. O'Dair, E.E. Mast, C.N. Shapiro, M.J. Alter. 
Infect Cont Hosp Epidemiol 1999; 20:731-5. 
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Objective:  
To investigate a cluster of hepatitis B virus (HBV) infections between December 1995 and May 
1996 among chronic hemodialysis patients in one county.  
Setting:  
Two dialysis centers (A and B) and a hospital (C) in one county.  
Patients: 
Six case-patients who were dialyzed in one of two centers, A and B, and had all been hospitalized 
between January and February 1996 at hospital C.  
Methods: 
Patient 1, usually dialyzed in center A, sero-converted to hepatitis B surface antigen (HBsAg) in 
December 1995 and could have been the source of infection for the others, who seroconverted 
between March and April 1996. Two cohort studies were conducted: one among patients 
dialyzed in center A, to determine where transmission had occurred, and one among patients 
dialyzed at hospital C at the time patient 1 was hospitalized, to identify factors associated with 
infection. 
Results: 
Four (15%) of the 26 susceptible patients dialyzed at center A became infected with HBV. 
Hospitalization at hospital C when patient 1 was hospitalized was associated with infection (P = 
.002). A cohort study of the 10 susceptible patients dialyzed at hospital C during the time patient 
1 was hospitalized did not identify specific risk factors for infection. However, supplies and 
multidose vials were shared routinely among patients, providing opportunities for transmission.  
Conclusion: 
When chronic hemodialysis patients require dialysis while hospitalized, their HBsAg status should 
be reviewed, and no instrument, supplies, or medications should be shared among them. 
Abstract 9: Multiple Modes of Hepatitis A Virus Transmission among 
Methamphetamine Users 
Y.J. Hutin, K.M. Sabin, L.C. Hutwagner, L. Schaben, G.M. Shipp, D.M. Lord, J.S. Conner, M.P. 
Quinlisk, C.N. Shapiro, B.P. Bell. Am  J Epidemiol 2000; 152:186-92. 
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Methamphetamine users are at increased risk of hepatitis A, but modes of transmission are 
unclear. The authors conducted a case control study among methamphetamine users during an 
outbreak in Iowa in 1997. Twenty-eight reported, laboratory-confirmed, hepatitis A cases did not 
differ from 18 susceptible controls with respect to age, sex, or number of doses used. When 
compared with controls in multivariate analysis, case-patients were more likely to have injected 
methamphetamine (odds ratio (OR) = 5.5, 95% confidence interval (CI): 1.1, 27), to have used 
methamphetamine with another case-patient (OR = 6.2, 95% CI: 0.95, 41), and to have used 
brown methamphetamine (OR = 5.5, 95% CI: 0.51, 59). Receptive needle sharing was reported 
by 10 of the 20 case-patients who injected. Methamphetamine use with another case-patient was 
also associated with hepatitis A in an analysis restricted to noninjectors (OR = 17, 95% CI: 1.0, 
630). During this outbreak, hepatitis A may have been transmitted from person to person among 
methamphetamine users through the fecal-oral and the percutaneous routes. Methamphetamine 
users should be vaccinated against hepatitis A and should be given immune globulin if they used 
methamphetamine with a case-patient in the last 2 weeks. Persons who intend to continue using 
methamphetamine should be advised about safer practices. 
Abstract 10: Pilot Testing the Injection Safety Assessment Tool in Burkina 
Faso 
J.F.Aguilera. Presentation given at the annual SIGN meeting, 23-24 September 2000, Cairo, 
Egypt. 
Unsafe delivery and overuse of injections are responsible for numerous transmissions of hepatitis 
B virus, hepatitis C virus and HIV in the developing world.  Following a report suggesting that in 
1995-96 only 11% of injections in rural health centres in Burkina Faso were performed with 
sterile equipment, in 1996 communities were given the responsibility of supplying injection 
equipment.  Stocks of new disposable injection equipment were then established in each 
community to be sold to patients when needed.  The aim of the present study was to estimate the 
frequency of unsafe injection practices in Burkina Faso. A two-stage cluster sample methodology 
was used to select eight clusters with probability proportional to population size. In each cluster, 
10 health centres were randomly selected. Information was collected in June 2000 through (1) 
structured observation of injection equipment supplies and injection practices and (2) staff 
interviews.  Confidence intervals for proportions were calculated taking into account design 
effect (DE) using Epi-Info software. A total of 116 injections were observed in 52 of the 80 
centres visited. In 50 centres (96% CI [85-99], DE=1.03) injections were given with a new 
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disposable syringe and in 51 (98% [85-99], DE= 1.03) with a new disposable needle.  All centres 
had a community stock to provide new disposable syringes and needles.  In 29 centres (56% [36-
74], DE=1.98), health staff recapped needles using two hands.  In 71 centres of the 80 centres 
visited, staff remembered suffering accidental needle-stick injuries in the last 12 months.  Used 
needles were discarded in open containers in 66 centres (83% [55-96], DE=4.56) and found in 
the environment of 46 centres (57% [32-80], DE=4.66). The increased availability of injection 
equipment in communities may have contributed to the increase in the use of sterile injection 
equipment observed between 1995 and 2000 in Burkina Faso. However, unsafe sharps waste 
collection and disposal persist, placing health care workers and patients at risk of infection.  To 
achieve safe injection practices in Burkina Faso, recommendations have been made for policy 
development in health care waste management and for increased availability of sharps containers. 
Abstract 11: Unsafe Injection Practices, Niger, 2000 
J.A. Painter, Y. Hutin. Presentation given at the 2001 EIS conference, Atlanta, GA, USA, 
April 2001. 
Background: 
Unsafe injection practices transmit bloodborne pathogens on a large scale worldwide.  To better 
direct prevention efforts in Niger, we assisted the Ministry of Health in conducting an assessment 
of injection safety in August 2000.   
Methods: 
We conducted interviews and observations of injection practices in a sample of health clinics in 
Niger.  First, eight clusters were selected from 25 regions with a probability proportional to 
population size.  Second, 10 clinics were randomly selected within each cluster.  Information was 
collected through an inventory of available equipment, structured observations, and staff 
interviews.   
Results: 
Of the 80 clinics selected, 79 provided partial or complete responses. During the previous year, 
clinics reported insufficient disposable syringes at 24 (46%) of 52 clinics and insufficient energy 
for sterilization at 13 (25%) of 52 clinics.  We observed attempts to inject patients with nonsterile 
equipment in 5 (11%) of 45 clinics before tactful interruption by the assessment team.   
Contaminated sharps waste were observed in open containers in 73 (95%) of 77 clinics and in the 
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environment surrounding 43 (61%) of 70 clinics.  Health care workers reported experiencing at 
least one needle-stick injury in the previous year at 56 (72%) of 77 clinics.  
Conclusions: 
Lack of supplies, unsafe behaviours, and poor sharps waste management lead to unsafe injection 
practices in Niger, exposing patients, health care workers, and the community to bloodborne 
infections.  A coordinated strategy to increase supplies of both disposable syringes and fuel 
sources for sterilizers, train health care workers, and encourage proper disposal of sharps is 
required to prevent injection-associated infections in Niger. 
Abstract 12: Increased Access to Injection Equipment in Burkina Faso: 
When Essential Drug Programmes Improve Injection Safety 
S. Logez. Presentation given at the annual SIGN meeting, 30-31 August 2001, New Delhi, India. 
The objective was to evaluate the impact of a National Drug Policy on injection safety between 
1992 and 2001. The methodology was a two-stage cluster sample of health care facilities. 
Compared to widespread reuse of injection equipment that exceeded 50% of health care facilities 
in 1995, reuse of equipment was observed in 4% of health care facilities in June 2000. Sharps 
were found in open containers in 83% of settings and found around 57% of health care centres.  
The national drug policy provided a framework for improved availability of essential drugs and 
injection equipment in Burkina Faso.  Inclusion of disposable injection equipment in the national 
essential drug list allowed tax exemptions.  At district level, wholesalers and supervisory teams 
were set up.  Community pharmacies provided supplies at the health care facility level using a 
cost recovery scheme that made drugs and injection equipment available at low cost to the 
population. The proportion of health care facilities that had access to a community pharmacy 
increased from 5% in 1992 to 95 % in 2000 in Burkina Faso. The number of 5 ml syringes sold in 
the country increased from 884 000 in 1996 to 1 840 000 in 2000.  The price of new 5 ml syringe 
is 10 cents and remained stable.  Injection equipment is judged affordable by 88% of pharmacists 
and 55% of buyers.  Thus, availability and affordability of injection equipment may have 
contributed to improved injection practices in Burkina Faso between 1995 and 2000. However, 
the most dramatic change observed was an improved geographical access since the price of 
injection equipment remained stable. Recommendations of the assessment included that access 
could be improved by monitoring prices and profit margins. Improved access to sharps boxes 
could occur through cost recovery and inclusion in essential drug lists since this mechanism was 
successful in the case of syringes and needles. 
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Abstract 13: Determinants of High Frequency of Therapeutic Injections, 
Chisinau, Republic of Moldova, 1998 
S. Vong, J. Perz, Y. Hutin, J. Drobeniuc, B. Bell & 1998 International Field Epidemiology Course 
Participants. Presentation given at the 2002 EIS conference, Atlanta, GA, USA, April 2002. 
Background: 
In many countries where hepatitis B is highly endemic, overuse of therapeutic injections and 
unsafe practices account for a large proportion of infections. We conducted a population-based 
survey in Chisinau, Moldova, an area of high hepatitis B endemicity, to determine factors 
associated with receiving injections.  
Methods: 
We sampled 704 households in 32 clusters in which one person ≥15 years was randomly selected 
and interviewed regarding frequency of injections received in the last 12 months and related 
knowledge, attitudes and practices.  
Results: 
Of 700 persons interviewed, 385 (55%) had received >1 injection (median 10, range 1-720). 
Persons receiving injections were similar to those who did not in terms of age (median 44 vs. 41 
years), sex (35% vs. 40% male), education (median 12 vs. 12 years), and awareness of hepatitis B 
and its consequences (45% vs. 46%). Compared to persons not receiving injections, persons 
receiving them were more likely to report a preference for injections to treat colds (Odds Ratio 
[OR]=1.72, 95% Confidence Interval [CI]=1.15–2.57) or fever (OR=1.58, 95% CI=1.08–2.31), 
and to request injections when oral treatments were prescribed (OR=1.84, 95% CI=1.19–2.85).  
However, none of these preferences were reported by more than 30% of participants.  Most 
participants reported knowing about risks from syringe reuse, but persons who received 
injections were less likely to have this knowledge (60% vs. 68%; OR=1.41, 95% CI=1.01–1.96).  
Conclusion: 
Despite a general awareness of their potential for bloodborne pathogen transmission, therapeutic 
injections were common among Chisinau residents. However, a minority of them reported 
attitudes favorable to injection use. Interventions to decrease injection overuse should include 
promoting alternative modes of therapy to both health care providers and the public. 
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Abstract 14: Could the WHO Model List of Essential Medicines do more for 
the safe and appropriate use of injections? 
S. M.D. Logez, Y.J.F. Hutin, K. Holloway, R. Gray, H.V. Hogerzeil. J Clin Pharmacol 2004; in 
press. 
Background: 
A national drug policy addressing the safe and appropriate use of injections is an important 
element to prevent overuse and unsafe use of injections. Because the WHO Model List of 
Essential Medicines is a keystone of national drug policies, we examined the way it addresses 
injection practices.  
Methods:  
We reviewed the eleventh WHO Model List of Essential Medicines to collect information on (1) 
injectable drugs, (2) diluents and (3) the recommendations regarding injection equipment 
procurement.   
Results: 
Of 306 active ingredients on the list, 135 (44%) are mentioned in injectable form. Of these, 41 
(30%) need diluents for reconstitution. The list does not mention the need to procure 
appropriate diluents, injection equipment and safety boxes in quantities that match the quantities 
of injectable medicines. In addition, the list provides limited information that can be used to 
forecast the needs of injection equipment to administer the injectable medicines that are included 
in the list.  
Conclusions: 
Future revisions of the WHO Model List of Essential Medicines should attempt to reduce the 
number of injectable references on the basis of evidence. In addition, the list should specify that 
when injectable medicines are being supplied, diluents, single use syringes and safety boxes 
should be supplied. The volume of necessary syringes should be specified to facilitate the 
forecasting of injection equipment needs. 
Abstract 15: Recycling of Injection Equipment in Pakistan 
S.A. Mujeeb, M.A. Malik, A. Altaf, Y. Hutin, S. Luby.  Recycling of injection equipment in 
Pakistan. Infect Cont Hosp Epidemiol 2003; 24:145-6. 
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The prevalence of hepatitis C virus (HCV) infection is high in the general population in Pakistan, 
ranging from 2% to 6%.1 Reuse of injection equipment in the absence of sterilization is 
common, particularly in health care facilities that serve low-income populations. Studies have 
identified unsafe injection practices as a major route of transmission of HCV in Pakistan. 
Changing the behaviour of injection providers so that they would use new freshly-opened 
disposable syringes would improve injection safety in Pakistan. However, frequent reports of 
recycling of injection equipment in the local media question the safety of apparently new syringes. 
Clinical laboratories are one of the major sources of production of used syringes. To evaluate the 
resale of used syringes, we followed the course of used syringes from their initial use to their final 
destination. 
Abstract 16: Rapid Assessment of Injection Practices in Mongolia, 2001 
S.M.D. Logez, G. Soyolgerel, R. Fields, S. Luby, Y. J.F. Hutin. Am J Infect Cont Pract 2004; 
2004; 32 :31-7.  
Background: 
Anecdotal reports of unsafe practices and a high prevalence of HCV infection suggest that unsafe 
use of injections may transmit bloodborne pathogens in Mongolia. To achieve safe and 
appropriate use of injections, the Ministry of Health of Mongolia conducted a rapid assessment. 
Methods:  
Information on injection practices, their determinants and their consequences was collected 
through interviews and observations of a small convenience sample of prescribers, injection 
providers and members of the general population.  
Results: 
The 65 members of the general population reported receiving an average of 13 injections per 
year. New, locally produced, disposable injection equipment was used in the 20 health care 
facilities visited. There were breaks in infection control practices while administering injections, 
including observations of 500 ml intravenous infusion bottles used as multi-dose diluent vials and 
eight of the 28 providers (28%) reporting reusing syringes and/or needles for the same patient. 
Injection providers reported an average of 2.6 needle-stick injuries per year. Contaminated sharps 
were burned in a drum, without any incinerator. Among persons interviewed, 19 of the 21 
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prescribers (90%) and 49% of the population was aware of the potential risk of HIV transmission 
through unsafe injections. 
Conclusions:  
A multi-disciplinary initiative is necessary to achieve safe and appropriate use of injections in 
Mongolia through (1) development of key behaviours among patients and health care workers to 
reduce injection overuse and to ensure safe practices, (2) increasing availability and affordability 
of injection equipment and sharps boxes and (3) appropriate sharps waste management. 
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